WO1998004576A1 - Sequences de virus uniques associees au sarcome de kaposi et utilisations de ces dernieres - Google Patents
Sequences de virus uniques associees au sarcome de kaposi et utilisations de ces dernieres Download PDFInfo
- Publication number
- WO1998004576A1 WO1998004576A1 PCT/US1997/013346 US9713346W WO9804576A1 WO 1998004576 A1 WO1998004576 A1 WO 1998004576A1 US 9713346 W US9713346 W US 9713346W WO 9804576 A1 WO9804576 A1 WO 9804576A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- kshv
- nucleic acid
- kaposi
- sarcoma
- polypeptide
- Prior art date
Links
- 208000007766 Kaposi sarcoma Diseases 0.000 title claims abstract description 158
- 241000700605 Viruses Species 0.000 title claims abstract description 83
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims abstract description 312
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 252
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 239
- 229920001184 polypeptide Polymers 0.000 claims abstract description 227
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 164
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 155
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 155
- 238000000034 method Methods 0.000 claims abstract description 119
- 238000011282 treatment Methods 0.000 claims abstract description 40
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 29
- 229960005486 vaccine Drugs 0.000 claims abstract description 28
- 238000011321 prophylaxis Methods 0.000 claims abstract description 7
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 200
- 108020004414 DNA Proteins 0.000 claims description 100
- 239000000427 antigen Substances 0.000 claims description 65
- 108091007433 antigens Proteins 0.000 claims description 65
- 102000036639 antigens Human genes 0.000 claims description 65
- 239000003795 chemical substances by application Substances 0.000 claims description 59
- 241001529453 unidentified herpesvirus Species 0.000 claims description 58
- 230000003612 virological effect Effects 0.000 claims description 47
- 239000002773 nucleotide Substances 0.000 claims description 43
- 125000003729 nucleotide group Chemical group 0.000 claims description 43
- 238000009396 hybridization Methods 0.000 claims description 40
- 239000013598 vector Substances 0.000 claims description 31
- 230000003902 lesion Effects 0.000 claims description 29
- 239000003443 antiviral agent Substances 0.000 claims description 28
- 102000004889 Interleukin-6 Human genes 0.000 claims description 26
- 108090001005 Interleukin-6 Proteins 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 210000001124 body fluid Anatomy 0.000 claims description 20
- 108010087398 viral interferon regulatory factors Proteins 0.000 claims description 19
- JOEHPBQVSCDCHE-BKGQOYFSSA-N (4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-34-amino-22-(4-aminobutyl)-10-(3-amino-3-oxopropyl)-31-benzyl-13,19-bis[3-(diaminomethylideneamino)propyl]-25-[(1r)-1-hydroxyethyl]-28-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-7-propan-2-yl-1,2-dithia-5, Chemical compound N1C(=O)[C@@H](N)CSSC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CC1=CC=CC=C1 JOEHPBQVSCDCHE-BKGQOYFSSA-N 0.000 claims description 17
- 108090000288 Glycoproteins Proteins 0.000 claims description 14
- 239000013612 plasmid Substances 0.000 claims description 14
- 102000003886 Glycoproteins Human genes 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 10
- 108090000565 Capsid Proteins Proteins 0.000 claims description 9
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 239000002299 complementary DNA Substances 0.000 claims description 8
- 230000003053 immunization Effects 0.000 claims description 8
- 101000999689 Saimiriine herpesvirus 2 (strain 11) Transcriptional regulator ICP22 homolog Proteins 0.000 claims description 7
- 102000033815 complement binding proteins Human genes 0.000 claims description 7
- 108091009760 complement binding proteins Proteins 0.000 claims description 7
- 239000003550 marker Substances 0.000 claims description 7
- 108020001507 fusion proteins Proteins 0.000 claims description 6
- 102000037865 fusion proteins Human genes 0.000 claims description 6
- 229940100601 interleukin-6 Drugs 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 4
- 230000009261 transgenic effect Effects 0.000 claims description 4
- 241000701959 Escherichia virus Lambda Species 0.000 claims description 3
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 101000953872 Human herpesvirus 8 type P (isolate GK18) Viral macrophage inflammatory protein 2 Proteins 0.000 claims 1
- 102000005936 beta-Galactosidase Human genes 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 40
- 238000002255 vaccination Methods 0.000 abstract description 5
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 description 158
- 108700026244 Open Reading Frames Proteins 0.000 description 153
- 102000004169 proteins and genes Human genes 0.000 description 87
- 235000018102 proteins Nutrition 0.000 description 85
- 239000000523 sample Substances 0.000 description 69
- 241000282414 Homo sapiens Species 0.000 description 54
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 43
- 230000002401 inhibitory effect Effects 0.000 description 40
- 108010022394 Threonine synthase Proteins 0.000 description 38
- 241000701062 Saimiriine gammaherpesvirus 2 Species 0.000 description 35
- 238000003556 assay Methods 0.000 description 35
- 239000003814 drug Substances 0.000 description 34
- 235000001014 amino acid Nutrition 0.000 description 32
- 230000000694 effects Effects 0.000 description 32
- 229940024606 amino acid Drugs 0.000 description 30
- 150000001413 amino acids Chemical class 0.000 description 30
- 102000004190 Enzymes Human genes 0.000 description 29
- 108090000790 Enzymes Proteins 0.000 description 29
- 239000000203 mixture Substances 0.000 description 27
- 230000010076 replication Effects 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- 229940079593 drug Drugs 0.000 description 26
- 210000001519 tissue Anatomy 0.000 description 26
- 208000030507 AIDS Diseases 0.000 description 23
- 101100058191 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) bcp-1 gene Proteins 0.000 description 23
- 230000001413 cellular effect Effects 0.000 description 23
- 108020004999 messenger RNA Proteins 0.000 description 23
- 150000001875 compounds Chemical class 0.000 description 22
- 102000004419 dihydrofolate reductase Human genes 0.000 description 21
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 19
- 239000006228 supernatant Substances 0.000 description 19
- 230000003602 anti-herpes Effects 0.000 description 18
- 238000003752 polymerase chain reaction Methods 0.000 description 18
- 238000012163 sequencing technique Methods 0.000 description 18
- 102000005497 Thymidylate Synthase Human genes 0.000 description 17
- 230000000840 anti-viral effect Effects 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 239000012634 fragment Substances 0.000 description 17
- -1 125I Chemical compound 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 238000009739 binding Methods 0.000 description 16
- 108010054167 vMIP-II Proteins 0.000 description 16
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 15
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 15
- 108091054729 IRF family Proteins 0.000 description 15
- 102000006601 Thymidine Kinase Human genes 0.000 description 15
- 108020004440 Thymidine kinase Proteins 0.000 description 15
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 15
- 230000027455 binding Effects 0.000 description 15
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 15
- 230000001900 immune effect Effects 0.000 description 15
- 102000004127 Cytokines Human genes 0.000 description 14
- 108090000695 Cytokines Proteins 0.000 description 14
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 14
- 102000043138 IRF family Human genes 0.000 description 14
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 230000006698 induction Effects 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 238000010186 staining Methods 0.000 description 14
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 13
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 13
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 13
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 13
- 229960004150 aciclovir Drugs 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 229960002963 ganciclovir Drugs 0.000 description 13
- 238000003018 immunoassay Methods 0.000 description 13
- 210000004698 lymphocyte Anatomy 0.000 description 13
- 230000002101 lytic effect Effects 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 239000002853 nucleic acid probe Substances 0.000 description 13
- 108020005202 Viral DNA Proteins 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 12
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 12
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 101710186352 Probable membrane antigen 3 Proteins 0.000 description 11
- 101710181078 Probable membrane antigen 75 Proteins 0.000 description 11
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 11
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 11
- 101710178472 Tegument protein Proteins 0.000 description 11
- 238000013459 approach Methods 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 10
- 241000725303 Human immunodeficiency virus Species 0.000 description 10
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 10
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 229940116886 human interleukin-6 Drugs 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 230000004807 localization Effects 0.000 description 10
- 230000002441 reversible effect Effects 0.000 description 10
- 238000010561 standard procedure Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 230000029812 viral genome replication Effects 0.000 description 10
- 230000004543 DNA replication Effects 0.000 description 9
- 210000003719 b-lymphocyte Anatomy 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 229940031626 subunit vaccine Drugs 0.000 description 9
- 238000013519 translation Methods 0.000 description 9
- 102100034612 Annexin A4 Human genes 0.000 description 8
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 8
- 102000053602 DNA Human genes 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 8
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 8
- 102100037111 Uracil-DNA glycosylase Human genes 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 238000012744 immunostaining Methods 0.000 description 8
- 230000003389 potentiating effect Effects 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 108020004635 Complementary DNA Proteins 0.000 description 7
- 208000031886 HIV Infections Diseases 0.000 description 7
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 7
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 102000014150 Interferons Human genes 0.000 description 7
- 108010050904 Interferons Proteins 0.000 description 7
- KPZWRGGWUNBLMX-UHFFFAOYSA-N N(6)-[N(6)-(N(6)-{6-[(5-nitro-2-furoyl)amino]hexanoyl}lysyl)lysyl]lysyl-N(6)-[4-(indol-3-yl)butanoyl]lysinamide Chemical compound C=1NC2=CC=CC=C2C=1CCCC(=O)NCCCCC(C(N)=O)NC(=O)C(N)CCCCNC(=O)C(N)CCCCNC(=O)C(N)CCCCNC(=O)CCCCCNC(=O)C1=CC=C([N+]([O-])=O)O1 KPZWRGGWUNBLMX-UHFFFAOYSA-N 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 description 7
- 108091023040 Transcription factor Proteins 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 238000010804 cDNA synthesis Methods 0.000 description 7
- XUYJLQHKOGNDPB-UHFFFAOYSA-N carboxymethyl phosphonic acid Natural products OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 108010051621 interferon regulatory factor-8 Proteins 0.000 description 7
- 210000001165 lymph node Anatomy 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 239000002777 nucleoside Substances 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 102100034613 Annexin A2 Human genes 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 6
- 108090000259 Cyclin D Proteins 0.000 description 6
- 102000003910 Cyclin D Human genes 0.000 description 6
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 6
- 101710116602 DNA-Binding protein G5P Proteins 0.000 description 6
- 108060002716 Exonuclease Proteins 0.000 description 6
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 6
- 102100038069 Interferon regulatory factor 8 Human genes 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 6
- 101710162453 Replication factor A Proteins 0.000 description 6
- 101710176758 Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 description 6
- 101710176276 SSB protein Proteins 0.000 description 6
- 101710126859 Single-stranded DNA-binding protein Proteins 0.000 description 6
- 238000002105 Southern blotting Methods 0.000 description 6
- 102000040945 Transcription factor Human genes 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000005754 cellular signaling Effects 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 102000013165 exonuclease Human genes 0.000 description 6
- 229960005102 foscarnet Drugs 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 230000002637 immunotoxin Effects 0.000 description 6
- 239000002596 immunotoxin Substances 0.000 description 6
- 229940051026 immunotoxin Drugs 0.000 description 6
- 231100000608 immunotoxin Toxicity 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 150000003833 nucleoside derivatives Chemical class 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 238000012552 review Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 230000001131 transforming effect Effects 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- HWTAKVLMACWHLD-UHFFFAOYSA-N 2-(9h-carbazol-1-yl)ethanamine Chemical compound C12=CC=CC=C2NC2=C1C=CC=C2CCN HWTAKVLMACWHLD-UHFFFAOYSA-N 0.000 description 5
- 101000787133 Acidithiobacillus ferridurans Uncharacterized 12.3 kDa protein in mobL 3'region Proteins 0.000 description 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 5
- 101000827603 Bacillus phage SPP1 Uncharacterized 10.2 kDa protein in GP2-GP6 intergenic region Proteins 0.000 description 5
- 102000053642 Catalytic RNA Human genes 0.000 description 5
- 108090000994 Catalytic RNA Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 5
- 208000007514 Herpes zoster Diseases 0.000 description 5
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 5
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 5
- 101000977786 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized 9.7 kDa protein in PE 3'region Proteins 0.000 description 5
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 5
- 102100034256 Mucin-1 Human genes 0.000 description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 5
- 101001113905 Rice tungro bacilliform virus (isolate Philippines) Protein P4 Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 5
- 238000000137 annealing Methods 0.000 description 5
- 230000003432 anti-folate effect Effects 0.000 description 5
- 229940127074 antifolate Drugs 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000004052 folic acid antagonist Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 230000010534 mechanism of action Effects 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 238000010369 molecular cloning Methods 0.000 description 5
- 229940127073 nucleoside analogue Drugs 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 108091092562 ribozyme Proteins 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 108091006024 signal transducing proteins Proteins 0.000 description 5
- 102000034285 signal transducing proteins Human genes 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- ZEKJSNVOQKQOFO-LYFYHCNISA-N 2-amino-9-[(1s,3r,4s)-3-hydroxy-4-(hydroxymethyl)cyclopentyl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1C[C@@H](O)[C@H](CO)C1 ZEKJSNVOQKQOFO-LYFYHCNISA-N 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- 241000701066 Bovine gammaherpesvirus 4 Species 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 102100032768 Complement receptor type 2 Human genes 0.000 description 4
- 101710160937 DNA replication protein Proteins 0.000 description 4
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 4
- 208000009889 Herpes Simplex Diseases 0.000 description 4
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 4
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 4
- 102100025136 Macrosialin Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- 102000043276 Oncogene Human genes 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 101710118890 Photosystem II reaction center protein Ycf12 Proteins 0.000 description 4
- 241000701037 Rhadinovirus Species 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 4
- GCQYYIHYQMVWLT-HQNLTJAPSA-N Sorivudine Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 GCQYYIHYQMVWLT-HQNLTJAPSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 101710198378 Uncharacterized 10.8 kDa protein in cox-rep intergenic region Proteins 0.000 description 4
- 101710134973 Uncharacterized 9.7 kDa protein in cox-rep intergenic region Proteins 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 4
- 101710098071 Viral protein kinase Proteins 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 4
- 239000012491 analyte Substances 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 230000002457 bidirectional effect Effects 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 125000002837 carbocyclic group Chemical group 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000008045 co-localization Effects 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229960000633 dextran sulfate Drugs 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- ODZBBRURCPAEIQ-PIXDULNESA-N helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 102000052611 human IL6 Human genes 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000007420 reactivation Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 4
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 3
- GWFOVSGRNGAGDL-FSDSQADBSA-N 2-amino-9-[(1r,2r,3s)-2,3-bis(hydroxymethyl)cyclobutyl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1C[C@H](CO)[C@H]1CO GWFOVSGRNGAGDL-FSDSQADBSA-N 0.000 description 3
- 101710115267 ATP synthase protein MI25 Proteins 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 101000977023 Azospirillum brasilense Uncharacterized 17.8 kDa protein in nodG 5'region Proteins 0.000 description 3
- 101000961984 Bacillus thuringiensis Uncharacterized 30.3 kDa protein Proteins 0.000 description 3
- ODZBBRURCPAEIQ-DJLDLDEBSA-N Brivudine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=CBr)=C1 ODZBBRURCPAEIQ-DJLDLDEBSA-N 0.000 description 3
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 3
- 101710149858 C-C chemokine receptor type 7 Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108020004638 Circular DNA Proteins 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 102100031725 Cortactin-binding protein 2 Human genes 0.000 description 3
- 108050006400 Cyclin Proteins 0.000 description 3
- 102000016736 Cyclin Human genes 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- 101000644901 Drosophila melanogaster Putative 115 kDa protein in type-1 retrotransposable element R1DM Proteins 0.000 description 3
- 101000747702 Enterobacteria phage N4 Uncharacterized protein Gp2 Proteins 0.000 description 3
- 241000725578 Equid gammaherpesvirus 2 Species 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 101000758599 Escherichia coli Uncharacterized 14.7 kDa protein Proteins 0.000 description 3
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 101710121996 Hexon protein p72 Proteins 0.000 description 3
- 101000805434 Human herpesvirus 8 type P (isolate GK18) viral cyclin homolog Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 101000768930 Lactococcus lactis subsp. cremoris Uncharacterized protein in pepC 5'region Proteins 0.000 description 3
- 101000976302 Leptospira interrogans Uncharacterized protein in sph 3'region Proteins 0.000 description 3
- 101000778886 Leptospira interrogans serogroup Icterohaemorrhagiae serovar Lai (strain 56601) Uncharacterized protein LA_2151 Proteins 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 101710125418 Major capsid protein Proteins 0.000 description 3
- 101000747945 Marchantia polymorpha Uncharacterized mitochondrial protein ymf34 Proteins 0.000 description 3
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 3
- 241000700560 Molluscum contagiosum virus Species 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 101000783504 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 15.4 kDa protein Proteins 0.000 description 3
- 101000768120 Oryza nivara Uncharacterized protein ycf76 Proteins 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 102100036473 Phosphoribosylformylglycinamidine synthase Human genes 0.000 description 3
- 208000007452 Plasmacytoma Diseases 0.000 description 3
- 101710197985 Probable protein Rev Proteins 0.000 description 3
- 108020004518 RNA Probes Proteins 0.000 description 3
- 239000003391 RNA probe Substances 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 3
- 101001121571 Rice tungro bacilliform virus (isolate Philippines) Protein P2 Proteins 0.000 description 3
- 101000818098 Spirochaeta aurantia Uncharacterized protein in trpE 3'region Proteins 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 101001026590 Streptomyces cinnamonensis Putative polyketide beta-ketoacyl synthase 2 Proteins 0.000 description 3
- 101000750896 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized protein Synpcc7942_2318 Proteins 0.000 description 3
- 101710110895 Uncharacterized 7.3 kDa protein in cox-rep intergenic region Proteins 0.000 description 3
- 108700005077 Viral Genes Proteins 0.000 description 3
- 101000916321 Xenopus laevis Transposon TX1 uncharacterized 149 kDa protein Proteins 0.000 description 3
- 101000760088 Zymomonas mobilis subsp. mobilis (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1) 20.9 kDa protein Proteins 0.000 description 3
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 description 3
- 230000002788 anti-peptide Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229960001169 brivudine Drugs 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000012677 causal agent Substances 0.000 description 3
- 210000004970 cd4 cell Anatomy 0.000 description 3
- 239000002771 cell marker Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 3
- 230000008482 dysregulation Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 230000037433 frameshift Effects 0.000 description 3
- 101150055782 gH gene Proteins 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 229940125721 immunosuppressive agent Drugs 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 102000010681 interleukin-8 receptors Human genes 0.000 description 3
- 108010038415 interleukin-8 receptors Proteins 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 238000007899 nucleic acid hybridization Methods 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 229960003636 vidarabine Drugs 0.000 description 3
- 229960002555 zidovudine Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- UQQHOWKTDKKTHO-ICQCTTRCSA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-5-(6-methoxypurin-9-yl)oxolane-3,4-diol Chemical compound C1=NC=2C(OC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O UQQHOWKTDKKTHO-ICQCTTRCSA-N 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
- LOLNFJHUEIDGNH-PIXDULNESA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-[(e)-2-iodoethenyl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\I)=C1 LOLNFJHUEIDGNH-PIXDULNESA-N 0.000 description 2
- LSIXBBPOJBJQHN-UHFFFAOYSA-N 2,3-Dimethylbicyclo[2.2.1]hept-2-ene Chemical compound C1CC2C(C)=C(C)C1C2 LSIXBBPOJBJQHN-UHFFFAOYSA-N 0.000 description 2
- XHXFQGAZAVKMFF-UHFFFAOYSA-N 2-(2,6-diaminopurin-9-yl)ethoxymethylphosphonic acid Chemical compound NC1=NC(N)=C2N=CN(CCOCP(O)(O)=O)C2=N1 XHXFQGAZAVKMFF-UHFFFAOYSA-N 0.000 description 2
- AJKVQEKCUACUMD-UHFFFAOYSA-N 2-Acetylpyridine Chemical class CC(=O)C1=CC=CC=N1 AJKVQEKCUACUMD-UHFFFAOYSA-N 0.000 description 2
- OKQHSIGMOWQUIK-UHFFFAOYSA-N 2-[(2-aminopurin-9-yl)methoxy]ethanol Chemical compound NC1=NC=C2N=CN(COCCO)C2=N1 OKQHSIGMOWQUIK-UHFFFAOYSA-N 0.000 description 2
- BCSLVBZWCFTDPK-UDJQAZALSA-N 2-amino-9-[(2r,3r,4s)-3,4-bis(hydroxymethyl)oxetan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](CO)[C@H]1CO BCSLVBZWCFTDPK-UDJQAZALSA-N 0.000 description 2
- MTVWFVDWRVYDOR-UHFFFAOYSA-N 3,4-Dihydroxyphenylglycol Chemical compound OCC(O)C1=CC=C(O)C(O)=C1 MTVWFVDWRVYDOR-UHFFFAOYSA-N 0.000 description 2
- LHYQAEFVHIZFLR-UHFFFAOYSA-L 4-(4-diazonio-3-methoxyphenyl)-2-methoxybenzenediazonium;dichloride Chemical compound [Cl-].[Cl-].C1=C([N+]#N)C(OC)=CC(C=2C=C(OC)C([N+]#N)=CC=2)=C1 LHYQAEFVHIZFLR-UHFFFAOYSA-L 0.000 description 2
- QHTFEANXLNNBOX-UHFFFAOYSA-N 8-methyl-7-propanoyl-11h-indolizino[1,2-b]quinolin-9-one Chemical compound C1=CC=C2C=C(CN3C4=CC(=C(C3=O)C)C(=O)CC)C4=NC2=C1 QHTFEANXLNNBOX-UHFFFAOYSA-N 0.000 description 2
- FBHWXSOQXQBXER-UHFFFAOYSA-N 9-[1,3-di(propan-2-yloxy)propan-2-yloxymethyl]purin-2-amine Chemical compound N1=C(N)N=C2N(COC(COC(C)C)COC(C)C)C=NC2=C1 FBHWXSOQXQBXER-UHFFFAOYSA-N 0.000 description 2
- 101000748061 Acholeplasma phage L2 Uncharacterized 16.1 kDa protein Proteins 0.000 description 2
- 101000818089 Acholeplasma phage L2 Uncharacterized 25.6 kDa protein Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 108090000668 Annexin A2 Proteins 0.000 description 2
- 108090000669 Annexin A4 Proteins 0.000 description 2
- 102100034278 Annexin A6 Human genes 0.000 description 2
- 101000748781 Anthoceros angustus Uncharacterized 3.0 kDa protein in psbT-psbN intergenic region Proteins 0.000 description 2
- 101100480489 Arabidopsis thaliana TAAC gene Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101100214868 Autographa californica nuclear polyhedrosis virus AC54 gene Proteins 0.000 description 2
- 101100074342 Autographa californica nuclear polyhedrosis virus LEF-11 gene Proteins 0.000 description 2
- 101100351191 Autographa californica nuclear polyhedrosis virus PCNA gene Proteins 0.000 description 2
- 101000743047 Autographa californica nuclear polyhedrosis virus Protein AC23 Proteins 0.000 description 2
- 101000770875 Autographa californica nuclear polyhedrosis virus Uncharacterized 14.2 kDa protein in PK1-LEF1 intergenic region Proteins 0.000 description 2
- 101150013616 BHRF1 gene Proteins 0.000 description 2
- 101150074429 BKRF4 gene Proteins 0.000 description 2
- 101000736076 Bacillus subtilis (strain 168) Uncharacterized protein YcbR Proteins 0.000 description 2
- 101000786247 Bacillus subtilis (strain 168) Uncharacterized protein YqaT Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 101000774107 Borrelia burgdorferi (strain ATCC 35210 / B31 / CIP 102532 / DSM 4680) Uncharacterized protein BB_0266 Proteins 0.000 description 2
- 101000631235 Borrelia burgdorferi (strain ATCC 35210 / B31 / CIP 102532 / DSM 4680) Uncharacterized protein BB_0268 Proteins 0.000 description 2
- 108010040471 CC Chemokines Proteins 0.000 description 2
- 102000001902 CC Chemokines Human genes 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
- 101000736909 Campylobacter jejuni Probable nucleotidyltransferase Proteins 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 208000005024 Castleman disease Diseases 0.000 description 2
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 2
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 2
- 101000748745 Chlamydomonas reinhardtii Uncharacterized 6.2 kDa protein in psaC-petL intergenic region Proteins 0.000 description 2
- 101000626907 Chlamydomonas reinhardtii Uncharacterized 7.3 kDa protein in petA 5'region Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- 101000947615 Clostridium perfringens Uncharacterized 38.4 kDa protein Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 102100039200 Constitutive coactivator of PPAR-gamma-like protein 2 Human genes 0.000 description 2
- 101000792449 Cyanophora paradoxa Uncharacterized 3.4 kDa protein in atpE-petA intergenic region Proteins 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical group C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 102100023933 Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial Human genes 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102100024101 DnaJ homolog subfamily C member 28 Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101000747774 Enterobacteria phage 82 Uncharacterized protein in rusA 3'region Proteins 0.000 description 2
- 101000964391 Enterococcus faecalis UPF0145 protein Proteins 0.000 description 2
- 101100173936 Escherichia coli (strain K12) flmA gene Proteins 0.000 description 2
- 101000748786 Euglena longa Uncharacterized 7.2 kDa protein in rps2-rps9 intergenic region Proteins 0.000 description 2
- 101000792446 Euglena longa Uncharacterized 8.7 kDa protein in rpl22-rpl23 intergenic region Proteins 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101710181600 Glycoprotein gp2 Proteins 0.000 description 2
- 101000626903 Guillardia theta Uncharacterized 6.1 kDa protein Proteins 0.000 description 2
- 101000792437 Guillardia theta Uncharacterized 7.8 kDa protein Proteins 0.000 description 2
- 101000933958 Haemophilus phage HP1 (strain HP1c1) Major capsid protein Proteins 0.000 description 2
- 101000743338 Haemophilus phage HP1 (strain HP1c1) Probable head completion/stabilization protein Proteins 0.000 description 2
- 101001052021 Haemophilus phage HP1 (strain HP1c1) Probable tail fiber protein Proteins 0.000 description 2
- 101000854890 Haemophilus phage HP1 (strain HP1c1) Probable terminase, ATPase subunit Proteins 0.000 description 2
- 101000743335 Haemophilus phage HP1 (strain HP1c1) Probable terminase, endonuclease subunit Proteins 0.000 description 2
- 101000748063 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 11.1 kDa protein in rep-hol intergenic region Proteins 0.000 description 2
- 101000758973 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 11.3 kDa protein in lys 3'region Proteins 0.000 description 2
- 101000758963 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 12.7 kDa protein in lys 3'region Proteins 0.000 description 2
- 101000976893 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 14.1 kDa protein in cox-rep intergenic region Proteins 0.000 description 2
- 101000786921 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 26.0 kDa protein in rep-hol intergenic region Proteins 0.000 description 2
- 101000768945 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 7.9 kDa protein in int-C1 intergenic region Proteins 0.000 description 2
- 101000748060 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.3 kDa protein in rep-hol intergenic region Proteins 0.000 description 2
- 101000768938 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.9 kDa protein in int-C1 intergenic region Proteins 0.000 description 2
- 101000977016 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.9 kDa protein in int-C1 intergenic region Proteins 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 241000175212 Herpesvirales Species 0.000 description 2
- 101000623276 Herpetosiphon aurantiacus Uncharacterized 10.2 kDa protein in HgiBIM 5'region Proteins 0.000 description 2
- 101000623175 Herpetosiphon aurantiacus Uncharacterized 10.2 kDa protein in HgiCIIM 5'region Proteins 0.000 description 2
- 101000626850 Herpetosiphon aurantiacus Uncharacterized 10.2 kDa protein in HgiEIM 5'region Proteins 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000946926 Homo sapiens C-C chemokine receptor type 5 Proteins 0.000 description 2
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 2
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 2
- 101001053999 Homo sapiens DnaJ homolog subfamily C member 28 Proteins 0.000 description 2
- 101001032345 Homo sapiens Interferon regulatory factor 8 Proteins 0.000 description 2
- 101001028836 Homo sapiens M-phase-specific PLK1-interacting protein Proteins 0.000 description 2
- 101000652805 Homo sapiens Protein shisa-8 Proteins 0.000 description 2
- 101000820589 Homo sapiens Succinate-hydroxymethylglutarate CoA-transferase Proteins 0.000 description 2
- 101000667300 Homo sapiens WD repeat-containing protein 19 Proteins 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 101100122503 Human herpesvirus 6A (strain Uganda-1102) gN gene Proteins 0.000 description 2
- 101100064352 Human herpesvirus 8 type P (isolate GK18) DUT gene Proteins 0.000 description 2
- 101001120831 Human herpesvirus 8 type P (isolate GK18) E3 ubiquitin-protein ligase MIR2 Proteins 0.000 description 2
- 101100540534 Human herpesvirus 8 type P (isolate GK18) ORF K4 gene Proteins 0.000 description 2
- 101100283436 Human herpesvirus 8 type P (isolate GK18) gM gene Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 102100029838 Interferon regulatory factor 2 Human genes 0.000 description 2
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 description 2
- 101000578717 Klebsiella pneumoniae Mannose-1-phosphate guanylyltransferase Proteins 0.000 description 2
- 101000957786 Klebsiella pneumoniae Phosphomannomutase Proteins 0.000 description 2
- 101000790838 Klebsiella pneumoniae UPF0053 protein in cps region Proteins 0.000 description 2
- 101000790837 Klebsiella pneumoniae Uncharacterized 18.9 kDa protein in cps region Proteins 0.000 description 2
- 101000790840 Klebsiella pneumoniae Uncharacterized 49.5 kDa protein in cps region Proteins 0.000 description 2
- 101000768313 Klebsiella pneumoniae Uncharacterized membrane protein in cps region Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical group [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 2
- 101000904276 Lactococcus phage P008 Gene product 38 Proteins 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 101000756286 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized 10.9 kDa protein in LEF8-FP intergenic region Proteins 0.000 description 2
- 102100037185 M-phase-specific PLK1-interacting protein Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 101000626970 Marchantia polymorpha Uncharacterized 3.3 kDa protein in psbT-psbN intergenic region Proteins 0.000 description 2
- 101000626905 Marchantia polymorpha Uncharacterized 3.8 kDa protein in ycf12-psaM intergenic region Proteins 0.000 description 2
- 101000748779 Marchantia polymorpha Uncharacterized 6.4 kDa protein in atpA-psbA intergenic region Proteins 0.000 description 2
- 101000788487 Marchantia polymorpha Uncharacterized mitochondrial protein ymf25 Proteins 0.000 description 2
- 101000788489 Marchantia polymorpha Uncharacterized mitochondrial protein ymf26 Proteins 0.000 description 2
- 101000747949 Marchantia polymorpha Uncharacterized mitochondrial protein ymf32 Proteins 0.000 description 2
- 101710159527 Maturation protein A Proteins 0.000 description 2
- 101710091157 Maturation protein A2 Proteins 0.000 description 2
- 101000804418 Methanothermobacter thermautotrophicus (strain ATCC 29096 / DSM 1053 / JCM 10044 / NBRC 100330 / Delta H) Uncharacterized protein MTH_1463 Proteins 0.000 description 2
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
- 101000823719 Nicotiana tabacum Putative uncharacterized protein ycf15 Proteins 0.000 description 2
- 101100521838 Nicotiana tabacum pbf1 gene Proteins 0.000 description 2
- 101150020791 ORF37 gene Proteins 0.000 description 2
- 101150016564 ORF39 gene Proteins 0.000 description 2
- 101150075249 ORF40 gene Proteins 0.000 description 2
- 101150006817 ORF43 gene Proteins 0.000 description 2
- 101150050790 ORF49 gene Proteins 0.000 description 2
- 101150104094 ORF52 gene Proteins 0.000 description 2
- 101150098690 ORF54 gene Proteins 0.000 description 2
- 101100389785 Orgyia pseudotsugata multicapsid polyhedrosis virus ETM gene Proteins 0.000 description 2
- 101100306237 Orgyia pseudotsugata multicapsid polyhedrosis virus LEF-8 gene Proteins 0.000 description 2
- 101000666843 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 24.0 kDa protein Proteins 0.000 description 2
- 101000770899 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 24.3 kDa protein Proteins 0.000 description 2
- 101000770870 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 37.2 kDa protein Proteins 0.000 description 2
- 101710160107 Outer membrane protein A Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 101100378791 Paenarthrobacter nicotinovorans aldh gene Proteins 0.000 description 2
- 101100156835 Paenarthrobacter nicotinovorans xdh gene Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010089430 Phosphoproteins Proteins 0.000 description 2
- 102000007982 Phosphoproteins Human genes 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 101100481711 Pneumococcus phage Dp-1 TMP gene Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 101000764206 Porphyra purpurea Uncharacterized protein in rpl9-rpl11 intergenic region Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102000007327 Protamines Human genes 0.000 description 2
- 108010007568 Protamines Proteins 0.000 description 2
- 102100040307 Protein FAM3B Human genes 0.000 description 2
- 101000748499 Rhodobacter capsulatus Uncharacterized 104.1 kDa protein in hypE 3'region Proteins 0.000 description 2
- 101000748505 Rhodobacter capsulatus Uncharacterized 16.1 kDa protein in hypE 3'region Proteins 0.000 description 2
- 101000827754 Rhodobacter capsulatus Uncharacterized 5.8 kDa protein in puhA 5'region Proteins 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 101000814063 Salmonella phage P22 Uncharacterized 6.6 kDa protein in eae-abc2 intergenic region Proteins 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 101000708364 Streptomyces griseus Uncharacterized 31.2 kDa protein in rplA-rplJ intergenic region Proteins 0.000 description 2
- 102100021652 Succinate-hydroxymethylglutarate CoA-transferase Human genes 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 101000764204 Trieres chinensis Uncharacterized 3.3 kDa protein in rpl11-trnW intergenic region Proteins 0.000 description 2
- 101000792450 Trieres chinensis Uncharacterized 4.7 kDa protein in ycf33-trnY intergenic region Proteins 0.000 description 2
- 101000768114 Triticum aestivum Uncharacterized protein ycf70 Proteins 0.000 description 2
- 101710173665 Uncharacterized 5.8 kDa protein Proteins 0.000 description 2
- 101710172361 Uncharacterized protein ycf17 Proteins 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 102100039744 WD repeat-containing protein 19 Human genes 0.000 description 2
- FRPXSOOHWNMLPH-LURJTMIESA-N [(2s)-1-(6-aminopurin-9-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid Chemical compound NC1=NC=NC2=C1N=CN2C[C@@H](CO)OCP(O)(O)=O FRPXSOOHWNMLPH-LURJTMIESA-N 0.000 description 2
- 210000005221 acidic domain Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 108010070944 alanylhistidine Proteins 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000003443 anti-oncogenic effect Effects 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 102000055102 bcl-2-Associated X Human genes 0.000 description 2
- 108700000707 bcl-2-Associated X Proteins 0.000 description 2
- KQHXBDOEECKORE-UHFFFAOYSA-L beryllium sulfate Chemical compound [Be+2].[O-]S([O-])(=O)=O KQHXBDOEECKORE-UHFFFAOYSA-L 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 108091092356 cellular DNA Proteins 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960003677 chloroquine Drugs 0.000 description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000002967 competitive immunoassay Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 2
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 2
- 108010011219 dUTP pyrophosphatase Proteins 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 102000048160 human CCR5 Human genes 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 108010012058 leucyltyrosine Proteins 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 108091008819 oncoproteins Proteins 0.000 description 2
- 229940042443 other antivirals in atc Drugs 0.000 description 2
- 229960005030 other vaccine in atc Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 2
- 150000004633 phorbol derivatives Chemical class 0.000 description 2
- 239000002644 phorbol ester Substances 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229940048914 protamine Drugs 0.000 description 2
- 208000009305 pseudorabies Diseases 0.000 description 2
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 2
- 239000002212 purine nucleoside Substances 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229950009279 sorivudine Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 108010061238 threonyl-glycine Proteins 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 2
- 229950003873 triciribine Drugs 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- DFHAXXVZCFXGOQ-UHFFFAOYSA-K trisodium phosphonoformate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)P([O-])([O-])=O DFHAXXVZCFXGOQ-UHFFFAOYSA-K 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000010464 virion assembly Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- YZMVLKJJJCMVGX-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline-2,4-dione Chemical class C1=CC=C2NC(=O)CC(=O)C2=C1 YZMVLKJJJCMVGX-UHFFFAOYSA-N 0.000 description 1
- SJCDBQHCQSIZHN-UHFFFAOYSA-N 1,2-dihydrotriazole-3-carboxamide Chemical compound NC(=O)N1NNC=C1 SJCDBQHCQSIZHN-UHFFFAOYSA-N 0.000 description 1
- IPVFGAYTKQKGBM-BYPJNBLXSA-N 1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 IPVFGAYTKQKGBM-BYPJNBLXSA-N 0.000 description 1
- PCDQBRGMSMVLDZ-IQJOONFLSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-thiophen-2-ylpyrimidine-2,4-dione Chemical class C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=2SC=CC=2)=C1 PCDQBRGMSMVLDZ-IQJOONFLSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FXEDIXLHKQINFP-UHFFFAOYSA-N 12-O-tetradecanoylphorbol-13-acetate Natural products CCCCCCCCCCCCCC(=O)OC1CC2(O)C(C=C(CO)CC3(O)C2C=C(C)C3=O)C4C(C)(C)C14OC(=O)C FXEDIXLHKQINFP-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- CULZQHDSLBXFDU-UHFFFAOYSA-N 2-amino-n-formylacetamide Chemical compound NCC(=O)NC=O CULZQHDSLBXFDU-UHFFFAOYSA-N 0.000 description 1
- UTCHNZLBVKHYKC-UHFFFAOYSA-N 2-hydroxy-2-phosphonoacetic acid Chemical class OC(=O)C(O)P(O)(O)=O UTCHNZLBVKHYKC-UHFFFAOYSA-N 0.000 description 1
- BLZBVHFRNUTFCH-UHFFFAOYSA-N 3-(6-aminopurin-9-yl)propan-1-ol Chemical compound NC1=NC=NC2=C1N=CN2CCCO BLZBVHFRNUTFCH-UHFFFAOYSA-N 0.000 description 1
- DUJGMZAICVPCBJ-VDAHYXPESA-N 4-amino-1-[(1r,4r,5s)-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)C(CO)=C1 DUJGMZAICVPCBJ-VDAHYXPESA-N 0.000 description 1
- GIMSJJHKKXRFGV-BYPJNBLXSA-N 4-amino-1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidin-2-one Chemical compound C1=C(I)C(N)=NC(=O)N1[C@H]1[C@@H](F)[C@H](O)[C@@H](CO)O1 GIMSJJHKKXRFGV-BYPJNBLXSA-N 0.000 description 1
- PXJDBUCDNZAPJK-RRKCRQDMSA-N 4-amino-1-[(2r,4s,5r)-5-(aminomethyl)-4-hydroxyoxolan-2-yl]-5-iodopyrimidin-2-one Chemical compound C1[C@H](O)[C@@H](CN)O[C@H]1N1C(=O)N=C(N)C(I)=C1 PXJDBUCDNZAPJK-RRKCRQDMSA-N 0.000 description 1
- YXQUGSXUDFTPLL-LURJTMIESA-N 4-amino-1-[[(5s)-2-hydroxy-2-oxo-1,4,2$l^{5}-dioxaphosphinan-5-yl]methyl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1C[C@@H]1OCP(O)(=O)OC1 YXQUGSXUDFTPLL-LURJTMIESA-N 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- UWDMKTDPDJCJOP-UHFFFAOYSA-N 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ium-4-carboxylate Chemical compound CC1(C)CC(O)(C(O)=O)CC(C)(C)N1 UWDMKTDPDJCJOP-UHFFFAOYSA-N 0.000 description 1
- RQZRQHNKLHIOQI-VAOFZXAKSA-N 5-(5-chlorothiophen-2-yl)-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=2SC(Cl)=CC=2)=C1 RQZRQHNKLHIOQI-VAOFZXAKSA-N 0.000 description 1
- IGUZFFOBAZCVRK-VAOFZXAKSA-N 5-bromothienyldeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=2SC(Br)=CC=2)=C1 IGUZFFOBAZCVRK-VAOFZXAKSA-N 0.000 description 1
- SWFJAJRDLUUIOA-IBCQBUCCSA-N 5-ethyl-1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(CC)=CN1[C@H]1[C@@H](F)[C@H](O)[C@@H](CO)O1 SWFJAJRDLUUIOA-IBCQBUCCSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- DSOJUSIKEHUEGN-UHFFFAOYSA-N 9-(ethoxymethyl)purin-2-amine Chemical compound N1=C(N)N=C2N(COCC)C=NC2=C1 DSOJUSIKEHUEGN-UHFFFAOYSA-N 0.000 description 1
- LNUMZUZGQXHRIL-LURJTMIESA-N 9-[[(5s)-2-hydroxy-2-oxo-1,4,2$l^{5}-dioxaphosphinan-5-yl]methyl]purin-6-amine Chemical compound C1=NC=2C(N)=NC=NC=2N1C[C@H]1COP(O)(=O)CO1 LNUMZUZGQXHRIL-LURJTMIESA-N 0.000 description 1
- 101000977065 Acidithiobacillus ferridurans Uncharacterized 11.6 kDa protein in mobS 3'region Proteins 0.000 description 1
- 101000708563 Acidithiobacillus ferrooxidans Uncharacterized 9.0 kDa protein in mobE 3'region Proteins 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- WYPUMLRSQMKIJU-BPNCWPANSA-N Ala-Arg-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O WYPUMLRSQMKIJU-BPNCWPANSA-N 0.000 description 1
- KIUYPHAMDKDICO-WHFBIAKZSA-N Ala-Asp-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O KIUYPHAMDKDICO-WHFBIAKZSA-N 0.000 description 1
- ZIWWTZWAKYBUOB-CIUDSAMLSA-N Ala-Asp-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O ZIWWTZWAKYBUOB-CIUDSAMLSA-N 0.000 description 1
- ZPXCNXMJEZKRLU-LSJOCFKGSA-N Ala-His-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CN=CN1 ZPXCNXMJEZKRLU-LSJOCFKGSA-N 0.000 description 1
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
- VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 1
- IORKCNUBHNIMKY-CIUDSAMLSA-N Ala-Pro-Glu Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O IORKCNUBHNIMKY-CIUDSAMLSA-N 0.000 description 1
- SYIFFFHSXBNPMC-UWJYBYFXSA-N Ala-Ser-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N SYIFFFHSXBNPMC-UWJYBYFXSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241001439211 Almeida Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- PBSOQGZLPFVXPU-YUMQZZPRSA-N Arg-Glu-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PBSOQGZLPFVXPU-YUMQZZPRSA-N 0.000 description 1
- SKTGPBFTMNLIHQ-KKUMJFAQSA-N Arg-Glu-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SKTGPBFTMNLIHQ-KKUMJFAQSA-N 0.000 description 1
- OQCWXQJLCDPRHV-UWVGGRQHSA-N Arg-Gly-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O OQCWXQJLCDPRHV-UWVGGRQHSA-N 0.000 description 1
- NKNILFJYKKHBKE-WPRPVWTQSA-N Arg-Gly-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O NKNILFJYKKHBKE-WPRPVWTQSA-N 0.000 description 1
- OTZMRMHZCMZOJZ-SRVKXCTJSA-N Arg-Leu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OTZMRMHZCMZOJZ-SRVKXCTJSA-N 0.000 description 1
- RTDZQOFEGPWSJD-AVGNSLFASA-N Arg-Leu-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O RTDZQOFEGPWSJD-AVGNSLFASA-N 0.000 description 1
- VIINVRPKMUZYOI-DCAQKATOSA-N Arg-Met-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O VIINVRPKMUZYOI-DCAQKATOSA-N 0.000 description 1
- IJYZHIOOBGIINM-WDSKDSINSA-N Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N IJYZHIOOBGIINM-WDSKDSINSA-N 0.000 description 1
- FTCGGKNCJZOPNB-WHFBIAKZSA-N Asn-Gly-Ser Chemical compound NC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FTCGGKNCJZOPNB-WHFBIAKZSA-N 0.000 description 1
- SVFOIXMRMLROHO-SRVKXCTJSA-N Asp-Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SVFOIXMRMLROHO-SRVKXCTJSA-N 0.000 description 1
- RWHHSFSWKFBTCF-KKUMJFAQSA-N Asp-His-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(=O)O)N RWHHSFSWKFBTCF-KKUMJFAQSA-N 0.000 description 1
- AYFVRYXNDHBECD-YUMQZZPRSA-N Asp-Leu-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AYFVRYXNDHBECD-YUMQZZPRSA-N 0.000 description 1
- UXIPUCUHQBIQOS-SRVKXCTJSA-N Asp-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O UXIPUCUHQBIQOS-SRVKXCTJSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 101000666833 Autographa californica nuclear polyhedrosis virus Uncharacterized 20.8 kDa protein in FGF-VUBI intergenic region Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 101000977027 Azospirillum brasilense Uncharacterized protein in nodG 5'region Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 101150112145 B16L gene Proteins 0.000 description 1
- 101150100241 BBLF1 gene Proteins 0.000 description 1
- 101150059303 BBRF1 gene Proteins 0.000 description 1
- 101150106783 BBRF2 gene Proteins 0.000 description 1
- 101150003602 BDLF2 gene Proteins 0.000 description 1
- 101150097170 BGLF2 gene Proteins 0.000 description 1
- 101150112338 BLRF2 gene Proteins 0.000 description 1
- 101150062763 BMRF1 gene Proteins 0.000 description 1
- 101150000167 BMRF2 gene Proteins 0.000 description 1
- 101150118014 BNRF1 gene Proteins 0.000 description 1
- 101150113819 BOLF1 gene Proteins 0.000 description 1
- 101150015024 BPLF1 gene Proteins 0.000 description 1
- 101150078891 BRLF1 gene Proteins 0.000 description 1
- 101150008118 BRRF1 gene Proteins 0.000 description 1
- 101150070472 BRRF2 gene Proteins 0.000 description 1
- 101150047566 BSRF1 gene Proteins 0.000 description 1
- 101150072951 BTRF1 gene Proteins 0.000 description 1
- 101150065426 BVRF2 gene Proteins 0.000 description 1
- 101100138645 Bacillus licheniformis pelA gene Proteins 0.000 description 1
- 101000765606 Bacillus subtilis (strain 168) FlaA locus uncharacterized protein YlxG Proteins 0.000 description 1
- 101000962005 Bacillus thuringiensis Uncharacterized 23.6 kDa protein Proteins 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 102100023701 C-C motif chemokine 18 Human genes 0.000 description 1
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 108091028690 C-myc mRNA Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108010018956 CTP synthetase Proteins 0.000 description 1
- 101150010802 CVC2 gene Proteins 0.000 description 1
- 101100039010 Caenorhabditis elegans dis-3 gene Proteins 0.000 description 1
- 101100338243 Caenorhabditis elegans hil-6 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010082155 Chemokine CCL18 Proteins 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 101000861180 Cupriavidus necator (strain ATCC 17699 / DSM 428 / KCTC 22496 / NCIMB 10442 / H16 / Stanier 337) Uncharacterized protein H16_B0147 Proteins 0.000 description 1
- 101000861181 Cupriavidus necator (strain ATCC 17699 / DSM 428 / KCTC 22496 / NCIMB 10442 / H16 / Stanier 337) Uncharacterized protein H16_B0148 Proteins 0.000 description 1
- 101000748771 Cuscuta reflexa Uncharacterized 6.8 kDa protein in trnL 3'region Proteins 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 101150116298 D12L gene Proteins 0.000 description 1
- 101150026402 DBP gene Proteins 0.000 description 1
- HOOWCUZPEFNHDT-UHFFFAOYSA-N DHPG Natural products OC(=O)C(N)C1=CC(O)=CC(O)=C1 HOOWCUZPEFNHDT-UHFFFAOYSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000016559 DNA Primase Human genes 0.000 description 1
- 108010092681 DNA Primase Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101150040913 DUT gene Proteins 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical class CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101000785191 Drosophila melanogaster Uncharacterized 50 kDa protein in type I retrotransposable element R1DM Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108700039964 Duplicate Genes Proteins 0.000 description 1
- 101710104129 E3 ubiquitin-protein ligase MIR1 Proteins 0.000 description 1
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 206010063045 Effusion Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101000747704 Enterobacteria phage N4 Uncharacterized protein Gp1 Proteins 0.000 description 1
- 101000861206 Enterococcus faecalis (strain ATCC 700802 / V583) Uncharacterized protein EF_A0048 Proteins 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 101710122228 Epstein-Barr nuclear antigen 2 Proteins 0.000 description 1
- 101710147543 Epstein-Barr nuclear antigen leader protein Proteins 0.000 description 1
- 101100487860 Epstein-Barr virus (strain B95-8) BBLF2 gene Proteins 0.000 description 1
- 101100493802 Epstein-Barr virus (strain B95-8) BDLF3 gene Proteins 0.000 description 1
- 101100316060 Epstein-Barr virus (strain B95-8) BFLF1 gene Proteins 0.000 description 1
- 101100004334 Epstein-Barr virus (strain B95-8) BFRF2 gene Proteins 0.000 description 1
- 101100208858 Epstein-Barr virus (strain B95-8) BGLF3 gene Proteins 0.000 description 1
- 101100191368 Epstein-Barr virus (strain B95-8) BSLF1 gene Proteins 0.000 description 1
- 101100208832 Epstein-Barr virus (strain B95-8) BXRF1 gene Proteins 0.000 description 1
- 101100070290 Epstein-Barr virus (strain B95-8) HELI gene Proteins 0.000 description 1
- 101100026179 Epstein-Barr virus (strain B95-8) NEC2 gene Proteins 0.000 description 1
- 101100476885 Epstein-Barr virus (strain B95-8) SCP gene Proteins 0.000 description 1
- 101100261341 Epstein-Barr virus (strain B95-8) TRM1 gene Proteins 0.000 description 1
- 101100261978 Epstein-Barr virus (strain B95-8) TRX1 gene Proteins 0.000 description 1
- 101100538619 Epstein-Barr virus (strain B95-8) TRX2 gene Proteins 0.000 description 1
- 101100155425 Epstein-Barr virus (strain B95-8) UNG gene Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 101100192384 Escherichia coli (strain K12) manY gene Proteins 0.000 description 1
- 101000769180 Escherichia coli Uncharacterized 11.1 kDa protein Proteins 0.000 description 1
- 101000947627 Escherichia coli Uncharacterized 5.3 kDa protein Proteins 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102000011652 Formyl peptide receptors Human genes 0.000 description 1
- 108010076288 Formyl peptide receptors Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 101150065273 GN gene Proteins 0.000 description 1
- 229940126656 GS-4224 Drugs 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- YBAFDPFAUTYYRW-YUMQZZPRSA-N Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O YBAFDPFAUTYYRW-YUMQZZPRSA-N 0.000 description 1
- FBEJIDRSQCGFJI-GUBZILKMSA-N Glu-Leu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O FBEJIDRSQCGFJI-GUBZILKMSA-N 0.000 description 1
- YBTCBQBIJKGSJP-BQBZGAKWSA-N Glu-Pro Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O YBTCBQBIJKGSJP-BQBZGAKWSA-N 0.000 description 1
- UMZHHILWZBFPGL-LOKLDPHHSA-N Glu-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O UMZHHILWZBFPGL-LOKLDPHHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 241000720950 Gluta Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- KQDMENMTYNBWMR-WHFBIAKZSA-N Gly-Asp-Ala Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O KQDMENMTYNBWMR-WHFBIAKZSA-N 0.000 description 1
- ZRZILYKEJBMFHY-BQBZGAKWSA-N Gly-Asp-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CN ZRZILYKEJBMFHY-BQBZGAKWSA-N 0.000 description 1
- NSTUFLGQJCOCDL-UWVGGRQHSA-N Gly-Leu-Arg Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NSTUFLGQJCOCDL-UWVGGRQHSA-N 0.000 description 1
- CCBIBMKQNXHNIN-ZETCQYMHSA-N Gly-Leu-Gly Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CCBIBMKQNXHNIN-ZETCQYMHSA-N 0.000 description 1
- GAFKBWKVXNERFA-QWRGUYRKSA-N Gly-Phe-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 GAFKBWKVXNERFA-QWRGUYRKSA-N 0.000 description 1
- OHUKZZYSJBKFRR-WHFBIAKZSA-N Gly-Ser-Asp Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O OHUKZZYSJBKFRR-WHFBIAKZSA-N 0.000 description 1
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 1
- FNXSYBOHALPRHV-ONGXEEELSA-N Gly-Val-Lys Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN FNXSYBOHALPRHV-ONGXEEELSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000626971 Guillardia theta Uncharacterized 8.1 kDa protein Proteins 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 101000708358 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 23.3 kDa protein in lys 3'region Proteins 0.000 description 1
- 101000948764 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 58.7 kDa protein in lys 3'region Proteins 0.000 description 1
- 208000005794 Hairy Leukoplakia Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000000903 Herpes simplex encephalitis Diseases 0.000 description 1
- 206010019972 Herpes viral infections Diseases 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 101000626607 Herpetosiphon aurantiacus Putative type II restriction enzyme HgiDII Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- TXLQHACKRLWYCM-DCAQKATOSA-N His-Glu-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O TXLQHACKRLWYCM-DCAQKATOSA-N 0.000 description 1
- STWGDDDFLUFCCA-GVXVVHGQSA-N His-Glu-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O STWGDDDFLUFCCA-GVXVVHGQSA-N 0.000 description 1
- CCUSLCQWVMWTIS-IXOXFDKPSA-N His-Thr-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O CCUSLCQWVMWTIS-IXOXFDKPSA-N 0.000 description 1
- GBMSSORHVHAYLU-QTKMDUPCSA-N His-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CN=CN1)N)O GBMSSORHVHAYLU-QTKMDUPCSA-N 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 1
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 description 1
- 101001032341 Homo sapiens Interferon regulatory factor 9 Proteins 0.000 description 1
- 101001072338 Homo sapiens Proliferating cell nuclear antigen Proteins 0.000 description 1
- 101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
- 101000625842 Homo sapiens Tubulin-specific chaperone E Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000235789 Hyperoartia Species 0.000 description 1
- 108010087227 IMP Dehydrogenase Proteins 0.000 description 1
- 102000006674 IMP dehydrogenase Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102000004289 Interferon regulatory factor 1 Human genes 0.000 description 1
- 108090000890 Interferon regulatory factor 1 Proteins 0.000 description 1
- 108090000908 Interferon regulatory factor 2 Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 108700042652 LMP-2 Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 101710192602 Latent membrane protein 1 Proteins 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- 101000976301 Leptospira interrogans Uncharacterized 35 kDa protein in sph 3'region Proteins 0.000 description 1
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 1
- HASRFYOMVPJRPU-SRVKXCTJSA-N Leu-Arg-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O HASRFYOMVPJRPU-SRVKXCTJSA-N 0.000 description 1
- UCOCBWDBHCUPQP-DCAQKATOSA-N Leu-Arg-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O UCOCBWDBHCUPQP-DCAQKATOSA-N 0.000 description 1
- YKNBJXOJTURHCU-DCAQKATOSA-N Leu-Asp-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YKNBJXOJTURHCU-DCAQKATOSA-N 0.000 description 1
- NFHJQETXTSDZSI-DCAQKATOSA-N Leu-Cys-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NFHJQETXTSDZSI-DCAQKATOSA-N 0.000 description 1
- IFMPDNRWZZEZSL-SRVKXCTJSA-N Leu-Leu-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(O)=O IFMPDNRWZZEZSL-SRVKXCTJSA-N 0.000 description 1
- IEWBEPKLKUXQBU-VOAKCMCISA-N Leu-Leu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IEWBEPKLKUXQBU-VOAKCMCISA-N 0.000 description 1
- LVTJJOJKDCVZGP-QWRGUYRKSA-N Leu-Lys-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O LVTJJOJKDCVZGP-QWRGUYRKSA-N 0.000 description 1
- IDGZVZJLYFTXSL-DCAQKATOSA-N Leu-Ser-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IDGZVZJLYFTXSL-DCAQKATOSA-N 0.000 description 1
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 1
- SQUFDMCWMFOEBA-KKUMJFAQSA-N Leu-Ser-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 SQUFDMCWMFOEBA-KKUMJFAQSA-N 0.000 description 1
- ZDJQVSIPFLMNOX-RHYQMDGZSA-N Leu-Thr-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N ZDJQVSIPFLMNOX-RHYQMDGZSA-N 0.000 description 1
- HGLKOTPFWOMPOB-MEYUZBJRSA-N Leu-Thr-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HGLKOTPFWOMPOB-MEYUZBJRSA-N 0.000 description 1
- LFXSPAIBSZSTEM-PMVMPFDFSA-N Leu-Trp-Phe Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)N LFXSPAIBSZSTEM-PMVMPFDFSA-N 0.000 description 1
- LHSGPCFBGJHPCY-STQMWFEESA-N Leu-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-STQMWFEESA-N 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 101000759330 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized protein in LEF8-FP intergenic region Proteins 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- ABHIXYDMILIUKV-CIUDSAMLSA-N Lys-Asn-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ABHIXYDMILIUKV-CIUDSAMLSA-N 0.000 description 1
- HVAUKHLDSDDROB-KKUMJFAQSA-N Lys-Lys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HVAUKHLDSDDROB-KKUMJFAQSA-N 0.000 description 1
- TWPCWKVOZDUYAA-KKUMJFAQSA-N Lys-Phe-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O TWPCWKVOZDUYAA-KKUMJFAQSA-N 0.000 description 1
- 108010066345 MHC binding peptide Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 101000788491 Marchantia polymorpha Uncharacterized mitochondrial protein ymf27 Proteins 0.000 description 1
- 101000747938 Marchantia polymorpha Uncharacterized mitochondrial protein ymf31 Proteins 0.000 description 1
- 241001599018 Melanogaster Species 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- RPEPZINUYHUBKG-FXQIFTODSA-N Met-Cys-Ala Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O RPEPZINUYHUBKG-FXQIFTODSA-N 0.000 description 1
- GPAHWYRSHCKICP-GUBZILKMSA-N Met-Glu-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O GPAHWYRSHCKICP-GUBZILKMSA-N 0.000 description 1
- AFFKUNVPPLQUGA-DCAQKATOSA-N Met-Leu-Ala Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O AFFKUNVPPLQUGA-DCAQKATOSA-N 0.000 description 1
- NTYQUVLERIHPMU-HRCADAONSA-N Met-Phe-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N NTYQUVLERIHPMU-HRCADAONSA-N 0.000 description 1
- 101000982327 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF4a Proteins 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100346764 Mus musculus Mtln gene Proteins 0.000 description 1
- 241001135743 Mycoplasma penetrans Species 0.000 description 1
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 101150041636 NEC1 gene Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 101000658690 Neisseria meningitidis serogroup B Transposase for insertion sequence element IS1106 Proteins 0.000 description 1
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 description 1
- 101100462611 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) prr-1 gene Proteins 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710091700 Non-structural protein ORF4b Proteins 0.000 description 1
- 102100021010 Nucleolin Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 108010023064 ORF 50 transactivator Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 101100069690 Orgyia pseudotsugata multicapsid polyhedrosis virus GTA gene Proteins 0.000 description 1
- 108010055012 Orotidine-5'-phosphate decarboxylase Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- SCKXCAADGDQQCS-UHFFFAOYSA-N Performic acid Chemical compound OOC=O SCKXCAADGDQQCS-UHFFFAOYSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- SHUFSZDAIPLZLF-BEAPCOKYSA-N Phe-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N)O SHUFSZDAIPLZLF-BEAPCOKYSA-N 0.000 description 1
- ZOGICTVLQDWPER-UFYCRDLUSA-N Phe-Tyr-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O ZOGICTVLQDWPER-UFYCRDLUSA-N 0.000 description 1
- VIIRRNQMMIHYHQ-XHSDSOJGSA-N Phe-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N VIIRRNQMMIHYHQ-XHSDSOJGSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100029740 Poliovirus receptor Human genes 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OGRYXQOUFHAMPI-DCAQKATOSA-N Pro-Cys-His Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O OGRYXQOUFHAMPI-DCAQKATOSA-N 0.000 description 1
- VYWNORHENYEQDW-YUMQZZPRSA-N Pro-Gly-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 VYWNORHENYEQDW-YUMQZZPRSA-N 0.000 description 1
- GBRUQFBAJOKCTF-DCAQKATOSA-N Pro-His-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(O)=O GBRUQFBAJOKCTF-DCAQKATOSA-N 0.000 description 1
- YTWNSIDWAFSEEI-RWMBFGLXSA-N Pro-His-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@@H]3C(=O)O YTWNSIDWAFSEEI-RWMBFGLXSA-N 0.000 description 1
- ZVEQWRWMRFIVSD-HRCADAONSA-N Pro-Phe-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N3CCC[C@@H]3C(=O)O ZVEQWRWMRFIVSD-HRCADAONSA-N 0.000 description 1
- PGSWNLRYYONGPE-JYJNAYRXSA-N Pro-Val-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O PGSWNLRYYONGPE-JYJNAYRXSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- 108010087705 Proto-Oncogene Proteins c-myc Proteins 0.000 description 1
- 102000009092 Proto-Oncogene Proteins c-myc Human genes 0.000 description 1
- 101000850960 Pseudomonas phage Pf1 3.2 kDa protein Proteins 0.000 description 1
- 101000808066 Pseudomonas phage Pf3 6.4 kDa protein Proteins 0.000 description 1
- 101000748660 Pseudomonas savastanoi Uncharacterized 21 kDa protein in iaaL 5'region Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 101150093191 RIR1 gene Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 101000584469 Rice tungro bacilliform virus (isolate Philippines) Protein P1 Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101100477602 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SIR3 gene Proteins 0.000 description 1
- 101000953980 Salmonella phage P22 Uncharacterized 7.7 kDa protein in gp5-gp4 intergenic region Proteins 0.000 description 1
- 101000953981 Salmonella phage P22 Uncharacterized 7.8 kDa protein in ral-gp17 intergenic region Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- YUSRGTQIPCJNHQ-CIUDSAMLSA-N Ser-Arg-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O YUSRGTQIPCJNHQ-CIUDSAMLSA-N 0.000 description 1
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 1
- XXNYYSXNXCJYKX-DCAQKATOSA-N Ser-Leu-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O XXNYYSXNXCJYKX-DCAQKATOSA-N 0.000 description 1
- VZQRNAYURWAEFE-KKUMJFAQSA-N Ser-Leu-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 VZQRNAYURWAEFE-KKUMJFAQSA-N 0.000 description 1
- DINQYZRMXGWWTG-GUBZILKMSA-N Ser-Pro-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DINQYZRMXGWWTG-GUBZILKMSA-N 0.000 description 1
- WUXCHQZLUHBSDJ-LKXGYXEUSA-N Ser-Thr-Asp Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC(O)=O)C(O)=O WUXCHQZLUHBSDJ-LKXGYXEUSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 101000792544 Spinacia oleracea Putative uncharacterized protein ycf15 Proteins 0.000 description 1
- 101000818096 Spirochaeta aurantia Uncharacterized 15.5 kDa protein in trpE 3'region Proteins 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 101000766081 Streptomyces ambofaciens Uncharacterized HTH-type transcriptional regulator in unstable DNA locus Proteins 0.000 description 1
- 101000814062 Streptomyces lividans Uncharacterized 6.0 kDa protein Proteins 0.000 description 1
- 101000953979 Streptomyces lividans Uncharacterized 6.6 kDa protein Proteins 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101000804403 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HIT-like protein Synpcc7942_1390 Proteins 0.000 description 1
- 101000750910 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HTH-type transcriptional regulator Synpcc7942_2319 Proteins 0.000 description 1
- 101000644897 Synechococcus sp. (strain ATCC 27264 / PCC 7002 / PR-6) Uncharacterized protein SYNPCC7002_B0001 Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- SLUWOCTZVGMURC-BFHQHQDPSA-N Thr-Gly-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O SLUWOCTZVGMURC-BFHQHQDPSA-N 0.000 description 1
- YDWLCDQXLCILCZ-BWAGICSOSA-N Thr-His-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O YDWLCDQXLCILCZ-BWAGICSOSA-N 0.000 description 1
- TZJSEJOXAIWOST-RHYQMDGZSA-N Thr-Lys-Arg Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CCCN=C(N)N TZJSEJOXAIWOST-RHYQMDGZSA-N 0.000 description 1
- MUAFDCVOHYAFNG-RCWTZXSCSA-N Thr-Pro-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MUAFDCVOHYAFNG-RCWTZXSCSA-N 0.000 description 1
- 101000748762 Trieres chinensis Uncharacterized 5.4 kDa protein in trnK-psbC intergenic region Proteins 0.000 description 1
- 101000626900 Trieres chinensis Uncharacterized 5.5 kDa protein in ccsA-rps6 intergenic region Proteins 0.000 description 1
- QNTBGBCOEYNAPV-CWRNSKLLSA-N Trp-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N)C(=O)O QNTBGBCOEYNAPV-CWRNSKLLSA-N 0.000 description 1
- HJTYJQVRIQXMHM-XIRDDKMYSA-N Trp-Asp-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N HJTYJQVRIQXMHM-XIRDDKMYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100024769 Tubulin-specific chaperone E Human genes 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- QSFJHIRIHOJRKS-ULQDDVLXSA-N Tyr-Leu-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QSFJHIRIHOJRKS-ULQDDVLXSA-N 0.000 description 1
- SINRIKQYQJRGDQ-MEYUZBJRSA-N Tyr-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 SINRIKQYQJRGDQ-MEYUZBJRSA-N 0.000 description 1
- ZZDYJFVIKVSUFA-WLTAIBSBSA-N Tyr-Thr-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O ZZDYJFVIKVSUFA-WLTAIBSBSA-N 0.000 description 1
- RGJZPXFZIUUQDN-BPNCWPANSA-N Tyr-Val-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O RGJZPXFZIUUQDN-BPNCWPANSA-N 0.000 description 1
- 101710159648 Uncharacterized protein Proteins 0.000 description 1
- 101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 description 1
- 101100076195 Vaccinia virus (strain Western Reserve) VACWR117 gene Proteins 0.000 description 1
- TZVUSFMQWPWHON-NHCYSSNCSA-N Val-Asp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N TZVUSFMQWPWHON-NHCYSSNCSA-N 0.000 description 1
- DDNIHOWRDOXXPF-NGZCFLSTSA-N Val-Asp-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N DDNIHOWRDOXXPF-NGZCFLSTSA-N 0.000 description 1
- JMCOXFSCTGKLLB-FKBYEOEOSA-N Val-Phe-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N JMCOXFSCTGKLLB-FKBYEOEOSA-N 0.000 description 1
- QIVPZSWBBHRNBA-JYJNAYRXSA-N Val-Pro-Phe Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O QIVPZSWBBHRNBA-JYJNAYRXSA-N 0.000 description 1
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 101710136524 X polypeptide Proteins 0.000 description 1
- 101000916336 Xenopus laevis Transposon TX1 uncharacterized 82 kDa protein Proteins 0.000 description 1
- 101001000760 Zea mays Putative Pol polyprotein from transposon element Bs1 Proteins 0.000 description 1
- 101000736254 Zea mays Uncharacterized protein ycf70 Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 101000678262 Zymomonas mobilis subsp. mobilis (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1) 65 kDa protein Proteins 0.000 description 1
- PYJIWOQTJHPDAK-PRJMDXOYSA-N [(1s,2r,3s)-3-(6-aminopurin-9-yl)-2-(hydroxymethyl)cyclobutyl]methanol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](CO)[C@H]1CO PYJIWOQTJHPDAK-PRJMDXOYSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- SUPKOOSCJHTBAH-UHFFFAOYSA-N adefovir Chemical compound NC1=NC=NC2=C1N=CN2CCOCP(O)(O)=O SUPKOOSCJHTBAH-UHFFFAOYSA-N 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940103272 aluminum potassium sulfate Drugs 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229960001040 ammonium chloride Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- DRTQHJPVMGBUCF-CCXZUQQUSA-N arauridine Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-CCXZUQQUSA-N 0.000 description 1
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- JPIYZTWMUGTEHX-UHFFFAOYSA-N auramine O free base Chemical compound C1=CC(N(C)C)=CC=C1C(=N)C1=CC=C(N(C)C)C=C1 JPIYZTWMUGTEHX-UHFFFAOYSA-N 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000023549 cell-cell signaling Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000009614 chemical analysis method Methods 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical class NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 108010060199 cysteinylproline Proteins 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007711 cytoplasmic localization Effects 0.000 description 1
- 238000012303 cytoplasmic staining Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229940087451 cytovene Drugs 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- SSJJWVREPZVNBF-DGXVIIAXSA-N dG10 Chemical compound C1=NC(C(NC(N)=N2)=O)=C2N1[C@H](O[C@@H]1COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)C[C@@H]1OP(O)(=O)OC[C@@H](O1)[C@@H](O)C[C@@H]1N1C(N=C(NC2=O)N)=C2N=C1 SSJJWVREPZVNBF-DGXVIIAXSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 229940026692 decadron Drugs 0.000 description 1
- 239000003954 decarboxylase inhibitor Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 229950000330 desciclovir Drugs 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 108010054813 diprotin B Proteins 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007878 drug screening assay Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- KGPPDNUWZNWPSI-UHFFFAOYSA-N flurotyl Chemical group FC(F)(F)COCC(F)(F)F KGPPDNUWZNWPSI-UHFFFAOYSA-N 0.000 description 1
- 229950000929 flurotyl Drugs 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 229960000848 foscarnet sodium Drugs 0.000 description 1
- 229940108452 foscavir Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 101150040331 gM gene Proteins 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 230000000423 heterosexual effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 102000054896 human PML Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000011997 immunoflourescence assay Methods 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000013198 immunometric assay Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007850 in situ PCR Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000012739 integrated shape imaging system Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 108010051920 interferon regulatory factor-4 Proteins 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- DQRZDIMTJNNJHB-UHFFFAOYSA-N isis 2922 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(O)=S)C(OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(S)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 DQRZDIMTJNNJHB-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 108010091138 kutapressin Proteins 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- HEHQDWUWJVPREQ-XQJZMFRCSA-N lipid X Chemical compound CCCCCCCCCCC[C@@H](O)CC(=O)N[C@H]1[C@@H](OP(O)(O)=O)O[C@H](CO)[C@@H](O)[C@@H]1OC(=O)C[C@H](O)CCCCCCCCCCC HEHQDWUWJVPREQ-XQJZMFRCSA-N 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 201000001268 lymphoproliferative syndrome Diseases 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 108010005942 methionylglycine Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 208000015325 multicentric Castleman disease Diseases 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 108700024542 myc Genes Proteins 0.000 description 1
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 238000001216 nucleic acid method Methods 0.000 description 1
- 108010044762 nucleolin Proteins 0.000 description 1
- 230000037360 nucleotide metabolism Effects 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 101150055367 orf47 gene Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 101150044611 pel gene Proteins 0.000 description 1
- 229960001179 penciclovir Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 108010089198 phenylalanyl-prolyl-arginine Proteins 0.000 description 1
- 108010073101 phenylalanylleucine Proteins 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000005499 phosphonyl group Chemical group 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 108010048507 poliovirus receptor Proteins 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 159000000018 pyrido[2,3-d]pyrimidines Chemical class 0.000 description 1
- ZLIBICFPKPWGIZ-UHFFFAOYSA-N pyrimethanil Chemical compound CC1=CC(C)=NC(NC=2C=CC=CC=2)=N1 ZLIBICFPKPWGIZ-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000413 sensory ganglia Anatomy 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000006258 serine-glycosylation Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 108010071207 serylmethionine Proteins 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000005309 stochastic process Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000025889 stromal keratitis Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000003803 thymidine kinase inhibitor Substances 0.000 description 1
- 239000003734 thymidylate synthase inhibitor Substances 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- HOGVTUZUJGHKPL-HTVVRFAVSA-N triciribine Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HOGVTUZUJGHKPL-HTVVRFAVSA-N 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- YFNGWGVTFYSJHE-UHFFFAOYSA-K trisodium;phosphonoformate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)C([O-])=O.OP(O)(=O)C([O-])=O.OP(O)(=O)C([O-])=O YFNGWGVTFYSJHE-UHFFFAOYSA-K 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 206010055031 vascular neoplasm Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000007442 viral DNA synthesis Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229940107931 zovirax Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- Kaposi's sarcoma-associated herpesvirus is a new human herpesvirus (HHV8) believed to cause Kaposi's sarcoma (KS) [1,2].
- Kaposi's sarcoma is the most common neoplasm occurring in persons with acquired immunodeficiency syndrome (AIDS) . Approximately 15-20% of AIDS patients develop this neoplasm which rarely occurs in immunocompetent individuals . Epidemiologic evidence suggests that AIDS-associated KS (AIDS-KS) has an infectious etiology. Gay and bisexual AIDS patients are approximately twenty times more likely than hemophiliac AIDS patients to develop KS, and KS may be associated with specific sexual practices among gay men with AIDS. KS is uncommon among adult AIDS patients infected through heterosexual or parenteral HIV transmission, or among pediatric AIDS patients infected through vertical HIV transmission.
- AIDS-KS AIDS-associated KS
- KS cytomegalovirus
- hepatitis B virus human papillomavirus
- Epstein-Barr virus EBV
- human herpesvirus 6 human immunodeficiency virus
- HIV Mycoplasma penetrans
- Non- infectious environmental agents such as nitrite inhalants, also have been proposed to play a role in KS tumorigenesis . Extensive investigations, however, have not demonstrated an etiologic association between any of these agents and AIDS-KS.
- This invention provides an isolated nucleic acid molecule which encodes Kaposi's Sarcoma-Associated Herpesvirus (KSHV) polypeptides.
- KSHV Kaposi's Sarcoma-Associated Herpesvirus
- This invention provides an isolated polypeptide molecule of KSHV.
- This invention provides an antibody specific to the polypeptide.
- Antisense and triplex oligonucleotide molecules are also provided.
- This invention provides a vaccine for Kaposi's Sarcoma (KS) .
- This invention provides methods of vaccination, prophylaxis, diagnosis and treatment of a subject with KS and of detecting expression of a DNA virus associated with Kaposi's sarcoma in a cell.
- LUR long unique region
- TR terminal repeat
- FIG. 2A Sequence of terminal repeat unit (TR) demonstrating its high G+C content (SEQ ID NO: 16) . Sequences highly similar to conserved herpesvirus pacl sites are underlined with less similar sites to specific pacl and pac2 sequences italicized.
- FIG. 2B Southern blot of DNA from BC-1 (lane 1) , BCP-1 (lane 2) and a KS lesion (lane 3) digested with Ndell which cuts once in the TR sequence and probed with a plasmid containing the TR sequence. The intense hybridization band at 0.8 kb represents multiple copies of the NdelI-digested single unit TR (Fig. 2C) .
- FIG. 2C A schematic representation (Fig. 2C) of genome structures of KSHV in BCP-1 and BC-1 cell lines consistent with the data presented in (Fig.
- BCP-1 TR hybridization shows laddering consistent with a virus population having variable TR region lengths within this cell line due to lytic replication.
- the absence of TR laddering in KS lesion DNA suggests that a clonal virus population is present in the tumor.
- FIGS 3A-3C CLUSTAL W alignments of KSHV-encoded polypeptide sequences to corresponding human cell signaling pathway polypeptide sequences.
- Fig. 3A Two KSHV MlP-like polypeptides (vMIP-I and vMIP-II) are compared to human MlP-l ⁇ , MIP-1/3 and RANTES (amino acid identity to vMIP-I indicated by black reverse shading, to vMIP-II alone by gray reverse shading, and the C-C dimer motif is italicized) .
- Both KSHV MIP genes encode 19 residue N-termmus hydrophobic secretory leader sequences which are relatively poorly conserved (vMIP-I also has a second C-C dimer in the hydrophobic leader sequence without similarity to the chemokine dicysteine motif) .
- Potential O-linked glycosylation sites for vMIP-I are not present in vMIP-II, which has only one predicted potential serine glycosylation site (position 51) not found in vMIP-I.
- Fig. 3B are examples of potential O-linked glycosylation sites for vMIP-I (gapped positions 22 and 27) are not present in vMIP-II, which has only one predicted potential serine glycosylation site (position 51) not found in vMIP-I.
- Fig. 5A Immunoblot of rabbit antipeptide antibodies generated from amino acid sequences of vIL-6, THYSPPKFDR (SEQ ID NO : 2 ) and PDVTPDVHDR (SEQ ID N0:3), against cell lysates of BCP-1,
- BC-1 P3HR1 cell lines with and without TPA induction (lanes 1-6) , 1 ⁇ g human rIL-6 (lane 7) , and concentrated COS7 rvIL-6 and 6-LIv supernatants (lanes 8-9) .
- Anti-vIL-6 antibodies specifically recognize the viral IL-6 polypeptide in both recombinant supernatants and cell lines but not human IL-6.
- the BCP-1 cell line constitutively expresses low levels of vIL-6 whereas polypeptide expression increases on TPA treatment for both BC-1 (KSHV and EBV coinfected) and BCP-1 (KSHV infection alone) indicating lytic phase expression. Preimmune sera from immunized rabbits did not react on immunoblotting to any of the preparations.
- Fig. 5B Anti-huIL-6 monoclonal antibodies do not cross-react with cell-associated or recombinant vIL-6 preparations.
- KS lesions Of eight KS lesions, only one had readily identifiable vIL-6 staining of a subpopulation of cells. In contrast, the majority of pelleted lymphoma cells from a nonAIDS, EBV-negative PEL have intense vIL-6 staining (Fig. 7E) . No immunostaining is present in control angiosarcoma (Fig. 7D) or multiple myeloma tissues (Fig. 7F) .
- Double antibody labeling of anti-vIL-6 and cell surface antigens were found in a KS lesion.
- Fig. 8A CD34 (red) and vIL-6 colocalize (blue) in a KS spindle cell (arrow) . Purple coloration is due to overlapping chromagen staining (100X) .
- Fig. 8B CD45 common leukocyte antigen staining (blue, arrow) on vIL-6 (red) expressing Kaposi's sarcoma cells (100X) .
- FIG. 8D Colocalization of CD20 (brown, arrows) with vIL-6 (red) in an AIDS-KS patient's lymph node (10OX) .
- FIG. 9 Quantification of CCC/CD4 cell infection by primary NSI SF162 and M23 HIV-1 strains and HIV-2 strain ROD/B in the presence or absence of vMIP-I.
- CCC/CD4 cells were transiently cotransfected with CCR5 alone, CCR5 plus empty pMET7 vector, CCR5 plus vMIP-I in pMET7 vector, or CCR5 plus the reverse orientation I-PIMv. The results after 72 hours of incubation with each retrovirus are expressed as a percentage of the foci forming units for cells transfected with
- nucleic acid refers to either DNA or RNA, including complementary DNA (cDNA) , genomic DNA and messenger RNA (mRNA) .
- genomic means both coding and non-coding regions of the isolated nucleic acid molecule.
- Nucleic acid sequence refers to a single- or double- stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. It includes both self-replicating plasmids, infectious polymers of DNA or RNA and nonfunctional DNA or RNA.
- polypeptide refers to either the full length gene product encoded by the nucleic acid, or portions thereof. Thus, “polypeptide” includes not only the full-length protein, but also partial -length fragments, including peptides less than fifty amino acid residues in length.
- SSC refers to a citrate-saline solution of 0.15 M sodium chloride and 20 mM sodium citrate. Solutions are often expressed as multiples or fractions of this concentration. For example, 6XSSC refers to a solution having a sodium chloride and sodium citrate concentration of 6 times this amount or 0.9 M sodium chloride and 120 mM sodium citrate. 0.2XSSC refers to a solution 0.2 times the SSC concentration or 0.03 M sodium chloride and 4 mM sodium citrate.
- selectively hybridizing to and the phrase “specific hybridization” describe a nucleic acid probe that hybridizes, duplexes or binds only to a particular target DNA or RNA sequence when the target sequences are present in a preparation of total cellular DNA or RNA.
- selectively hybridizing it is meant that a probe binds to a given target in a manner that is detectable in a different manner from non- target sequence under high stringency conditions of hybridization .
- “Complementary” or “target” nucleic acid sequences refer to those nucleic acid sequences which selectively hybridize to a nucleic acid probe. Proper annealing conditions depend, for example, upon a probe's length, base composition, and the number of mismatches and their position on the probe, and must often be determined empirically. For discussions of nucleic acid probe design and annealing conditions, see, for example, Sambrook et al . (1989) Molecular Cloning: A Labora tory Manual (2nd ed. ) . Cold Spring Harbor Laboratory, Vols. 1-3 or Ausubel, F., et al . (1987) Current Protocols in Molecular Biology, New York .
- nucleic acid molecule encoding refers to a nucleic acid molecule which directs the expression of a specific polypeptide.
- the nucleic acid sequences include both the DNA strand sequence that is transcribed into RNA, the complementary DNA strand, and the RNA sequence that is translated into protein.
- the nucleic acid molecule includes both the full length nucleic acid sequence as well as non- full length sequences. It being further understood that the sequence includes the degenerate codons of the native sequence or sequences which may be introduced to provide codon preference in a specific host cell.
- a nucleic acid probe is "specific" for a target organism of interest if it includes a nucleotide sequence which when detected is determinative of the presence of the organism in the presence of a heterogeneous population of proteins and other biologies.
- a specific nucleic acid probe is targeted to that portion of the sequence which is determinative of the organism and will not hybridize to other sequences, especially those of the host, where a pathogen is being detected.
- expression cassette refers to nucleotide sequences which are capable of affecting expression of a structural gene in hosts compatible with such sequences.
- Such cassettes include at least promoters and optionally, transcription termination signals. Additional factors necessary or helpful in effecting expression may also be used as described herein.
- operably linked refers to linkage of a promoter upstream from a DNA sequence such that the promoter mediates transcription of the DNA sequence .
- vector refers to viral expression systems, autonomous self-replicating circular DNA (plasmids) , and includes both expression and nonexpression plasmids. Where a recombinant microorganism or cell culture is described as hosting an “expression vector, " this includes both extrachromosomal circular DNA and DNA that has been incorporated into the host chromosome (s) . Where a vector is being maintained by a host cell, the vector may either be stably replicated by the cells during mitosis as an autonomous structure, or is incorporated within the host ' s genome .
- plasmid refers to an autonomous circular DNA molecule capable of replication in a cell, and includes both the expression and nonexpression types . Where a recombinant microorganism or cell culture is described as hosting an "expression plasmid", this includes latent viral DNA integrated into the host chromosome (s) . Where a plasmid is being maintained by a host cell, the plasmid is either being stably replicated by the cells during mitosis as an autonomous structure or is incorporated within the host's genome.
- recombinant protein or “recombinantly produced protein” refers to a polypeptide produced using non-native cells.
- the cells produce the protein because they have been genetically altered by the introduction of the appropriate nucleic acid sequence.
- reference sequence is a defined sequence used as a basis for a sequence comparison; a reference sequence may be a subset of a larger sequence, for example, as a segment of a full-length cDNA or gene sequence given in a sequence listing or may comprise a complete cDNA or gene sequence .
- Optimal alignment of sequences in a comparison window may be conducted by the algorithm of Smith and Waterman (1981) Adv. Appl . Ma th . 2:482, by the algorithm of Needleman and Wunsch (1970) J. Mol . Biol . 48:443, by the search-for-similarity method of Pearson and Lipman (1988) Proc . Na tl . Acad . Sci . 85:2444, or by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in GCG, the Wisconsin Genetics Software Package Release 8.0, Genetics Computer Group, 575 Science Dr., Madison, WI ) .
- the terms "substantial identity” or “substantial sequence identity” mean that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap which share at least 90 percent sequence identity, preferably at least 95 percent sequence identity, more preferably at least 99 percent sequence identity or more .
- Percentage amino acid identity or “percentage amino acid sequence identity” refers to a comparison of the amino acids of two polypeptides which, when optimally aligned, have approximately the designated percentage of the same amino acids.
- 95% amino acid identity refers to a comparison of the amino acids of two polypeptides which when optimally aligned have 95% amino acid identity.
- residue positions which are not identical differ by conservative amino acid substitutions. For example, the substitution of amino acids having similar chemical properties, such as charge or polarity, are not likely to effect the properties of a protein. Examples include glutamine for asparagine or gluta ic acid for aspartic acid.
- substantially purified when referring to a herpesvirus polypeptide, means a chemical composition which is essentially free of other cellular components. It is preferably in a homogeneous state although it can be in either a dry or aqueous solution. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography.
- a protein which is the predominant species present in a preparation is substantially purified. Generally, a substantially purified or isolated protein will comprise more than 80% of all macromolecular species present in the preparation. Preferably, the protein is purified to represent greater than 90% of all macromolecular species present. More preferably the protein is purified to greater than 95%, and most preferably the protein is purified to essential homogeneity, wherein other macromolecular species are not detected by conventional techniques.
- the specified antibodies bind to the KSHV antigen and do not bind in a significant amount to other antigens present in the sample .
- Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular antigen.
- antibodies raised to KSHV antigens described herein can be selected to obtain antibodies specifically immunoreactive with KSHV polypeptides and not with other polypeptides.
- Biological sample refers to any sample obtained from a living organism or from an organism that has died. Examples of biological samples include body fluids and tissue specimens.
- This invention provides an isolated nucleic acid molecule which encodes a Kaposi's sarcoma-associated herpesvirus (KSHV) polypeptide.
- KSHV Kaposi's sarcoma-associated herpesvirus
- the isolated nucleic acid molecule which encodes a KSHV polypeptide has the nucleotide sequence as set forth in GenBank Accession Number U75698 and the start and stop codons set forth in Table 1. In another embodiment, the isolated nucleic acid molecule which encodes a KSHV polypeptide has the amino acid sequence defined by the translation of the nucleotide sequence set forth in GenBank Accession Number U75698 and the start and stop codons set forth in Table 1.
- the isolated nucleic acid molecule for a KSHV polypeptide has the 5' untranslated sequence as set forth in GenBank Accession Number
- the isolated nucleic acid molecule for a KSHV polypeptide has the 3' untranslated sequence as set forth in GenBank Accession Number U75698 downstream of the stop codon.
- the isolated nucleic acid molecule is genomic DNA. In another embodiment the isolated nucleic acid molecule is cDNA. In another embodiment RNA is derived from the isolated nucleic acid molecule or is capable of hybridizing with the isolated nucleic acid molecule.
- the nucleic acid molecule above may be associated with lymphoproliferative diseases including, but not limited to: Hodgkin's disease, non- Hodgkin's lymphoma, lymphatic leukemia, lymphosarcoma , splenomegaly, reticular cell sarcoma, Sezary's syndrome, mycosis fungoides, central nervous system lymphoma, AIDS related central nervous system lymphoma, post- transplant lymphoproliferative disorders, and Burkitt's lymphoma.
- a lymphoproliferative disorder is characterized as being the uncontrolled clonal or polyclonal expansion of lymphocytes involving lymph nodes, lymphoid tissue and other organs.
- KSHV can be propagated in vi tro.
- techniques for growing herpesviruses have been described by Ablashi et al . in Virology 184, 545-552.
- PHA stimulated cord blood ononuclear cells, macrophage, neuronal, or glial cell lines are cocultivated with cerebrospinal fluid, plasma, peripheral blood leukocytes, or tissue extracts containing viral infected cells or purified virus.
- the recipient cells are treated with 5 ⁇ g/ml polybrene for 2 hours at 37° C prior to infection. Infected cells are observed by demonstrating morphological changes, as well as being viral antigen positive.
- the virus is either harvested directly from cell culture fluid by centrifugation, or the infected cells are harvested, homogenized or lysed and the virus is separated from cellular debris and purified by standard methods of isopycnic sucrose density gradient centrifugation.
- KSHV KSHV
- Long- term establishment of a B lymphoid cell line infected with KSHV e.g., RCC-1, HBL-6 or BCBL-1
- body-cavity based lymphomas and standard techniques Glick, 1980, Fundamentals of Human Lymphoid Cul ture, Marcel Dekker, New York; Knowles et al . , 1989, Blood 73, 792-798; Metcalf, 1984, Clonal Culture of Hematopoei tic Cells : Techniques and
- Fresh lymphoma tissue containing viable infected cells is filtered to form a single cell suspension.
- the cells are separated by Ficoll-Plaque centrifugation and lymphocyte layer is removed.
- the lymphocytes are then placed at >lxl0 6 cells/ml into standard lymphocyte tissue culture medium, such as RPMI 1640 supplemented with 10% fetal calf serum.
- Immortalized lymphocytes containing KSHV are indefinitely grown in the culture media while non-immortalized cells die during course of prolonged cultivation.
- KSHV may be propagated in a new cell line by removing media supernatant containing the virus from a continuously- infected cell line at a concentration of >lxl0 6 cells/ml.
- the media is centrifuged at 2000xg for 10 minutes and filtered through a 0.45 ⁇ filter to remove cells.
- the media is applied in a 1:1 volume with cells growing at >lxl0 6 cells/ml for 48 hours. The cells are washed, pelleted and placed in fresh culture medium, then tested for KSHV after 14 days.
- KSHV may be isolated from a cell line in the following manner.
- An infected cell line is lysed using standard methods, such as hyposmotic shock or Dounce homogenization or using repeated cycles of freezing and thawing in a small volume ( ⁇ 3 ml) , and pelleted at 2000xg for 10 minutes.
- the supernatant is removed and centrifuged again at 10,000xg for 15 minutes to remove nuclei and organelle ⁇ .
- the resulting low-speed, cell- free supernatant is filtered through a 0.45 ⁇ filter and centrifuged at 100,000xg for 1 hour to pellet the virus.
- the virus can then be washed and re-pelleted.
- the DNA is extracted from the viral pellet by standard techniques (e.g., phenol/ chloroform) and tested for the presence of KSHV by Southern blotting and/or PCR using the specific probes described above.
- the low-speed cell -free supernatant is adjusted to contain 7% PEG-8000.
- the PEG-supernatant is spun at 10,000 xg for 30 min.
- the supernatant is poured off and the pellet collected and resuspended in a small volume (1-2 ml) of virus buffer (VB, 0.1 M NaCl, 0.01 M Tris, pH 7.5) .
- the virion are isolated by centrifugation at 25,000 rpm in a 10-50% sucrose gradient made with VB .
- One ml fractions of the gradient are obtained by standard techniques (e.g., using a fractionator) and each fraction is tested by dot blotting using specific hybridizing probes to determine the gradient fraction containing the purified virus (preparation of the fraction is needed in order to detect the presence of the virus, i.e., standard DNA extraction) .
- the method for isolating the KSHV genome is Pased on Pellicer et al . , 1978, Cell 14, 133-141 and Gibson and Roizmann, 1972, J. Virol . 10, 1044-52.
- a final method for isolating the KSHV genome is clamped homogeneous electric field (CHEF) gel electrophoresis.
- Agarose plugs are prepared by resuspending cells infected with KSHV in 1% LMP agarose (Biorad) and 0.9% NaCl at 42 °C to a final concentration of 2.5 x 10 7 cells/ml.
- Solidified agarose plugs are transferred into lysis buffer ( 0.5M EDTA pH 8.0, 1% sarcosyl, proteinase K at 1 mg/ml final concentration) and incubated for 24 hours. Approximately 10 7 cells are loaded in each lane.
- RCC-1 Raji cell line newly- infected with KSHV.
- RCC-i and RCC-l 2Fb were deposited on October 19, 1994 under ATCC Accession No.
- This invention provides a nucleic acid molecule of at least 14 nucleotides capable of specifically hybridizing with the isolated nucleic acid molecule as set forth in GenBank Accession Numbers U75698, U75699, U75700.
- nucleic acid molecule set forth in GenBank Accession Number U75698 comprises the long unique region (LUR) encoding KSHV polypeptides.
- nucleic acid molecule set forth in GenBank Accession Number U75699 comprises the prototypical terminal repeat (TR) .
- nucleic acid molecule set forth in GenBank Accession Number U75700 comprises the incomplete terminal repeat (ITR) .
- the molecule is 8 to 36 nucleotides. In another embodiment the molecule is 12 to 25 nucleotides. In another embodiment the molecule is 14 nucleotides . In one embodiment the molecule is DNA. In another embodiment the molecule is RNA.
- the TR molecule contains cis-active elements required for DNA replication and packaging. In another embodiment the TR molecule is contained in a gene-cloning vector. In another embodiment the TR molecule is contained in a gene-therapy vector. In another embodiment the gene-therapy vector is expressed in lymphoid cells. In another embodiment, the TR comprises a molecular marker for determining the clonality of a tumor. In another embodiment, the marker provides a defining feature of the natural history of a tumor in a diagnostic assay.
- This invention provides a B-lymphotrophic DNA vector comprising a plasmid or other self-replicable DNA molecule containing the 801 bp KSHV TR or a portion thereof .
- High stringency hybridization conditions are selected at about 5°C lower than the thermal melting point (TJ for the specific sequence at a defined ionic strength and pH.
- the T m is the temperature (under defined ionic strength and pH) at which 50% of the salt concentration is at least about 0.02 molar at pH 7 and the temperature is at least about 60 °C.
- the combination of parameters is more important than the absolute measure of any one. For example, high stringency may be attained by overnight hybridization at about 68°C in a 6X SSC solution, washing at room temperature with 6X SSC solution, followed by washing at about 68°C in a 0.6X SSC solution.
- Hybridization with moderate stringency may be attained for example by: 1) filter pre-hybridizing and hybridizing with a solution of 3X SSC, 50% formamide, 0. IM Tris buffer at pH 7.5 , 5X Denhardt ' s solution ; 2.) pre-hybridization at 37°C for 4 hours; 3) hybridization at 37°C with amount of labeled probe equal to 3,000,000 cpm total for 16 hours; 4) wash in x SSC and 0.1% SDS solution; 5) wash 4X for 1 minute each at room temperature in 4X SSC at 60°C for 30 minutes each; and 6) dry and expose to film.
- Nucleic acid probe technology is well known to those skilled in the art who readily appreciate that such probes may vary greatly in length and may be labeled with a detectable label, such as a radioisotope or fluorescent dye, to facilitate detection of the probe.
- DNA probe molecules may be produced by insertion of a
- DNA molecule having the full-length or a fragment of the isolated nucleic acid molecule of the DNA virus into suitable vectors, such as plasmids or bacteriophages, followed by transforming into suitable bacterial host cells, replication in the transformed bacterial host cells and harvesting of the DNA probes, using methods well known in the art.
- probes may be generated chemically from DNA synthesizers .
- RNA probes may be generated by inserting the full length or a fragment of the isolated nucleic acid molecule of the DNA virus downstream of a bacteriophage promoter such as T3, T7 or SP6. Large amounts of RNA probe may be produced by incubating the labeled nucleotides with a linearized isolated nucleic acid molecule of the DNA virus or its fragment where it contains an upstream promoter in the presence of the appropriate RNA polymerase.
- nucleic acid probes may be DNA or RNA fragments.
- DNA fragments can be prepared, for example, by digesting plasmid DNA, or by use of PCR, or synthesized by either the phosphoramidite method described by Beaucage and Carruthers, 1981, Te trahedron Lett . 22, 1859-1862 or by the triester method according to Matteucci et al . , 1981, Am . Chem . Soc. 103:3185.
- a double stranded fragment may then be obtained, if desired, by annealing the chemically synthesized single strands together under appropriate conditions or by synthesizing the complementary strand using DNA polymerase with an appropriate primer sequence.
- nucleic acid probe where a specific sequence for a nucleic acid probe is given, it is understood that the complementary strand is also identified and included. The complementary strand will work equally well in situations where the target is a double-stranded nucleic acid. It is also understood that when a specific sequence is identified for use a nucleic probe, a subsequence of the listed sequence which is 25 base pairs (bp) or more in length is also encompassed for use as a probe.
- bp base pairs
- the nucleic acid molecules of the subject invention also include molecules coding for polypeptide analogs, fragments or derivatives of antigenic polypeptides which differ from naturally-occurring forms in terms of the identity or location of one or more amino acid residues (deletion analogs containing less than all of the residues specified for the polypeptide, substitution analogs wherein one or more residues specified are replaced by other residues and addition analogs where in one or more amino acid residues is added to a terminal or medial portion of the polypeptides) and which share some or all properties of naturally-occurring forms.
- These molecules include: the incorporation of codons "preferred" for expression by selected non-mammalian hosts; the provision of sites for cleavage by restriction endonuclease enzymes; and the provision of additional initial, terminal or intermediate DNA sequences that facilitate construction of readily expressed vectors.
- This invention provides an isolated KSHV polypeptide, one from the list as set forth in Table 1 and below.
- vMIP-III viral macrophage inflammatory protein III
- vMIP-III comprises an orphan cytokine .
- vMIP-III is encoded by nucleotides 22,529-22,185.
- vMIP-III comprises an anti-inflammatory drug.
- the drug is useful in treatment of an autoimmune disorder. In the most preferred embodiment, the drug is useful in treatment of rheumatoid arthritis.
- DHFR dihydrofolate reductase
- ORF 2 dihydrofolate reductase
- DHFR participates in KSHV nucleotide synthesis.
- DHFR comprises an enzyme essential for viral replication, inhibition of which prevents virus production.
- DHFR comprises a subunit vaccine.
- DHFR comprises an antigen for immunologic assays.
- DHFR has the amino acid sequence as set forth in SEQ ID NO : 1.
- KSHV DHFR is inhibited by a sulfa drug known to inhibit bacterial DHFR.
- KSHV DHFR is inhibited by methotrexate or a derivative thereof known to inhibit mammalian DHFR.
- the sulfa drug, methotrexate or a derivative thereof is selective among the human herpesviruses for inhibition of KSHV.
- This invention provides the isolated KSHV polypeptide comprising thymidylate synthase (TS) encoded by ORF 70.
- TS participates in KSHV nucleotide metabolism.
- TS comprises an enzyme essential for viral replication, inhibition of which prevents virus production.
- TS comprises a subunit vaccine.
- TS comprises an antigen for immunologic assays.
- DNA polymerase comprises an enzyme essential for viral replication, inhibition of which prevents virus production.
- DNA polymerase comprises a subunit vaccine .
- DNA polymerase comprises an antigen for immunologic assays.
- alkaline exonuclease packages KSHV DNA into the virus particle.
- alkaline exonuclease comprises an enzyme essential for viral replication, inhibition of which prevents virus production.
- alkaline exonuclease comprises a subunit vaccine.
- alkaline exonuclease comprises an antigen for immunologic assays.
- This invention provides the isolated KSHV polypeptide comprising helicase-primase, subunits 1, 2 and 3 encoded by ORFs 40, 41 and 44, respectively.
- helicase-primase comprises an enzyme activity essential for viral DNA replication.
- helicase-primase is inhibited by nucleotide analogs.
- helicase- primase is inhibited by known antiviral drugs.
- inhibition of helicase-primase prevents KSHV replication.
- This invention provides the isolated KSHV polypeptide comprising uracil DNA glycosylase (UDG) encoded by ORF 46.
- uracil DNA glycosylase comprises an enzyme essential for KSHV DNA repair during DNA replication.
- uracil DNA glycosylase is inhibited by known antiviral drugs.
- uracil DNA glycosylase comprises a subunit vaccine.
- uracil DNA glycosylase comprises an antigen for immunologic assays.
- This invention provides the isolated KSHV polypeptide comprising single-stranded DNA binding protein (SSBP) encoded by ORF 06.
- SSBP single-stranded DNA binding protein
- SSBP comprises an enzyme essential for KSHV DNA replication.
- SSBP is inhibited by known antiviral drugs.
- SSBP increases the processivity of polymerase reactions such as in the conventional PCR method for DNA amplification.
- This invention provides the isolated KSHV polypeptide comprising viral protein kinase encoded by ORF 36.
- viral protein kinase comprises an antigen for immunologic assays.
- viral protein kinase comprises a subunit vaccine .
- This invention provides the isolated KSHV polypeptide comprising lytic cycle transactivator protein (LCTP) encoded by ORF 50.
- LCTP lytic cycle transactivator protein
- LCTP is required for activation of productive infection from the latent state.
- LCTP is inhibited by known antiviral drugs.
- prevention of LCTP expression maintains the virus in a latent state unable to replicate.
- This invention provides the isolated KSHV polypeptide comprising ribonucleotide reductase, a two-subunit enzyme in which the small and large subunits are encoded by ORF 60 and ORF 61, respectively.
- ribonucleotide reductase catalyzes conversion of r ibonucleo t ide s into deoxyribonucleotides for DNA replication.
- ribonucleotide reductase is inhibited by known antiviral drugs in terminally differentiated cells not expressing cellular ribonucleotide reductase.
- ribonucleotide reductase comprises an antigen for immunologic assays.
- ribonucleotide reductase comprises a subunit vaccine.
- ribonucleotide reductase comprises a transforming agent for establishment of immortalized cell lines.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF Kl .
- This invention provides the isolated KSHV polypeptide comprising complement -binding protein (v-CBP; CCP) encoded by ORF 4.
- v-CBP complement -binding protein
- This invention provides the isolated KSHV polypeptide comprising transport protein encoded by ORF 7.
- This invention provides the isolated KSHV polypeptide comprising glycoprotein B encoded by ORF 8.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF 10.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF 11.
- This invention provides the isolated KSHV polypeptide comprising viral interleukin 6 (vIL-6) encoded by ORF K2.
- vIL-6 viral interleukin 6
- antibodies selectively recognizing vIL-6 allow differentiation among lymphomas .
- This invention provides the isolated KSHV polypeptide comprising BHV4-IE1 I encoded by ORF K3.
- vMIP-II comprises an anti-inflammatory drug.
- the drug is useful in treatment of an autoimmune disorder.
- the drug is useful in treatment of rheumatoid arthritis.
- vMIP-I comprises an anti- inflammatory drug.
- the drug is useful in treatment of an autoimmune disorder.
- the drug is useful in treatment of rheumatoid arthritis.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF K7.
- This invention provides the isolated KSHV polypeptide comprising Bel -2 encoded by ORF 16.
- This invention provides the isolated KSHV polypeptide comprising capsid protein I encoded by ORF 17.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF 18.
- This invention provides the isolated KSHV polypeptide comprising tegument protein I encoded by ORF 19.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF 20.
- This invention provides the isolated KSHV polypeptide comprising thymidine kinase encoded by ORF 21.
- This invention provides the isolated KSHV polypeptide comprising glycoprotein H encoded by ORF 22.
- the isolated KSHV polypeptide comprises the protein encoded by ORF 23.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF 24.
- This invention provides the isolated KSHV polypeptide comprising major capsid protein encoded by ORF 25.
- This invention provides the isolated KSHV polypeptide comprising capsid protein II encoded by ORF 26.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF 27.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF 28.
- This invention provides the isolated KSHV polypeptide comprising packaging protein II encoded by ORF 29b.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF 30.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF 31.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF 32.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF 33.
- This invention provides the isolated KSHV polypeptide comprising packaging protein I encoded by ORF 29a.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF 34.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF 35.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF 38.
- This invention provides the isolated KSHV polypeptide comprising glycoprotein M encoded by ORF 39.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF 42.
- This invention provides the isolated KSHV polypeptide comprising capsid protein III encoded by ORF 43.
- This invention provides the isolated KSHV polypeptide comprising virion assembly protein encoded by ORF 45.
- This invention provides the isolated KSHV polypeptide comprising glycoprotein L encoded by ORF 47.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF 48.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF 49.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF K8.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF 52.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF 53.
- This invention provides the isolated KSHV polypeptide comprising dUTPase encoded by ORF 54.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF 55.
- This invention provides the isolated KSHV polypeptide comprising DNA replication protein I encoded by ORF 56.
- This invention provides the isolated KSHV polypeptide comprising immediate early protein II (IEP-II) encoded by ORF 57.
- IEP-II immediate early protein II
- vIRFl viral interferon regulatory factor 1
- ICSBP viral interferon regulatory factor 1
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF K10.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF Kll.
- This invention provides the isolated KSHV polypeptide comprising phosphoprotein encoded by ORF 58.
- This invention provides the isolated KSHV polypeptide comprising DNA replication protein II encoded by ORF 59.
- This invention provides the isolated KSHV polypeptide comprising assembly/DNA maturation protein encoded by ORF 62.
- This invention provides the isolated KSHV polypeptide comprising tegument protein II encoded by ORF 63.
- This invention provides the isolated KSHV polypeptide comprising tegument protein III encoded by ORF 64.
- This invention provides the isolated KSHV polypeptide comprising capsid protein IV encoded by ORF 65.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF 66.
- This invention provides the isolated KSHV polypeptide comprising tegument protein IV encoded by ORF 67.
- This invention provides the isolated KSHV polypeptide comprising glycoprotein encoded by ORF 68.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF 69.
- This invention provides the isolated KSHV polypeptide comprising Kaposin encoded by ORF K12.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF K13.
- This invention provides the isolated KSHV polypeptide comprising cyclin D encoded by ORF 72.
- This invention provides the isolated KSHV polypeptide comprising immediate-early protein (IEP) encoded by ORF 73.
- IEP immediate-early protein
- This invention provides the isolated KSHV polypeptide comprising OX-2 encoded by ORF K14.
- This invention provides the isolated KSHV polypeptide comprising G-protein coupled receptor encoded by ORF 74.
- This invention provides the isolated KSHV polypeptide comprising tegument protein/FGARAT encoded by ORF 75.
- This invention provides the isolated KSHV polypeptide comprising the protein encoded by ORF K15.
- This invention provides the isolated KSHV polypeptide comprising viral interferon regulatory factor 2 (vIRF2) encoded by nucleotides 88,910-88,410.
- vIRF2 viral interferon regulatory factor 2
- This invention provides the isolated KSHV polypeptide comprising viral interferon regulatory factor 3 (vIRF3) encoded by nucleotides 90,541-89,600.
- vIRF3 viral interferon regulatory factor 3
- This invention provides the isolated KSHV polypeptide comprising viral interferon regulatory factor 4 (vIRF4) encoded by nucleotides 94,127-93,636.
- vIRF4 viral interferon regulatory factor 4
- This invention provides the isolated KSHV polypeptide comprising a precursor of secreted glycoprotein X (gX) encoded by nucleotides 90,173-90,643.
- This invention provides the isolated KSHV polypeptide comprising protein TI .1 (nut-1) encoded by nucleotides 28,661-29,741.
- the isolated polypeptide may be linked to a second polypeptide to form a fusion protein by linking the isolated nucleic acid molecule to a second nucleic acid molecule and expression in a suitable host cell .
- the second nucleic acid molecule encodes beta-galactosidase.
- Other nucleic acid molecules which are used to form a fusion protein are known to those skilled in the art.
- This invention provides an antibody which specifically binds to the polypeptide encoded by the isolated nucleic acid molecule.
- the antibody is a monoclonal antibody.
- the antibody recognizes an epitope of the KSHV polypeptide.
- the antibody is a polyclonal antibody.
- the antibody recognizes more than one epitope of the KSHV polypeptide.
- the antibody is an anti-idiotypic antibody.
- An antibody, polypeptide or isolated nucleic acid molecule may be labeled with a detectable marker including, but not limited to: a radioactive label, or a colorimetric, a luminescent, or a fluorescent marker, or gold.
- Radioactive labels include, but are not limited to: 3 H, "C, 32 P, 33 P; 35 S, 36 Cl , 51 Cr, 57 Co, 59 Co, 59 Fe, 90 Y, 125 I, 131 I, and 186 Re .
- Fluorescent markers include, but are not limited to: fluorescein, rhodamine and auramine.
- Colorimetric markers include, but are not limited to: biotin, and digoxigenin. Methods of producing the polyclonal or monoclonal antibody are known to those of ordinary skill in the art .
- the antibody, polypeptide or nucleic acid molecule may be detected by a second antibody which may be linked to an enzyme, such as alkaline phosphatase or horseradish peroxidase.
- an enzyme such as alkaline phosphatase or horseradish peroxidase.
- Other enzymes which may be employed are well known to one of ordinary skill in the art.
- This invention provides a method of producing a polypeptide encoded by the isolated nucleic acid molecule, which comprises growing a host-vector system under suitable conditions permitting production of the polypeptide and recovering the polypeptide so produced.
- Suitable host cells include bacteria, yeast, filamentous fungal, plant, insect and mammalian cells.
- Host -vector systems for producing and recovering a polypeptide are well known to those skilled in the art and include, but are not limited to, E.
- coli and pMAL New England Biolabs
- Sf9 insect cell-baculovirus expression system and mammalian cells (such as HeLa, COS, NIH 3T3 and HEK293) transfected with a mammalian expression vector by Lipofectin (Gibco-BRL) or calcium phosphate precipitation or other methods to achieve vector entry into the cell.
- mammalian cells such as HeLa, COS, NIH 3T3 and HEK293
- Lipofectin Gibco-BRL
- calcium phosphate precipitation or other methods to achieve vector entry into the cell.
- This invention provides a method to select specific regions on the polypeptide encoded by the isolated nucleic acid molecule of the DNA virus to generate antibodies.
- Amino acid sequences may be analyzed by methods well known to those skilled in the art to determine whether they produce hydrophobic or hydrophilic regions in the polypeptides which they build.
- hydrophobic regions are well known to form the part of the polypeptide that is inserted into the lipid bilayer of the cell membrane, while hydrophilic regions are located on the cell surface, in an aqueous environment.
- the hydrophilic regions will be more immunogenic than the hydrophobic regions.
- hydrophilic amino acid sequences may be selected and used to generate antibodies specific to polypeptide encoded by the isolated nucleic acid molecule encoding the DNA virus.
- the selected peptides may be prepared using commercially available machines.
- nucleic acid may be cloned and expressed and the resulting polypeptide recovered and used as an immunogen.
- Polyclonal antibodies against the polypeptide may be produced by immunizing animals using a selected KSHV polypeptide.
- Monoclonal antibodies are prepared using hybridoma technology by fusing antibody producing B cells from immunized animals with myeloma cells and selecting the resulting hybridoma cell line producing the desired antibody, as described further below.
- the antibodies raised against KSHV polypeptide antigens may be detectably labeled, utilizing conventional labelling techniques well-known to the art, as described above.
- enzymes may be used as labels. Suitable enzymes include alkaline phosphatase, beta- galactosidase, glucose-6-phosphate dehydrogenase, maleate dehydrogenase and peroxidase.
- ELISA enzyme- linked immunosorbent assay
- EMIT enzyme-multiplied immunoassay
- separation may be achieved, for example, by the use of antibodies coupled to a solid phase.
- the EMIT system depends on deactivation of the enzyme in the tracer-antibody complex; activity is thus measured without the need for a separation step.
- chemiluminescent compounds may be used as labels.
- Typical chemiluminescent compounds include luminol, isoluminol, aromatic acridinium esters, imidazoles, acridinium salts, and oxalate esters.
- bioluminescent compounds may be utilized for labelling, the bioluminescent compounds including luciferin, luciferase, and aequorin.
- RIA radioimmunoassay
- antibodies to KSHV polypeptide antigens can be used.
- the polypeptide being targeted is expressed and purified.
- the product is injected into a mammal capable of producing antibodies.
- Either polyclonal or monoclonal antibodies (including recombinant antibodies) specific for the gene product can be used in various immunoassays.
- assays include competitive immunoassays, radioimmunoassays, Western blots, ELISA/ indirect immunofluorescent assays and the like. For competitive immunoassays, see Harlow and Lane at pages 567-573 and 584-589.
- Monoclonal antibodies or recombinant antibodies may be obtained by techniques familiar to those skilled in the art. Briefly, spleen cells or other lymphocytes from an animal immunized with a desired antigen are immortalized, commonly by fusion with a myeloma cell (see, Kohler and Milstein, 1976, Eur. J " . Immunol . 6, 511-519) . Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods well known in the art.
- Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate host. Newer techniques using recombinant phage antibody expression systems can also be used to generate monoclonal antibodies. See. for example: McCafferty et al . (1990) Nature 348, 552: Hoogenboom et al . (1991) Nuc . Acids Res . 19, 4133; and Marks et al . (1991) J " . Mol Biol . 222, 581-597.
- polypeptides described herein produced by recombinant technology may be purified by standard techniques well known to those of skill in the art.
- Recombinantly produced viral polypeptides can be directly expressed or expressed as a fusion protein.
- the protein is then purified by a combination of cell lysis (e.g., sonication) and affinity chromatography. For fusion products, subsequent digestion of the fusion protein with an appropriate proteolytic enzyme releases the desired peptide.
- polypeptides may be purified to substantial purity by standard techniques well known in the art, including selective precipitation with such substances as ammonium sulfate, column chromatography, i munopurification methods, and others. See, for instance, Scopes, 1982, Protein Purification : Principles and Practi ce, Springer-Verlag, New York.
- Antibodies reactive with polypeptide antigens of KSHV can also be measured by a variety of immunoassay methods that are similar to the procedures described above for measurement of antigens.
- immunoassay methods that are similar to the procedures described above for measurement of antigens.
- immunoassays to measure antibodies reactive with polypeptide antigens of KSHV can be either competitive or noncompetitive binding assays.
- the sample analyte competes with a labeled analyte for specific binding sites on a capture agent bound to a solid surface.
- the capture agent is a purified recombinant human herpesvirus polypeptide produced as described above .
- Other sources of human herpesvirus polypeptides including isolated or partially purified naturally occurring polypeptide, may also be used.
- Noncompetitive assays are typically sandwich assays, in which the sample analyte is bound between two analyte-specific binding reagents.
- One of the binding agents is used as a capture agent and is bound to a solid surface.
- the second binding agent is labeled and is used to measure or detect the resultant complex by visual or instrument means.
- a number of combinations of capture agent and labeled binding agent can be used.
- a variety of different immunoassay formats, separation techniques and labels can also be used similar to those described above for the measurement of KSHV polypeptide antigens.
- Hemagglutination Inhibition HI
- Complement Fixation CF
- Serological methods can also be useful when one wishes to detect antibody to a specific viral variant. For example, one may wish to see how well a vaccine recipient has responded to a new preparation by assay of patient sera.
- This invention provides a replicable vector containing the isolated nucleic acid molecule encoding a KSHV polypeptide.
- the vector includes, but is not limited to: a plasmid, cosmid, ⁇ phage or yeast artificial chromosome (YAC) which contains the isolated nucleic acid molecule.
- insert and vector DNA can both be exposed to a restriction enzyme to create complementary ends on both molecules which base pair with each other and are then ligated together with DNA ligase.
- linkers can be ligated to the insert DNA which correspond to a restriction site in the vector DNA, which is then digested with the restriction enzyme which cuts at that site.
- Other means are available and well-known to those skilled in the art.
- Suitable host cells include, but are not limited to, bacteria (such as E. coli ) , yeast, fungi, plant, insect and mammalian cells.
- Suitable animal cells include, but are not limited to Vero cells, HeLa cells, Cos cells, CV1 cells and various primary mammalian cells.
- This invention provides a transgenic nonhuman mammal which comprises the isolated nucleic acid molecule introduced into the mammal at an embryonic stage. Methods of producing a transgenic nonhuman mammal are known to those skilled in the art. III . Diagnostic Assays for KS
- This invention embraces diagnostic test kits for detecting the presence of KSHV in biological samples, such as skin samples or samples of other affected tissue, comprising a container containing a nucleic acid sequence specific for a KSHV polypeptide and instructional material for performing the test.
- a container containing nucleic acid primers to any one of such sequences is optionally included.
- This invention further embraces diagnostic test kits for detecting the presence of KSHV in biological samples, such as serum or solid tissue samples, comprising a container containing antibodies to a KSHV polypeptide, and instructional material for performing the test.
- diagnostic test kits for detecting the presence of KSHV in biological samples, such as serum or solid tissue samples, comprising a container containing antibodies to a KSHV polypeptide, and instructional material for performing the test.
- inactivated viral particles or polypeptides derived from the human herpesvirus may be used in a diagnostic test kit to detect antibodies specific for a KSHV polypeptide.
- This invention provides a method of diagnosing Kaposi's sarcoma in a subject which comprises: (a) obtaining a nucleic acid molecule from a tumor lesion or a suitable bodily fluid of the subject; (b) contacting the nucleic acid molecule with a labeled nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with the isolated nucleic acid molecule of KSHV under hybridizing conditions; and (c) determining the presence of the nucleic acid molecule hybridized, the presence of which is indicative of Kaposi's sarcoma in the subject, thereby diagnosing Kaposi's sarcoma in the subject .
- the nucleic acid molecule from the tumor lesion is amplified before step (b) .
- the polymerase chain reaction PCR, is employed to amplify the nucleic acid molecule. Methods of amplifying nucleic acid molecules are known to those skilled in the art.
- DNA sample obtained by the above described method may be cleaved by restriction enzyme before analysis, a technique well-known in the art.
- a size fractionation may be employed which is effected by a polyacrylamide gel.
- the size fractionation is effected by an agarose gel.
- transferring the nucleic acid fragments into a solid matrix may be employed before a hybridization step.
- solid matrix is nitrocellulose paper.
- This invention provides a method of detecting expression of a KSHV gene in a cell which comprises obtaining mRNA from the cell, contacting the mRNA with a labeled nucleic acid molecule of KSHV under hybridizing conditions, determining the presence of mRNA hybridized to the molecule, thereby detecting expression of the KSHV gene.
- cDNA is prepared from the mRNA obtained from the cell and used to detect KSHV expression.
- Target-specific probes may be used in the nucleic acid hybridization diagnostic assays for KS .
- the probes are specific for or complementary to the target of interest.
- the probes should be about 14 nucleotides long and preferably about 20-30 nucleotides.
- nucleic acid probes are about 50 to 1000 nucleotides, most preferably about 200 to 400 nucleotides .
- a specific nucleic acid probe can be RNA, DNA, oligonucleotide, or their analogs.
- the probes may be single or double stranded nucleic acid molecules.
- the probes of the invention may be synthesized enzymatically, using methods well known in the art (e.g., nick translation, primer extension, reverse transcription, the polymerase chain reaction, and others) or chemically (e . g. , by methods described by Beaucage and Carruthers or Matteucci et al . , supra) .
- the probe must be of sufficient length to be able to form a stable duplex with its target nucleic acid in the sample, i.e., at least about 14 nucleotides, and may be longer ( e. g. , at least about 50 or 100 bases in length) . Often the probe will be more than about 100 bases in length. For example, when probe is prepared by nick-translation of DNA in the presence of labeled nucleotides the average probe length may be about 100- 600 bases.
- nucleic acid probe design and annealing conditions see, for example, Ausubel et al . , supra; Berger and Kimmel, Eds . , Methods in Enzymology Vol. 152, (1987) Academic Press, New York; or Hybridization wi th Nucleic Acid Probes , pp. 495-524, (1993) Elsevier, Amsterdam.
- the probe will have considerable sequence identity with the target nucleic acid.
- sequence identity required for specific hybridization will depend on the length of the probe and the hybridization conditions, the probe will usually have at least 70% identity to the target nucleic acid, more usually at least 80% identity, still more usually at least 90% identity and most usually at least 95% or 100% identity.
- a specific probe e . g. , a fluorescently labeled nucleic acid probe
- nucleic acid hybridizations i.e., in si tu , Southern, or Northern
- detergents e.g. , sodium dodecyl sulfate
- chelating agents e.g. , EDTA
- other reagents e.g., buffers, Denhardt's solution, dextran sulfate
- probes can be tested on host cells containing KSHV and compared with the results from cells containing non-KSHV virus.
- a convenient method for determining whether a probe is specific for a KSHV nucleic acid molecule utilizes a Southern blot (or Dot blot) using DNA prepared from the virus. Briefly, to identify a target-specific probe, DNA is isolated from the virus. Test DNA, either viral or cellular, is transferred to a solid (e.g., charged nylon) matrix. The probes are labeled by conventional methods. Following denaturation and/or prehybridization steps known in the art, the probe is hybridized to the immobilized DNAs under stringent conditions, such as defined above .
- a preferred method for detecting the KSHV polypeptide is the use of PCR and/or dot blot hybridization.
- Other methods to test for the presence or absence of KSHV for detection or prognosis, or risk assessment for KS includes Southern transfers, solution hybridization or non-radioactive detection systems, all of which are well known to those of skill in the art. Hybridization is carried out using probes. Visualization of the hybridized portions allows the qualitative determination of the presence or absence of the causal agent.
- a Northern transfer or reverse transcriptase PCR may be used for the detection of KSHV messenger RNA in a sample.
- These procedures are also well known in the art. See Sambrook et al . (1989) Molecular Cloning: A Labora tory Manual (2nd ed. ) , Cold Spring Harbor Laboratory, Vols. 1-3.
- An alternative means for determining the presence of the human herpesvirus is in si tu hybridization, or more recently, in si tu polymerase chain reaction. In si tu PCR is described in Neuvo et al .
- cells are fixed to a solid support, typically a glass slide.
- the cells are then contacted with a hybridization solution at a moderate temperature to permit annealing of target-specific probes that are labeled.
- the probes are preferably labeled with radioisotopes or fluorescent reporters.
- si tu hybridization is a sensitive localization method which is not dependent on expression of polypeptide antigens or native versus denatured conditions.
- Synthetic oligonucleotide (oligo) probes and riboprobes made from KSHV phagemids or plasmids are also provided. Successful hybridization conditions in tissue sections is readily transferrable from one probe to another.
- Commercially-synthesized oligonucleotide probes are prepared using the nucleotide sequence of the identified gene. These probes are chosen for length (45-65 mers) , high G-C content (50-70%) and are screened for uniqueness against other viral sequences in GenBank.
- Oligos are 3 ' end-labeled with [ ⁇ - 35 S]dATP to specific activities in the range of 1 x 10 10 dpm/ ⁇ g using terminal deoxynucleotidyl transferase. Unincorporated labeled nucleotides are removed from the oligo probe by centrifugation through a Sephadex G-25 column or by elution from a Waters Sep Pak C-18 column.
- KS tissue embedded in OCT compound and snap frozen in freezing isopentane cooled with dry ice is cut at 6 ⁇ m intervals and thawed onto 3-aminopropyltriethoxysilane treated slides and allowed to air dry.
- the slides are then fixed in 4% freshly prepared paraformaldehyde and rinsed m water.
- Formalin-fixed, paraffin embedded KS tissues cut at 6 ⁇ m and baked onto glass slides can also be used. These sections are then deparaffinized in xylenes and rehydrated through graded alcohols.
- sections are dehydrated through graded alcohols containing 0.3M ammonium acetate, and air dried.
- the slides are dipped in Kodak NTB2 emulsion, exposed for days to weeks, developed, and counterstained with hematoxylin and eosin (H&E) .
- H&E hematoxylin and eosin
- Alternative immunohistochemical protocols may be employed which are well known to those skilled in the art .
- This invention provides a method of diagnosing Kaposi's sarcoma in a subject, which comprises (a) obtaining a suitable bodily fluid sample from the subject, (b) contacting the suitable bodily fluid of the subject to a support having already bound thereto an antibody recognizing the KSHV polypeptide, so as to bind the antibody to a specific KSHV polypeptide antigen, (c) removing unbound bodily fluid from the support, and (d) determining the level of the antibody bound by the antigen, thereby diagnosing Kaposi's sarcoma.
- This invention provides a method of diagnosing Kaposi's sarcoma in a subject, which comprises (a) obtaining a suitable . bodily fluid sample from the subject, (b) contacting the suitable bodily fluid of the subject to a support having already bound thereto the KSHV polypeptide antigen, so as to bind the antigen to a specific Kaposi's sarcoma antibody, (c) removing unbound bodily fluid from the support, and (d) determining the level of the antigen bound by the Kaposi's sarcoma antibody, thereby diagnosing Kaposi's sarcoma .
- the suitable bodily fluid sample is any bodily fluid sample which would contain Kaposi's sarcoma antibody, antigen or fragments thereof.
- a suitable bodily fluid includes, but is not limited to: serum, plasma, cerebrospinal fluid, lymphocytes, urine, transudates, or exudates.
- the suitable bodily fluid sample is serum or plasma.
- the sample may be cells from bone marrow, or a supernatant from a cell culture.
- Methods of obtaining a suitable bodily fluid sample from a subject are known to those skilled in the art.
- Methods of determining the level of antibody or antigen include, but are not limited to: ELISA, IFA, and Western blotting. Other methods are known to those skilled in the art.
- a subject infected with KSHV may be diagnosed as infected with the above- described methods.
- the detection of KSHV and the detection of virus- associated KS are essentially identical processes.
- the basic principle is to detect the virus using specific ligands that bind to the virus but not to other polypeptides or nucleic acids in a normal human cell or its environs.
- the ligands can be nucleic acid molecules, polypeptides or antibodies.
- the ligands can be naturally-occurring or genetically or physically modified, such as nucleic acids with non- natural nucleotide bases or antibody derivatives, i . e . , Fab or chimeric antibodies.
- Serological tests for detection of antibodies to the virus present in subject sera may also be performed by using the KSHV polypeptide as an antigen, as described herein.
- Samples can be taken from patients with KS or from patients at risk for KS, such as AIDS patients. Typically the samples are taken from blood (cells, serum and/or plasma) or from solid tissue samples such as skin lesions. The most accurate diagnosis for KS will occur if elevated titers of the virus are detected in the blood or in involved lesions. KS may also be indicated if antibodies to the virus are detected and if other diagnostic factors for KS are present . See Immunoassays above for more details on the immunoreagents of the invention for use in diagnostic assays for KS .
- This invention provides a method for treating a subject with Kaposi's sarcoma (KS) comprising administering to the subject having KS a pharmaceutically effective amount of an antiviral agent in a pharmaceutically acceptable carrier, wherein the agent is effective to treat the subject with KSHV.
- KS Kaposi's sarcoma
- this invention provides a method of prophylaxis or treatment for Kaposi's sarcoma (KS) by administering to a patient at risk for KS, an antibody that binds to KSHV in a pharmaceutically acceptable carrier.
- KS Kaposi's sarcoma
- This invention provides a method of treating a subject with Kaposi's sarcoma comprising administering to the subject an effective amount of an antisense molecule capable of hybridizing to the isolated DNA molecule of KSHV under conditions such that the antisense molecule selectively enters a KS tumor cell of the subject, so as to treat the subject.
- This invention provides an antisense molecule capable of hybridizing to the isolated nucleic acid molecule of KSHV.
- the antisense molecule is DNA.
- the antisense molecule is RNA.
- the antisense molecule is a nucleic acid derivative (e.g., DNA or RNA with a protein backbone) .
- the present invention extends to the preparation of antisense nucleic acids and ribozymes that may be used to interfere with the expression of a polypeptide either by masking the mRNA with an antisense nucleic acid or cleaving it with a ribozyme, respectively.
- Inhibitory nucleic acids may be single-stranded nucleic acids, which can specifically bind to a complementary nucleic acid sequence. By binding to the appropriate target sequence, an RNA-RNA, a DNA-DNA, or RNA-DNA duplex or triplex is formed. These nucleic acids are often termed “antisense” because they are usually complementary to the sense or coding strand of the gene, although recently approaches for use of "sense” nucleic acids have also been developed.
- the inhibitory nucleic acid By binding to the target nucleic acid, the inhibitory nucleic acid can inhibit the function of the target nucleic acid. This could, for example, be a result of blocking DNA transcription, processing or poly (A) addition to mRNA, DNA replication, translation, or promoting inhibitory mechanisms of the cells, such as promoting RNA degradation. Inhibitory nucleic acid methods therefore encompass a number of different approaches to altering expression of herpesvirus genes. These different types of inhibitory nucleic acid technology are described in Helene and Toulme (1990) Biochim. Biophys . Acta . 1049, 99-125, which is referred to hereinafter as "Helene and Toulme.”
- inhibitory nucleic acid therapy approaches can be classified into those that target DNA sequences, those that target RNA sequences (including pre-mRNA and mRNA) , those that target proteins (sense strand approaches) , and those that cause cleavage or chemical modification of the target nucleic acids.
- Nucleic acids can be designed to bind to the major groove of the duplex DNA to form a triple helical or "triplex" structure.
- inhibitory nucleic acids are designed to bind to regions of single stranded DNA resulting from the opening of the duplex DNA during replication or transcription.
- inhibitory nucleic acids are designed to bind to mRNA or mRNA precursors. Inhibitory nucleic acids are used to prevent maturation of pre- mRNA. Inhibitory nucleic acids may be designed to interfere with RNA processing, splicing or translation.
- the inhibitory nucleic acids can be targeted to mRNA.
- the inhibitory nucleic acids are designed to specifically block translation of the encoded protein.
- the inhibitory nucleic acid can be used to selectively suppress certain cellular functions by inhibition of translation of mRNA encoding critical proteins.
- an inhibitory nucleic acid complementary to regions of c-myc mRNA inhibits c-myc protein expression in a human promyelocytic leukemia cell line, HL60, which overexpresses the c-myc proto- oncogene. See Wickstrom et al . (1988) PNAS 85, 1028- 1032 and Harel-Bellan et al . (1988) Exp . Med . 168, 2309-2318.
- inhibitory nucleic acids targeting mRNA have been shown to work by several different mechanisms to inhibit translation of the encoded protein (s) .
- the inhibitory nucleic acids introduced into the cell can also encompass the "sense" strand of the gene or mRNA to trap or compete for the enzymes or binding proteins involved in mRNA translation, as described in Helene and Toulme.
- inhibitory nucleic acids can be used to induce chemical inactivation or cleavage of the target genes or mRNA. Chemical inactivation can occur by the induction of crosslinks between the inhibitory nucleic acid and the target nucleic acid within the cell. Other chemical modifications of the target nucleic acids induced by appropriately derivatized inhibitory nucleic acids may also be used.
- Cleavage, and therefore inactivation, of the target nucleic acids may be effected by attaching a substituent to the inhibitory nucleic acid which can be activated to induce cleavage reactions.
- the substituent can be one that affects either chemical, or enzymatic cleavage.
- cleavage can be induced by the use of ribozymes or catalytic RNA.
- the inhibitory nucleic acids would comprise either naturally occurring RNA (ribozymes) or synthetic nucleic acids with catalytic activity.
- the targeting of inhibitory nucleic acids to specific cells of the immune system by conjugation with targeting moieties binding receptors on the surface of these cells can be used for all of the above forms of inhibitory nucleic acid therapy.
- This invention encompasses all of the forms of inhibitory nucleic acid therapy as described above and as described in Helene and Toulme.
- An example of an antiherpes virus inhibitory nucleic acid is ISIS 2922 (ISIS Pharmaceuticals) which has activity against CMV (see Biotechnology News 14:5) .
- a problem associated with inhibitory nucleic acid therapy is the effective delivery of the inhibitory nucleic acid to the target cell in vivo and the subsequent internalization of the inhibitory nucleic acid by that cell. This can be accomplished by linking the inhibitory nucleic acid to a targeting moiety to form a conjugate that binds to a specific receptor on the surface of the target infected cell, and which is internalized after binding.
- U.S. Patent Nos. 5,164,395 and 5,021,437 describe the use of a ribonucleotide reductase inhibitor (an acetylpyridine derivative) for treatment of herpes infections, including the use of the acetylpyridine derivative in combination with acyclovir.
- U.S. Patent No. 5,137,724 (Balzari et al . (1990) Mol . Pharm. 37,402-7) describes the use of thymidylate synthase inhibitors ⁇ e . g. , 5- fluoro-uracil and 5-fluro-2 ' -deoxyuridine) in combination with compounds having viral thymidine kinase inhibiting activity.
- antiviral agents have application here for treatment, such as interferons, nucleoside analogues, ribavirin, amantadine, and pyrophosphate analogues of phosphonoacetic acid
- Antiviral agents include agents or compositions that directly bind to viral products and interfere with disease progress; and, excludes agents that do not impact directly on viral multiplication or viral titer. Antiviral agents do not include immunoregulatory agents that do not directly affect viral titer or bind to viral products. Antiviral agents are effective if they inactivate the virus, otherwise inhibit its infectivity or multiplication, or alleviate the symptoms of KS .
- antiherpesvirus agents that will be useful for treating virus- induced KS can be grouped into broad classes based on their presumed modes of action. These classes include agents that act (1) by inhibition of viral DNA polymerase, (2) by targeting other viral enzymes and proteins, (3) by miscellaneous or incompletely understood mechanisms, or (4) by binding a target nucleic acid (i.e., inhibitory nucleic acid therapeutics, supra) . Antiviral agents may also be used in combination (i.e., together or sequentially) to achieve synergistic or additive effects or other benefits.
- antiviral agents Although it is convenient to group antiviral agents by their supposed mechanism of action, the applicants do not intend to be bound by any particular mechanism of antiviral action. Moreover, it will be understood by those of skill that an agent may act on more than one target in a virus or virus-infected cell or through more than one mechanism.
- nucleoside analogs believed to act through inhibition of viral DNA replication, especially through inhibition of viral DNA polymerase .
- These nucleoside analogs act as alternative substrates for the viral DNA polymerase or as competitive inhibitors of DNA polymerase substrates.
- these agents are preferentially phosphorylated by viral thymidine kinase (TK) , if one is present, and/or have higher affinity for viral DNA polymerase than for the cellular DNA polymerases, resulting in selective antiviral activity.
- TK viral thymidine kinase
- a nucleoside analogue is incorporated into the viral DNA, viral activity or reproduction may be affected in a variety of ways.
- the analogue may act as a chain terminator, cause increased lability (e . g. , susceptibility to breakage) of analogue-containing DNA, and/or impair the ability of the substituted DNA to act as template for transcription or replication (see, e . g. , Balzarini et al . , supra) .
- acyclovir is triphosphorylated to its active form, with the first phosphorylation being carried out by the herpes virus thymidine kinase, when present.
- Other examples are the reported conversion of the compound HOE 602 to ganciclovir in a three-step metabolic pathway (Winkler et al . , 1990, Antiviral Research 14, 61-74) and the phosphorylation of ganciclovir to its active form by, e. g.
- a CMV nucleotide kinase a CMV nucleotide kinase. It will be apparent to one of skill that the specific metabolic capabilities of a virus can affect the sensitivity of that virus to specific drugs, and is one factor in the choice of an antiviral drug. The mechanism of action of certain anti-herpesvirus agents is discussed in De Clercq (1993, Antimicrobial Chemotherapy 32, Suppl . A, 121- 132) and in other references cited supra and infra.
- Anti-herpesvirus medications suitable for treating viral induced KS include, but are not limited to, nucleoside analogs including acyclic nucleoside phosphonate analogs (e.g., phosphonyl- methoxyalkylpurines and -pyrimidines) , and cyclic nucleoside analogs.
- nucleoside analogs including acyclic nucleoside phosphonate analogs (e.g., phosphonyl- methoxyalkylpurines and -pyrimidines) , and cyclic nucleoside analogs.
- vidarabine (9-j ⁇ -D-arabinofuranosyladenine; adenine arabinoside, ara-A, Vira-A, Parke-Davis) ,- 1-/3-D- arabinofuranosyluracil (ara-U) ; 1-jS-D- arabinofuranosyl-cytosine (ara-C) ; HPMPC [(S)-i-[3- hydroxy-2- (phosphonylmethoxy) propyl] cytosine ( e . g.
- HPMPA [ (S) -9- (3-hydroxy-2-phosphonylmethoxypropyl) adenine] and its cyclic form (cHPMPA)
- S) -HPMPDAP [ (S) -9- (3-hydroxy-2-phosphonylmethoxypropyl) -2,6- diaminopurine]
- PMEDAP [9- (2-phosphonyl-methoxyethyl) - 2, 6-diaminopurine]
- HOE 602 [2-amino-9- (1, 3 - bis (isopropoxy) -2-propoxymethyl) purine]
- PMEA [9- (2- phosphonylmethoxyethyl ) adenine] ; bromovinyl - deoxyuridine (Burns and Sandford, 1990, J " .
- acyclovir 9- ( [2- hydroxyethoxyl methyl)guanine; e.g., Zovirax (Burroughs Wellcome)] ; penciclovir ( 9 - [4 - hydroxy- 2 - (hydroxymethy1) butyl] -guanine) ; ganciclovir [ (9- [1,3- dihydroxy-2 propoxymethyl] -guanine) e.g., Cymevene, Cytovene (Syntex) , DHPG (Stals et al . , 1993, Antimicrobial Agents Chemother.
- Triciribine and triciribine monophosphate are potent inhibitors against herpes viruses. (Ickes et al . , 1994, Antiviral Research 23, Seventh International Conf . on Antiviral Research, Abstract No. 122, Supp. 1.), HIV-l and HIV-2 (Kucera et al . , 1993, AIDS Res. Human Retroviruses 9, 307-314) and are additional nucleoside analogs that may be used to treat KS .
- An exemplary protocol for these agents is an intravenous injection of about 0.35 mg/meter 2 (0.7 mg/kg) once weekly or every other week for at least two doses, preferably up to about four to eight weeks.
- Acyclovir and ganciclovir are of interest because of their accepted use in clinical settings.
- Acyclovir an acyclic analogue of guanine, is phosphorylated by a herpesvirus thymidine kinase and undergoes further phosphorylation to be incorporated as a chain terminator by the viral DNA polymerase during viral replication.
- herpesviruses Herpes simplex Types 1 and 2, Varicella- Zoster, Cytomegalovirus, and Epstein-Barr Virus
- disease such as herpes encephalitis, neonatal herpesvirus infections, chickenpox in immunocompromised hosts, herpes zoster recurrences, CMV retinitis, EBV infections, chronic fatigue syndrome, and hairy leukoplakia in AIDS patients.
- Exemplary intravenous dosages or oral dosages are 250 mg/kg/m 2 body surface area, every 8 hours for 7 days, or maintenance doses of 200-400 mg IV or orally twice a day to suppress recurrence.
- Ganciclovir has been shown to be more active than acyclovir against some herpesviruses. See, e . g. , Oren and Soble, 1991, Clinical Infectious Diseases 14, 741-6. Treatment protocols for ganciclovir are 5 mg/kg twice a day IV or 2.5 mg/kg three times a day for 10-14 days. Maintenance doses are 5-6 mg/kg for 5-7 days.
- HPMPC HPMPC is reported to be more active than either acyclovir or ganciclovir in the chemotherapy and prophylaxis of various HSV-l, HSV-2, TK- HSV, VZV or CMV infections in animal models (De Clercq, supra) .
- Nucleoside analogs such as BVaraU are potent inhibitors of HSV-l, EBV, and VZV that have greater activity than acyclovir in animal models of encephalitis.
- FIAC fluroidoarbinosyl cytosine
- FEAU fluroethyl and iodo compounds
- HPMPA (S) -1- ( [3-hydroxy-2- phosphorylmethoxy] propyl) adenine
- Cladribine (2- chlorodeoxyadenosine) is another nucleoside analogue known as a highly specific antilymphocyte agent (i.e., a immunosuppressive drug) .
- 5-thien-2-yl- 2 ' -deoxyuridine derivatives e . g. , BTDU [5-5(5- bromoth ⁇ en-2-yl) -2' -deoxyuridine] and CTDU [b-(5- chlorothien-2-yl) -2' -deoxyuridine] ; and OXT-A [9- (2- deoxy-2-hydroxymethyl-j ⁇ -D-erythro-oxetanosyl) adenine] and OXT-G [9- (2-deoxy-2-hydroxymethyl-/3-D-erythro- oxetanosyl) guanine] .
- OXT-G is believed to act by inhibiting viral DNA synthesis its mechanism of action has not yet been elucidated.
- These and other compounds are described in Andrei et al . , 1992, Eur. J. Clin . Microbiol . Infect . Dis . 11, 143-51.
- Additional antiviral purine derivatives useful in treating herpesvirus infections are disclosed in US Pat. 5,108,994 (assigned to Beecha Group P.L.C.).
- 6- Methoxypurine arabinoside (ara-M; Burroughs Wellcome) is a potent inhibitor of varicella- zoster virus, and will be useful for treatment of KS.
- thymidine analogs e.g., idoxuridine (5-ido- 2 ' -deoxyuridine)
- triflurothymidine have antiherpes viral activity, but due to their systemic toxicity, are largely used for topical herpesviral infections, including HSV stromal keratitis and uveiti ⁇ , and are not preferred here unless other options are ruled out.
- Foscarnet sodium trisodium phosphonoformate, PFA, Foscavir (Astra)
- PAA phosphonoacetic acid
- Foscarnet is an inorganic pyrophosphate analogue that acts by competitively blocking the pyrophosphate -binding site of DNA polymerase. These agents which block DNA polymerase directly without processing by viral thymidine kinase. Foscarnet is reported to be less toxic than PAA.
- the antiherpes-virus agents described above are believed to act through inhibition of viral DNA polymerase.
- viral replication requires not only the replication of the viral nucleic acid but also the production of viral proteins and other essential components.
- the present invention contemplates treatment of KS by the inhibition of viral proliferation by targeting viral proteins other than DNA polymerase ( e . g. , by inhibition of their synthesis or activity, or destruction of viral proteins after their synthesis) .
- agents that inhibit a viral serine protease, e . g. such as one important in development of the viral capsid will be useful in treatment of viral induced KS .
- viral enzyme targets include: OMP decarboxylase inhibitors (a target of, e . g. , parazofurin) , CTP synthetase inhibitors (targets of, e.g., cyclopentenylcytosine) , IMP dehydrogenase, ribonucleotide reductase (a target of, e.g., carboxyl- containing N-alkyldipeptides as described in U.S. Patent No. 5,110,799 (Tolman et al . , Merck)), thymidine kinase (a target of, e . g.
- Poly (I) Poly(C 12 U) an accepted antiviral drug known as Ampligen from HEM Pharmaceuticals of Rockville, MD has been shown to inhibit herpesviruses and is another antiviral agent suitable for treating KS .
- Intravenous injection is the preferred route of administration. Dosages from about 100 to 600 mg/m 2 are administered two to three times weekly to adults averaging 150 pounds. It is best to administer at least 200 mg/m 2 per week.
- antiviral agents reported to show activity against herpes viruses (e.g., varicella zoster and herpes simplex) and will be useful for the treatment of herpesvirus-induced KS include mappicine ketone
- Interferon is known inhibit replication of herpes viruses. See Oren and Soble, supra . Interferon has known toxicity problems and it is expected that second generation derivatives will soon be available that will retain interferon' s antiviral properties but have reduced side affects .
- herpes virus- induced KS may be treated by administering a herpesvirus reactivating agent to induce reactivation of the latent virus.
- a herpesvirus reactivating agent to induce reactivation of the latent virus.
- the reactivation is combined with simultaneous or sequential administration of an anti-herpesvirus agent. Controlled reactivation over a short period of time or reactivation in the presence of an antiviral agent is believed to minimize the adverse effects of certain herpesvirus infections ( e . g. , as discussed in PCT Application WO 93/04683).
- Reactivating agents include agents such as estrogen, phorbol esters, forskolin and /3-adrenergic blocking agents .
- ganciclovir is an example of a antiviral guanine acyclic nucleotide of the type described in US Patent Nos. 4,355,032 and 4,603,219.
- Acyclovir is an example of a class of antiviral purine derivat ives , including 9 - ( 2 - hydroxyethylmethyl) adenine, of the type described in
- Brivudin is an example of an antiviral deoxyuridine derivative of the type described in US Patent No. 4,424,211.
- Vidarabine is an example of an antiviral purine nucleoside of the type described in British Pat. 1,159,290.
- Brovavir is an example of an antiviral deoxyuridine derivative of the type described in US Patent Nos. 4,542,210 and 4,386,076.
- BHCG is an example of an antiviral carbocyclic nucleoside analogue of the type described in US Patent Nos. 5,153,352, 5,034,394 and 5,126,345.
- HPMPC is an example of an antiviral phosphonyl methoxyalkyl derivative with of the type described in US Patent No. 5,142,051.
- CDG Carbocyclic 2 ' -deoxyguanosine
- CDG Carbocyclic 2 ' -deoxyguanosine
- Trifluridine and its corresponding ribonucleoside is described in US Patent No. 3,201,387.
- thymidine kinase inhibitors useful for treating HSV infections and for inhibiting herpes thymidine kinase.
- U.S. Patent No. 4,708,935 (Suhadolnik et al . , Research Corporation) describes a 3 ' -deoxyadenosine compound effective in inhibiting HSV and EBV.
- U.S. Patent No. 4,386,076 (Machida et al . , Yamasa Shoyu Kabushiki K a i s h a ) d e s c r i b e s u s e o f (E) -5- (2-halogenovinyl) -arabinofuranosyluracil as an antiherpesvirus agent.
- the subjects to be treated or whose tissue may be used herein may be a mammal, or more specifically a human, horse, pig, rabbit, dog, monkey, or rodent. In the preferred embodiment the subject is a human.
- compositions are administered in a manner compatible with the dosage formulation, and in a therapeutically effective amount .
- Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner and are peculiar to each subject.
- Suitable regimes for initial administration and booster shots are also variable, but are typified by an initial administration followed by repeated doses at one or more hour intervals by a subsequent injection or other administration.
- administration means a method of administering to a subject. Such methods are well known to those skilled in the art and include, but are not limited to, administration topically, parenterally, orally, intravenously, intramuscularly, subcutaneously or by aerosol. Administration of the agent may be effected continuously or intermittently such that the therapeutic agent in the patient is effective to treat a subject with Kaposi's sarcoma or a subject infected with a DNA virus associated with Kaposi's sarcoma.
- the antiviral compositions for treating herpesvirus - induced KS are preferably administered to human patients via oral, intravenous or parenteral administrations and other systemic forms. Those of skill in the art will understand appropriate administration protocol for the individual compositions to be employed by the physician.
- compositions of this invention may be in the dosage form of solid, semi-solid, or liquid such as, e . g. , suspensions, aerosols or the like.
- the compositions are administered in unit dosage forms suitable for single administration of precise dosage amounts.
- the compositions may also include, depending on the formulation desired, pharmaceutically-acceptable, non- toxic carriers or diluents, which are defined as vehicles commonly used to formulate pharmaceutical compositions for animal or human administration.
- the diluent is selected so as not to affect the biological activity of the combination. Examples of such diluents are distilled water, physiological saline, Ringer's solution, dextrose solution, and Hank's solution.
- composition or formulation may also include other carriers, adjuvants; or nontoxic, nontherapeutic, nonimmunogenic stabilizers and the like.
- Effective amounts of such diluent or carrier are those amounts which are effective to obtain a pharmaceutically acceptable formulation in terms of solubility of components, or biological activity, etc.
- immunosuppressive therapies that can modulate the immunologic dysfunction that arises from the presence of viral-infected tissue.
- agents that block the immunological attack of the viral- infected cells will ameliorate the symptoms of KS and/or reduce disease progression.
- Such therapies include antibodies that prevent immune system targeting of viral-infected cells.
- agents include antibodies which bind to cytokines that otherwise upregulate the immune system in response to viral infection.
- the antibody may be administered to a patient either singly or in a cocktail containing two or more antibodies, other therapeutic agents, compositions, or the like, including, but not limited to, immunosuppressive agents, potentiators and side-effect relieving agents.
- immunosuppressive agents useful in suppressing allergic re- actions of a host.
- Immunosuppressive agents of interest include prednisone, prednisolone, DECADRON (Merck, Sharp & Dohme, West Point, PA) , cyclophosphamide, cyclosporine, ⁇ 6-mercaptopurine, methotrexate, azathioprine and i.v. gamma globulin or their combination.
- Potentiators of interest include monensin, ammonium chloride and chloroquine . All of these agents are administered in generally accepted efficacious dose ranges such as those disclosed in the Physician Desk Reference, 41st Ed. (1987) , Publisher Edward R. Barnhart , New Jersey.
- Immune globulin from persons previously infected with human herpesviruses or related viruses can be obtained using standard techniques. Appropriate titers of antibodies are known for this therapy and are readily applied to the treatment of KS . Immune globulin can be administered via parenteral injection or by intrathecal shunt. In brief, immune globulin preparations may be obtained from individual donors who are screened for antibodies to the KS-associated human herpesvirus, and plasmas from high-titered donors are pooled. Alternatively, plasmas from donors are pooled and then tested for antibodies to the human herpesvirus of the invention; high-titered pools are then selected for use in KS patients.
- Antibodies may be formulated into an injectable preparation.
- Parenteral formulations are known and are suitable for use in the invention, preferably for i. . or i.v. administration.
- the formulations containing therapeutically effective amounts of antibodies or immunotoxins are either sterile liquid solutions, liquid suspensions or lyophilized versions and optionally contain stabilizers or excipients.
- Lyophilized compositions are reconstituted with suitable diluents, e.g., water for injection, saline, 0.3% glycine and the like, at a level of about from .01 mg/kg of host body weight to 10 mg/kg where appropriate.
- the pharmaceutical compositions containing the antibodies or immunotoxins will be administered m a therapeutically effective dose in a range of from about .01 mg/kg to about 5 mg/kg of the treated mammal .
- a preferred therapeutically effective dose of the pharmaceutical composition containing antibody or immunotoxin will be in a range of from about 0.01 mg/kg to about 0.5 mg/kg body weight of the treated mammal administered over several days to two weeks by daily intravenous infusion, each given over a one hour period, in a sequential patient dose-escalation regimen.
- Antibody may be administered systemically by injection i.m., subcutaneously or intraperitoneally or directly into KS lesions.
- the dose will be dependent upon the properties of the antibody or immunotoxin employed, e . g. , its activity and biological half-life, the concentration of antibody in the formulation, the site and rate of dosage, the clinical tolerance of the patient involved, the disease afflicting the patient and the like as is well within the skill of the physician.
- the antibody of the present invention may be administered in solution.
- the pH of the solution should be in the range of pH 5 to 9.5, preferably pH 6.5 to 7.5.
- the antibody or derivatives thereof should be in a solution having a suitable pharmaceutically acceptable buffer such as phosphate, tris (hydroxymethyl) aminomethane-HC1 or citrate and the like. Buffer concentrations should be in the range of 1 to 100 mM.
- the solution of antibody may also contain a salt, such as sodium chloride or potassium chloride in a concentration of 50 to 150 mM.
- a stabilizing agent such as an albumin, a globulin, a gelatin, a protamine or a salt of protamine may also be included and may be added to a solution containing antibody or immunotoxin or to the composition from which the solution is prepared.
- Antibody or immunotoxin may also be administered via microspheres, liposomes or other microparticulate delivery systems placed in certain tissues including blood.
- the dosages of compounds used in accordance with the invention vary depending on the class of compound and the condition being treated.
- the age, weight, and clinical condition of the recipient patient; and the experience and judgment of the clinician or practitioner administering the therapy are among the factors affecting the selected dosage.
- the dosage of an immunoglobulin can range from about 0.1 milligram per kilogram of body weight per day to about 10 mg/kg per day for polyclonal antibodies and about 5% to about 20% of that amount for monoclonal antibodies.
- the immunoglobulin can be administered once daily as an intravenous infusion.
- the dosage is repeated daily until either a therapeutic result is achieved or until side effects warrant discontinuation of therapy.
- the dose should be sufficient to treat or ameliorate symptoms or signs of KS without producing unacceptable toxicity to the patient.
- An effective amount of the compound is that which provides either subjective relief of a symptom ( ⁇ ) or an objectively identifiable improvement as noted by the clinician or other qualified observer.
- the dosing range varies with the compound used, the route of administration and the potency of the particular compound.
- the vaccines are directed against KSHV and most preferably comprise antigens obtained from KSHV.
- the vaccine contains attenuated KSHV.
- the vaccine contains killed KSHV.
- the vaccine contains a nucleic acid vector encoding a KSHV polypeptide.
- the vaccine is a subunit vaccine containing a KSHV polypeptide.
- This invention provides a recombinant KSHV virus with a gene encoding a KSHV polypeptide deleted from the genome.
- the recombinant virus is useful as an attenuated vaccine to prevent KSHV infection.
- This invention provides a method of vaccinating a subject against Kaposi's sarcoma, comprising administering to the subject an effective amount of the peptide or polypeptide encoded by the isolated DNA molecule, and a suitable acceptable carrier, thereby vaccinating the subject.
- naked DNA is administered to the subject in an effective amount to vaccinate the subject against Kaposi's sarcoma.
- This invention provides a method of immunizing a subject against disease caused by KSHV which comprises administering to the subject an effective immunizing dose of an isolated herpesvirus subunit vaccine.
- the vaccine can be made using synthetic peptide or recombinantly-produced polypeptide described above as antigen.
- a vaccine will include from about 1 to 50 micrograms of antigen. More preferably, the amount of polypeptide is from about 15 to about 45 micrograms.
- the vaccine is formulated so that a dose includes about 0.5 milliliters.
- the vaccine may be administered by any route known in the art. Preferably, the route is parenteral. More preferably, it is subcutaneous or intramuscular.
- an antigen can be conjugated to a suitable carrier, usually a protein molecule. This procedure has several facets.
- the carrier may possess properties which facilitate transport, binding, absorption or transfer, of the antigen.
- Suitable carriers are the tetanus toxoid, the diphtheria toxoid, serum albumin and lamprey, or keyhole limpet, hemocyanin because they provide the resultant conjugate with minimum genetic restriction.
- Conjugates including these universal carriers can function as T cell clone activators in individuals having very different gene sets .
- the conjugation between a peptide and a carrier can be accomplished using one of the methods known in the art. Specifically, the conjugation can use bifunctional cross-linkers as binding agents as detailed, for example, by Means and Feeney, "A recent review of protein modification techniques," Bioconjugate Chem . 1, 2-12 (1990) .
- Vaccines against a number of the Herpesviruses have been successfully developed.
- Vaccines against Varicella-Zoster Virus using a live attenuated Oka strain is effective in preventing herpes zoster in the elderly, and in preventing chickenpox in both immunocompromised and normal children (Hardy, I., et al . , 1990, Inf . Dis . Clin . N. A er. 4, 159; Hardy, I. et al . , 1991, New Engl . J. Med. 325, 1545; Levin, M.J. et al . , 1992, J. Inf . Dis . 166, 253; Gershon, A.A.
- Vaccines against Herpes simplex Types 1 and 2 are also commercially available with some success in protection against primary disease, but have been less successful in preventing the establishment of latent infection in sensory ganglia (Roizman, B., 1991, Rev, Inf . Disease 13 (Suppl. 11), S892; Skinner, G.R. et al., 1992, Med. Microbiol . Immunol . 180, 305).
- Vaccines against KSHV can be made from the KSHV envelope glycoproteins . These polypeptides can be purified and used for vaccination (Lasky, L.A. , 1990, J " . Med. Virol . 31, 59). MHC-binding peptides from cells infected with the human herpesvirus can be identified for vaccine candidates per the methodology of Marloes, et al . , 1991, Eur. J. Immunol . 21, 2963- 2970.
- the KSHV antigen may be combined or mixed with various solutions and other compounds as is known in the art. For example, it may be administered in water, saline or buffered vehicles with or without various adjuvants or immunodiluting agents.
- adjuvants or agents include aluminum hydroxide, aluminum phosphate, aluminum potassium sulfate (alum) , beryllium sulfate, silica, kaolin, carbon, water-in- oil emulsions, oil-in-water emulsions, mura yl dipeptide, bacterial endotoxin, lipid X, Corynebacterium parvum (Propionibacterium acnes) , Bordetella pertussis, polyribonucleotides, sodium alginate, lanolin, lysolecithin, vitamin A, saponin, liposomes, levamisole, DEAE-dextran, blocked copolymers or other synthetic adjuvants.
- Such adjuvants are available commercially from various sources, for example, Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.) or Freund' s Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Michigan) .
- Other suitable adjuvants are Amphigen (oil-in-water) , Alhydrogel (aluminum hydroxide), or a mixture of Amphigen and Alhydrogel. Only aluminum is approved for human use.
- the proportion of antigen and adjuvant can be varied over a broad range so long as both are present in effective amounts.
- aluminum hydroxide can be present in an amount of about 0.5% of the vaccine mixture (A1 2 0 3 basis) .
- the amount of the antigen can range from about 0.1 ⁇ g to about 100 ⁇ g protein per patient.
- a preferable range is from about 1 ⁇ g to about 50 ⁇ g per dose.
- a more preferred range is about 15 ⁇ g to about 45 ⁇ g.
- a suitable dose size is about 0.5 ml. Accordingly, a dose for intramuscular injection, for example, would comprise 0.5 ml containing 45 ⁇ g of antigen in admixture with 0.5% aluminum hydroxide.
- the vaccine may be incorporated into a sterile container which is then sealed and stored at a low temperature, for example 4°C, or it may be freeze-dried. Lyophilization permits long-term storage in a stabilized form.
- the vaccines may be administered by any conventional method for the administration of vaccines including oral and parenteral ( e . g. , subcutaneous or intramuscular) injection. Intramuscular administration is preferred.
- the treatment may consist of a single dose of vaccine or a plurality of doses over a period of time. It is preferred that the dose be given to a human patient within the first 8 months of life.
- the antigen of the invention can be combined with appropriate doses of compounds including influenza antigens, such as influenza type A antigens. Also, the antigen could be a component of a recombinant vaccine which could be adaptable for oral administration .
- Vaccines of the invention may be combined with other vaccines for other diseases to produce multivalent vaccines.
- a pharmaceutically effective amount of the antigen can be employed with a pharmaceutically acceptable carrier such as a protein or diluent useful for the vaccination of mammals, particularly humans.
- Other vaccines may be prepared according to methods well-known to those skilled in the art.
- the epitopes are typically segments of amino acids which are a small portion of the whole protein.
- Such derivatives may include peptide fragments, amino acid substitutions, amino acid deletions and amino acid additions of the amino acid sequence for the viral polypeptides from the human herpesvirus.
- Therapeutic, intravenous, polyclonal or monoclonal antibodies can been used as a mode of passive immunotherapy of herpesviral diseases including perinatal varicella and CMV.
- Immune globulin from persons previously infected with the human herpesvirus and bearing a suitably high titer of antibodies against the virus can be given in combination with antiviral agents (e.g. ganciclovir) , or in combination with other modes of immunotherapy that are currently being evaluated for the treatment of KS, which are targeted to modulating the immune response (i.e. treatment with copolymer-1, antiidiotypic monoclonal antibodies, T cell "vaccination").
- Antibodies to human herpesvirus can be administered to the patient as described herein. Antibodies specific for an epitope expressed on cells infected with the human herpesvirus are preferred and can be obtained as described above.
- a polypeptide, analog or active fragment can be formulated into the therapeutic composition as neutralized pharmaceutically acceptable salt forms.
- Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide or antibody molecule) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed from the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.
- This invention provides a method for monitoring the therapeutic efficacy of treatment for Kaposi's sarcoma which comprises: (a) determining in a first sample from a subject with Kaposi's sarcoma the presence of the isolated nucleic acid molecule; (b) administering to the subject a therapeutic amount of an agent such that the agent is contacted to the cell in a sample; (c) determining after a suitable period of time the amount of the isolated nucleic acid molecule in the second sample from the treated subject; and (d) comparing the amount of isolated nucleic acid molecule determined in the first sample with the amount determined in the second sample, a difference indicating the effectiveness of the agent, thereby monitoring the therapeutic efficacy of treatment for Kaposi's sarcoma.
- amount is viral load or copy number. Methods of determining viral load or copy number are known to those skilled in the art .
- KS drug screening assays which determine whether or not a drug has activity against the virus described herein are contemplated in this invention. Such assays comprise incubating a compound to be evaluated for use in KS treatment with cells which express the KS associated human herpesvirus polypeptides or peptides and determining therefrom the effect of the compound on the activity of such agent. In vi tro assays in which the virus is maintained in suitable cell culture are preferred, though in vivo animal models would also be effective .
- vi tro assays include infecting peripheral blood leukocytes or susceptible T cell lines such as MT-4 with the agent of interest in the presence of varying concentrations of compounds targeted against viral replication, including nucleoside analogs, chain terminators, antisense oligonucleotides and random polypeptides (Asada et al . , 1989, J. Clin . Microbiol . 27, 2204; Kikuta et al . , 1989, Lancet Oct . 1 , 861).
- Infected cultures and their supernatants can be assayed for the total amount of virus including the presence of the viral genome by quantitative PCR, by dot blot assays or by using immunologic methods.
- a culture of susceptible cells could be infected with KSHV in the presence of various concentrations of drug, fixed on slides after a period of days, and examined for viral antigen by indirect immunofluorescence with monoclonal antibodies to viral polypeptides (Kikuta et al . , supra) .
- chemically adhered MT-4 cell monolayers can be used for an infectious agent assay using indirect immunofluorescent antibody staining to search for focus reduction (Higashi et al . , 1989, J. Clin . Micro . 27, 2204) .
- KSHV enzymes isolated from a host cell or produced by recombinant techniques can be used as targets for rational drug design to determine the effect of the potential drug on enzyme activity.
- KSHV enzymes amenable to this approach include, but are not limited to, dihydrofolate reductase (DHFR) , thymidylate synthase (TS) , thymidine kinase or DNA polymerase.
- DHFR dihydrofolate reductase
- TS thymidylate synthase
- DNA polymerase DNA polymerase
- This invention provides an assay for screening anti-KS chemotherapeutics .
- Infected cells can be incubated in the presence of a chemical agent that is a potential chemotherapeutic against KS (e.g., acyclo-guanosine) .
- a chemical agent that is a potential chemotherapeutic against KS (e.g., acyclo-guanosine) .
- the level of virus in the cells is then determined after several days by immunofluorescence assay for antigens, Southern blotting for viral genome DNA or Northern blotting for mRNA and compared to control cells.
- This assay can quickly screen large numbers of chemical compounds that may be useful against KS .
- this invention provides an assay system that is employed to identify drugs or other molecules capable of binding to the nucleic acid molecule or proteins, either in the cytoplasm or in the nucleus, thereby inhibiting or potentiating transcriptional activity.
- an assay system that is employed to identify drugs or other molecules capable of binding to the nucleic acid molecule or proteins, either in the cytoplasm or in the nucleus, thereby inhibiting or potentiating transcriptional activity.
- Such assay would be useful in the development of drugs that would be specific against particular cellular activity, or that would potentiate such activity, in time or in level of activity.
- This invention provides a method of screening for a KSHV-selective antiviral drug in vivo comprising: (a) expression of KSHV DHFR or KSHV TS in a bacterial auxotroph (nutritional mutant) ; (b) measuring bacterial growth rate in the absence and presence of the drug; and (c) comparing the rates so measured so as to identify the drug that inhibits KSHV DHFR or KSHV TS in vivo .
- This invention provides a method of determining the health of a subject with AIDS comprising: (a) measuring the plasma concentration of vMIP-I, vMIP-II or vMIP-III; and (b) comparing the measured value to a standard curve relating AIDS clinical course to the measured value so as to determine the health of the subject .
- This invention provides a method of inhibiting HIV replication, comprising administering to the subject or treating cells of a subject with an effective amount of a polypeptide which is encoded by a nucleic acid molecule, so as to inhibit replication of HIV.
- the polypeptide is one from the list provided in Table 1.
- the genome of the Kaposi's sarcoma-associated herpesvirus was mapped with cosmid and phage genomic libraries from the BC-1 cell line. Its nucleotide sequence was determined except for a 3 kb region at the right end of the genome that was refractory to cloning.
- the BC-1 KSHV genome consists of a 140.5 kb long unique coding region (LUR) flanked by multiple G+C rich 801 bp terminal repeat sequences. A genomic duplication that apparently arose in the parental tumor is present in this cell culture-derived strain.
- At least 81 open reading frames including 66 with similarity to herpesvirus saimiri ORFs, and 5 internal repeat regions are present in the LUR.
- the virus encodes genes similar to complement-binding proteins, three cytokines (two macrophage inflammatory proteins and interleukm-6) , dihydrofolate reductase, bcl-2, interferon regulatory factor, IL-8 receptor, NCAM-like adhesin, and a D-type cyclin, as well as viral structural and metabolic proteins. Terminal repeat analysis of virus DNA from a KS lesion suggests a monoclonal expansion of KSHV in the KS tumor. The complete genome sequence is set forth in Genbank Accession Numbers U75698 (LUR) , U75699 (TR) and U75700 (ITR) .
- Kaposi's sarcoma is a vascular tumor of mixed cellular composition (Tappero et al . , 1993, J “ . Am. Acad . Dermatol . 28, 371-395) .
- the histology and relatively benign course in persons without severe immunosuppression has led to suggestions that KS tumor cell proliferation is cytokine induced (Ensoli et al . , 1992, Immunol . Rev. 127, 147-155).
- Epidemiologic studies indicate the tumor is under strict immunologic control and is likely to be caused by a sexually transmitted infectious agent other than HIV (Peterman et al . 1993, AIDS 7, 605-611).
- KSHV KS-associated herpesvirus
- KSHV is a gammaherpesvirus related to herpesvirus saimiri (HVS) belonging to the genus Rhadinovirus (Moore et al . , 1996, J. Virol . 70, 549-558).
- HVS herpesvirus saimiri
- EBV equine herpesvirus 2
- EHV2 equine herpesvirus 2
- L54 and SGL-1) containing the KS631Bam sequence includes cyclm D and IL-8Ra genes unique to rhadinoviruses .
- KSHV is not readily transmitted to uninfected cell lines (Moore et al . , 1996, J. Virol . 70, 549-558), but it is present in a rare B cell primary effusion (body cavity-based) lymphoma (PEL) frequently associated with KS (Cesarman et al . , 1995, New Eng. J. Med. 332, 1186-1191).
- PEL body cavity-based lymphoma
- BC-1 is a PEL cell line containing a high KSHV genome copy number and is coinfected with EBV (Cesarman et al . , 1995, Blood 86, 2708-2714) .
- PFGE pulsed field gel electrophoresis
- the genome size based on encapsidated DNA from an EBV-negative cell line (Renne et al . , 1996, Nature Med. 2, 342-346) is estimated to be 165 kb (Moore et al . , 1996, J. Virol . 70, 549-558).
- Estimates from KS lesions indicate a genome size larger than that of EBV (172 kb) (Decker et al . , 1996, J. Exp . Med . 184, 283-288) .
- BC-1, HBL-6 and BCP-1 cells were maintained in RPMI 1640 with 20% fetal calf serum (Moore et al . , 1996, J " . Virol . 70, 549-558; Cesarman et al . , 1995, Blood 86, 2708-2714; Gao et al . , 1996, Nature Med . 2, 925-928).
- DNA from BC-1 cells was commercially cloned (Sambrook et al . , 1989, Molecular Cloning : A laboratory manual , Cold Spring Harbor Press, Salem, Mass.) into either Lambda FIX II or S-Cosl vectors (Stratagene, La Jolla, CA) . Phage and cosmid libraries were screened by standard methods (Benton et al . , 1977, Science 196, 180-182; Hanahan and Meselson, 1983, Methods Enzymol . 100, 333-342) .
- Lambda and cosmid DNA was purified by standard methods (Sambrook et al . , 1989, Molecular Cloning: A labora tory manual , Cold Spring Harbor Press, Salem,
- Shotgun sequencing (Deininger, 1983, Anal . Biochem . 129, 216-223; Bankier et al . , 1987, Meth . Enzymol . 155, 51-93) was performed on sonicated DNA.
- a 1-4 kb fraction was subcloned into M13mpl9 (New England Biolabs, Inc., Beverly, MA) and propagated in XLl-Blue cells (Stratagene, La Jolla, CA) (Sambrook et al .
- M13 phages were positively screened using insert DNA from the phage or cosmid, and negatively screened with vector arm DNA or adjacent genome inserts.
- Sequence data were edited using Factura (ABI, Foster City, CA) and assembled into contiguous sequences using electropherograms with AutoAssembler (ABI, Foster City, CA) and into larger assemblies with AssemblyLIGN (IBI-Kodak, Rochester NY) . Base positions not clearly resolved by multiple sequencing attempts (less than 10 bases in total) were assigned the majority base pair designation.
- the entire sequence (in 1-5 kb fragments) and all predicted open reading frames (ORFs) were analyzed using BLASTX, BLASTP and BLASTN (Altschul et al . , 1990, J. Mol . Biol . 215, 403-410). The sequence was further analyzed using MOTIFS (Moore et al . , 1996, J " . Virol . 70, 549-558), REPEAT and BESTFIT (GCG) , and MacVector (IBI, New Haven, CT) .
- ORFs were included in the map (Fig. 1) based on similarity to other known genes, optimum initiation codon context (Kozak, 1987, Nucl . Acids Res . 15, 8125-8148), size and position. Conservative selections were made to minimize spurious assignments; this underestimates the number of true reading frames.
- KSHV ORF nomenclature is based on HVS similarities; KSHV ORFs not similar to HVS genes are numbered in consecutive order with a K prefix. ORFs with sequence but not positional similarity to HVS ORFs were assigned the HVS ORF number (e.g., ORF 2). As new ORFs are identified, it is suggested that they be designated by decimal notation.
- the standard map orientation Fig.
- KSHV genome 1) of the KSHV genome is the same as for HVS (Albrecht et al . , 1992, J. Virol . 66, 5047-5058) and EHV2 (Telford et al . , 1995, J. Mol . Biol . 249, 520-528), and reversed relative to the EBV standard map (Baer et al . , 1984, Nature 310, 207-211) .
- Fig. 1 Complete genome mapping was achieved with 7 lambda and 3 cosmid clones (Fig. 1) .
- the structure of the BC-1 KSHV genome is similar to HVS in having a long unique region (LUR) flanked by TR units.
- the -140.5 kb LUR sequence has 53.5% G+C content and includes all identified KSHV ORFs.
- TR regions consist of multiple 801 bp direct repeat units having 84.5% G+C content (Fig. 2A) with potential packaging and cleavage sites.
- the genome sequence abutting the right terminal repeat region is incomplete due to a 3 kb region in the Z2 cosmid insert that could not be cloned into sequencing vectors.
- Partial sequence information from primer walking indicates that this region contains stretches of 16 bp A+G rich imperfect direct repeats interspersed with at least one stretch of 16 bp C + T rich imperfect direct repeats. These may form a larger inverted repeat that could have contributed to our difficulty in subcloning this region. Greater than 12-fold average sequence redundancy was achieved for the entire LUR with complete bidirectional coverage by at least 4 overlapping reads except in the unclonable region.
- BC-1 TR region was examined by Southern blotting since sequencing of the entire region is not possible due to its repeat structure.
- BC-1, BCP-1 (an EBV-negative, KSHV infected cell line) and KS lesion DNAs have an intense -800 bp signal consistent with the unit length repeat sequence when digested with enzymes that cut once in the TR and hybridized to a TR probe (Figs. 2B and 2C) .
- Digestion with enzymes that do not cut in the TR indicates that the BC-1 strain contains a unique region buried in the TR, flanked by ⁇ 7 kb and -35 kb TR sequences (Figs. 2C and 2D) .
- the polymorphic BCP-1 laddering pattern may reflect lytic virus replication and superinfection (Fig. 2C) .
- the EBV laddering pattern occurs when TR units are deleted or duplicated during lytic replication and is a stochastic process for each infected cell (Raab-Traub and Flynn, 1986, Cell 47, 883-889) .
- No laddering is present for BC-1 which is under tight latent KSHV replication control (Moore et al . , 1996, J " . Virol . 70, 549-558).
- KS lesion DNA also shows a single hybridizing band suggesting that virus in KS tumor cells may be of monoclonal origin.
- ORF analysis indicates that only 79% of the sequenced 137.5 kb LUR encodes 81 identifiable ORFs which is likely to be due to a conservative assignment of ORF positions.
- the overall LUR CpG dinucleotide observed/expected (O/E) ratio is 0.75 consistent with a moderate loss of methylated cytosines, but there is marked regional variation. The lowest CpG O/E ratios
- a 143 bp sequence is repeated within ORF Kll at positions 92,678-92,820 and 92,852-92,994 (waka/jwka) .
- Complex repeats are present in other regions of the genome: 20 and 30 bp repeats in the region from 24,285-24,902 (frnk), a 13 bp repeat between bases 29,775 and 29,942 (vnct) , two separate 23 bp repeat stretches between bases 118,123 and 118,697 (zppa), and 15 different 11-16 bp repeats throughout the region from 124,527 to 126,276 (moi) .
- a complex A-G rich repeat region begins at 137,099 and extends into the unsequenced gap.
- conserved ORFs with similar genes found in other herpesviruses are listed in Table 1, along with their polarity, map positions, sizes, relatedness to HVS and EBV ORFs, and putative functions.
- conserved ORFs coding for viral structural proteins and enzymes include genes involved in viral DNA replication (e.g., DNA polymerase (ORF 9)), nucleotide synthesis (e.g., dihydrofolate reductase (DHFR, ORF 2) , thymidylate synthase (TS, ORF 70) ) , regulators of gene expression (R transactivator (LCTP, ORF50) ) and 5 conserved herpesvirus structural capsid and 5 glycoprotein genes .
- ORF 9 DNA polymerase
- nucleotide synthesis e.g., dihydrofolate reductase (DHFR, ORF 2) , thymidylate synthase (TS, ORF 70)
- regulators of gene expression LCTP, OR
- ORF 45 has sequence similarity to nuclear and transcription factors (chick nucleolin and yeast SIR3) and has an extended acidic domain typical for transactivator proteins between amino acids 90 and 115.
- ORF73 also has an extended acidic domain separated into two regions by a glutamine-rich sequence encoded by the moi repeat. The first region consists almost exclusively of aspartic and glutamic acid residue repeats while the second glutamic acid rich region has a repeated leucine heptad motif suggestive of a leucine zipper structure.
- ORF 75 a putative tegument protein, has a high level of similarity to the purine biosynthetic enzyme of E. coli and D. melanogaster N-formylglycinamide ribotide amidotransferase (FGARAT) .
- ORFs K3 and K5 are not similar to HVS genes but are similar to the major immediate early bovine herpesvirus type 4 (BHV4) gene IE1 (12 and 13% identity respectively) (van Santen, 1991, J " . Virol . 65, 5211-5224). These genes have no significant similarity to the herpes simplex virus I (HSV1) aO (which is similar to BHV4 IE1) , but encode proteins sharing with the HSV1 ICPO protein a cysteine-rich region which may form a zinc finger motif (van Santen, 1991, J. Virol . 65, 5211-5224).
- the protein encoded by ORF K5 has a region similar to the nuclear localization site present in the late form of the BHV4 protein.
- ORF K8 has a purine binding motif (GLLVTGKS) in the C-terminus of the protein which is similar to a motif present in the KSHV TK (ORF21) (Moore et al . , 1996, J. Virol . 70, 549-558).
- GLLVTGKS purine binding motif
- HVS ORF 1 codes for a transforming protein, responsible for HVS-induced in vitro lymphocyte transformation (Akari et al . , 1996, Virology 218, 382-388) and has poor sequence conservation among HVS strains (Jung and Desrosiers, 1991, J. Virol . 65, 6953-6960; Jung and Desrosiers, 1995, Molec . Cellular Biol . 15, 6506-6512). Functional KSHV genes similar to this gene may be present but were not identifiable by sequence comparison.
- KSHV also does not have a gene similar to the BZLFl EBV transactivator gene.
- sequences between bp 90,173 and 90,643 are similar to the precursor of secreted glycoprotein X (gX) , encoded by a number of alphaherpesviruses (pseudorabies , EHV1) , and which does not form part of the virion structure.
- EHV1 alphaherpesviruses
- the KSHV form lacks the highly-acidic carboxy terminus of the pseudorabies gene .
- Tl.l Two polyadenylated transcripts expressed at high copy number in BCBL-1 are present at positions 28,661-29,741 (Tl.l) in IBb and 118,130-117,436 (TO.7) in IBh.
- TO .7 encodes a 60 residue polypeptide (ORF K12, also called Kaposin) and Tl.l (also referred to as nut-1) has been speculated to be a U RNA-like transcript .
- ORFs which are either unique to KSHV or shared only with other gammaherpesviruses encode genes similar to oncoproteins and cell signaling proteins.
- ORF 16 similar to EBV BHRF1 and HVS 0RF16, encodes a functional Bcl-2-like protein which can inhibit Bax-mediated apoptosis.
- ORF 72 encodes a functional cyclin D gene, also found in HVS (Nicholas et al . , 1992, Nature 355, 362-365), that can substitute for human cyclin D in phosphorylating the retinoblastoma tumor suppressor protein.
- KSHV encodes a functionally-active IL-6 (ORF K2 ) and two macrophage inflammatory proteins (MIPs) (ORFs K4 and K6) which are not found in other human herpesviruses.
- the vIL-6 has 62% amino acid similarity to the human IL-6 and can substitute for human IL-6 in preventing mouse myeloma cell apoptosis.
- Both MlP-like proteins have conserved C-C dimer signatures characteristic of /3-chemokines and near sequence identity to human MlP-l ⁇ in their N-terminus regions.
- vMIP-I (ORF K6) can inhibit CCR-5 dependent HIV-1 replication.
- ORF K9 vIRFl encodes a 449 residue protein with similarity to the family of interferon regulatory factors (IRF) (David, 1995, Pharmac . Ther . 65, 149-161). It has 13.4% amino acid identity to human interferon consensus sequence binding protein and partial conservation of the IRF DNA-binding domain.
- vIRF2 Three additional open reading frames at bp 88,910-88,410 (vIRF2), bp 90,541-89,600 (vIRF3) and bp 94,127-93,636 (vIRF4) also have low similarity to IRF-like proteins (p > 0.35) . No conserved interferon consensus sequences were found in this region of the genome.
- genes encoding signal transduction polypeptides which are also found in other herpesviruses, include a complement-binding protein (v-CBP, ORF 4) , a neural cell adhesion molecule (NCAM) -like protein (v-adh, ORF K14) and an IL8 receptor (ORF 74) .
- v-CBP complement-binding protein
- NCAM neural cell adhesion molecule
- ORF 74 an IL8 receptor
- OX-2 is in turn similar to ORF U85 of human herpesviruses 6 and 7 but there is no significant similarity between the KSHV and betaherpesvirus 0X-2/NCAM ORFs.
- v-adh has V-like, C-like, transmembrane and cytoplasmic domains, and an RGD binding site for fibronectin at residues 268-270.
- the vIL-8R has a seven transmembrane spanning domain structure characteristic of G-protein coupled chemoattractant receptors which includes the EBV-induced EBI1 protein (Birkenbach et al . , 1993, J. Virol . 67, 2209-2220) .
- the full-length sequence of the KSHV genome in BC-1 cells provides the opportunity to investigate molecular mechanisms of KSHV-associated pathogenesis .
- the KSHV genome has standard features of rhadinovirus genomes including a single unique coding region flanked by high G+C terminal repeat regions which are the presumed sites for genome circularization.
- KSHV is unique in encoding a number of proteins mimicking cell cycle regulatory and signaling proteins .
- KSHV Molecular mimicry by KSHV of cell cycle regulatory and signaling proteins is a prominent feature of the virus.
- the KSHV genome has genes similar to cellular complement-binding proteins (ORF 4) , cytokines (ORFs),
- K2, K4 and K6 a bcl-2 protein (ORF 16), a cytokine transduction pathway protein (K9) , an IL-8R-like protein (ORF74) and a D-type cyclin (ORF72) .
- CD21/CR2, bcl-2, an I - ⁇ R-like protein (EBI1) , IL-6 and adhesion molecules are upregulated by EBV infection (Birkenbach et al . , 1993, J. Virol . 61 , 2209-2220; Palmero et al . , 1993, Oncogene 8, 1049-1054; Finke et al . , 1992, Blood 80, 459-469; Finke et al . , 1994, Leukemia & Lymphoma 12, 413-419; Jones et al . , 1995, J. Exper . Med. 182, 1213-1221).
- KSHV modifies the same signaling and regulation pathways that EBV modifies after infection, but does so by introducing exogenous genes from its own genome.
- /3-chemokines are not known to be required for successful EBV infection of cells although EBV-infected B cells express higher levels of MlP-l ⁇ than normal tonsillar lymphocytes (Harris et al . , 1993, 151, 5975-5983).
- the autocrine dependence of EBV- infected B cells on small and uncharacterized protein factors in addition to IL-6 leads to speculation that /3-chemokines may also play a role in the EBV life cycle.
- KSHV has not formally been shown to be a transforming virus and genes similar to the major transforming genes of HVS and EBV are not present in the BC-1 strain KSHV. Nonetheless, dysregulation of cell proliferation control caused by the identified KSHV-encoded proto-oncogenes and cytokines may contribute to neoplastic expansion of virus-infected cells. Preliminary studies suggest that subgenomic KSHV fragments can transform NIH 3T3 cells.
- KSHV Kaposi's sarcoma-associated herpesvirus
- Kaposi's sarcoma-associated herpesvirus is a gammaherpesvirus related to Epstein-Barr virus (EBV) and herpesvirus saimiri (HVS) . It is present in nearly all KS lesions including the various types of HIV-related and HIV-unrelated KS (Chang et al . , 1994, Sci ence 265, 1865-1869; Boshoff et al . , 1995, Lancet 345, 1043-1044; Dupin et al . , 1995, Lancet 345, 761-762; Schalling et al . , 1995, Na ture Med. 1, 707-708) .
- EBV Epstein-Barr virus
- HVS herpesvirus saimiri
- genomic sequencing was performed using Supercos-1 and Lambda FIX II genomic libraries from BC-1, a nonHodgkin's lymphoma cell line stably infected with both KSHV and EBV (Cesarman et al . , 1995, Blood 86, 2708-2714) .
- the KSHV DNA fragments KS330Bam and KS631Bam were used as hybridization starting points for mapping and bi-directional sequencing.
- Open reading frame (ORF) analysis (see METHODS) of the Z6 cosmid sequence identified two separate coding regions (ORFs K4 and K6) with sequence similarity to ⁇ -chemokines and a third coding region (ORF K2) similar to human interleukin-6 (huIL-6) ; a fourth coding region (ORF K9) is present m the Z8 cosmid insert sequence with sequence similarity to interferon regulatory factor (IRF) polypeptides ( Figures 3A-3C) . None of these KSHV genes are similar to other known viral genes. Parenthetically, a protein with conserved cysteine motifs similar to /3-chemokine motif signatures has recently been reported in the molluscum contagiosum virus (MCV) genome. Neither vMIP-I nor vMIP-II has significant similarity to the MCV protein.
- the cellular counterparts to these four viral genes encode polypeptides involved in cell responses to infection.
- MIP/RANTES macrophage inflammatory protein/regulated on activation, normal T cell expressed and secreted
- chemokines a /3-chemoattractant cytokines
- /3-chemokines are the natural ligand for CCR5 and can block entry of non-syncytium inducing (NSI) , primary lymphocyte and macrophage-tropic HIV-l strains in vi tro by binding to this HIV co-receptor (Cocchi et al .
- IL-6 initially described by its effect on B cell differentiation (Hirano et al . , 1985, Proc Natl Acad Sci , USA 85, 5490; Kishimoto et al . , 1995, Blood 86, 1243-1254) , has pleiotropic effects on a wide variety of cells and may play a pathogenic role in multiple myeloma, multicentric Castleman's disease (a KSHV-related disorder) , AIDS-KS and EBV-related postransplant lymphoproliferative disease (Klein et al . , 1995, Blood 85, 863-872; Hubert et al .
- IL-6 production is induced by either EBV or CMV infection and is an autocrine factor for EBV-infected lymphoblastoid cells that enhances their tumorigenicity in nude mice (Tosato et al .
- IRF-1 and IRF-2 are secreted cytokines
- IRF-1 and IRF-2 are secreted cytokines
- IRF-2 are secreted cytokines
- IRF-1 and IRF-2 have opposing anti-oncogenic and oncogenic activities
- ORF K6 The 289 bp ORF K6 (ORF MIPl) gene encodes a 10.5 kDa polypeptide (vMIP-I; MIPl) having 37.9% amino acid identity (71% similarity) to huMIP-l ⁇ and slightly lower similarity to other (S-chemokines ( Figure 3A) .
- ORF K4 also encodes a predicted 10.5 kDa polypeptide (vMIP-II; vMIPl ⁇ ;-II) with close similarity and amino acid hydrophobicity profile to vMIP-I.
- the two KSHV-encoded MIP ⁇ -chemokines are separated from each other on the KSHV genome by 5.5 kb of intervening sequence containing at least 4 ORFs (see METHODS) .
- Figure 3A residues 17-55 which include a characteristic C-C dicysteine dimer (Figure 3A, residues 36-37) , and have near sequence identity to human MIP-l ⁇ at residues 56-84.
- the two polypeptides show only 49.0% amino acid identity to each other and are markedly divergent at the nucleotide level indicating that this duplication is not a cloning artifact.
- the two viral polypeptides are more closely related to each other phylogenetically than to huMIP-l ⁇ * , huMIP-13 or huRANTES suggesting that they arose by gene duplication rather than independent acquisition from the host genome ( see Sequence alignment in METHODS) . The reason for this double gene dosage in the viral genome is unknown.
- the KSHV ORF K2 ( Figure 3B) encodes a hypothetical 204 residue, 23.4 kDa IL-6-like polypeptide with a hydrophobic 19 amino acid secretory signaling peptide having 24.8% amino acid identity and 62.2% similarity to the human polypeptide.
- vIL-6 also has a conserved sequence characteristic for IL-6-like interleukins
- IL-6 is a glycosylated cytokine and potential N-linked glycosylation sites in the vIL-6 sequence are present at gapped positions 96 and 107 in Figure 3C.
- the 449 residue KSHV vIRF polypeptide encoded by ORF K9 has lower overall amino acid identity (approximately 13%) to its human cellular counterparts than either of the vMIPs or the vIL-6, but has a conserved region derived from the IRF family of polypeptides (Figure 3C, gapped residues 88-121) .
- This region includes the tryptophan-rich IRF ICS DNA binding domain although only two of four tryptophans thought to be involved in DNA binding are positionally conserved. It is preceded by an 87-residue hydrophilic N-terminus with little apparent IRF similarity. A low degree of amino acid similarity is present at the C-terminus corresponding to the IRF family transactivator/repressor region.
- the four KSHV cell signaling pathway genes show similar patterns of expression in virus-infected lymphocyte cell lines by Northern blotting ⁇ see METHODS) .
- Whole RNA was extracted from BCP-1 (a cell line infected with KSHV alone) and BC-1 (EBV and KSHV coinfected, see Cesarman et al . , 1995, Blood 86, 2708-2714) with or without pretreat ent with 20 ng/ml 12-0-tetradecanoylphorbol-13-acetate (TPA, Sigma, St. Louis MO) for 48 hours. While constitutive expression of these genes was variable between the two cell lines, expression of all four gene transcripts increased in BCP-1 and BC-1 cells after TPA induction
- Figures 4A-4D This pattern is consistent with expression occurring primarily during lytic phase virus replication. Examination of viral terminal repeat sequences of BCP-1 and BC-1 demonstrates that low level of virus lytic replication occurs in BCP-1 but not BC-1 without TPA induction (see METHODS) , and both cell lines can be induced to express lytic phase genes by TPA treatment despite repression of DNA replication in BC-1. Lower level latent expression is also likely, particularly for vIL-6 ( Figure 4C) and vIRF ( Figure 4D) , since these transcripts are detectable without TPA induction in BC-1 cells which are under tight latency control.
- vIL-6 was examined in more detail using bioassays and antibody localization studies to determine whether it is functionally conserved.
- Recombinant vIL-6 (rvIL-6) is specifically recognized by antipeptide antibodies which do not cross-react with huIL-6 ( Figures 5A-5B) (see METHODS) .
- vIL-6 is produced constitutively in BCP-1 cells and increases markedly after 48 hour TPA induction, consistent with Northern hybridization experiments.
- the BC-1 cell line coinfected with both KSHV and EBV only shows vIL-6 polypeptide expression after TPA induction ( Figure 5A, lanes 3-4) and control EBV-infected P3HR1 cells are negative for vIL-6 expression ( Figure 5A, lanes 5-6) .
- vIL-6 vIL-6 -dependent mouse plasmacytoma cell line B9
- COS7 supernatants from the forward construct support B9 cell proliferation measured by 3 H-thymidine uptake indicating that vIL-6 can substitute for cellular IL-6 in preventing B9 apoptosis ( Figure 6) .
- vIL-6 supported B9 proliferation is dose dependent with the unconcentrated supernatant from the experiment shown in Figure 6 having biologic activity equivalent to approximately 20 pg per ml huIL-6.
- FIG. 7A Forty-three percent of noninduced BCP-1 cells ( Figure 7A) have intracellular cytoplasmic vIL-6 immunostaining ( see METHODS) suggestive of constitutive virus polypeptide expression in cultured infected cells, whereas no specific immunoreactive staining is present in uninfected control P3HR1 cells ( Figure 7B) . vIL-6 production was rarely detected in
- KS tissues and only one of eight KS lesions examined showed clear, specific vIL-6 immunostaining in less than 2% of cells (Figure 7C) .
- the specificity of this low positivity rate was confirmed using preimmune sera and neutralization with excess vIL-6 peptides.
- Rare vIL- 6 -producing cells in the KS lesion are positive for either CD34, an endothelial cell marker (Figure 8A) , or CD45, a pan-hematopoietic cell marker ( Figure 8B) , demonstrating that both endothelial and hematopoietic cells in KS lesions produce vIL6.
- Virus dissemination to nonKS tissues was found by examining a lymph node from a patient with AIDS-KS who did not develop PEL. Numerous vIL- 6 -staining hematopoietic cells were present in this lymph node ( Figure 8C) which was free of KS microscopically. vIL-6 positive lymph node cells were present in relatively B-cell rich areas and some express CD20 B cell surface antigen ( Figure 8D) , but not EMA surface antigen (unlike PEL cells) (Cesarman et al . , 1995, Blood 86, 2708-2714) . No colocalization of vIL-6 positivity with the T cell surface antigen CD3 or the macrophage antigen CD68 was detected, although phagocytosis of vIL-6 immunopositive cells by macrophages was frequently observed.
- HIV-1 virus entry human CD4+ cat kidney cells
- CCC/CD4 were transiently transfected with plasmids expressing human CCR5 and vMIP-I or its reverse construct I-PIMv (see CCR5 and vMIP-I cloning in METHODS) . These cells were infected with either M23 or SF162 primary NSI HIV-1 isolates which are known to use CCR5 as a co-receptor (Clapham et al . , 1992, J Virol 66, 3531-3537) or with the HIV-2 variant ROD/B which can infect CD4+ CCC cells without human CCR5. Virus entry and replication was assayed by immunostaining for retroviral antigen production ( Figure 9) . vMIP-I cotransfection reduced NSI HIV-1 foci generation to less than half that of the reverse-construct negative control but had no effect on ROD/B HIV-2 replication.
- Molecular piracy of host cell genes is a newly recognized feature of some DNA viruses, particularly herpesviruses and poxviruses (Murphy, 1994, Infect Agents Dis 3, 137-154; Albrecht et al . , 1992, J Virol 66, 5047-5058; Gao and Murphy, 1994, J Biol Chem 269, 28539-28542; Chee et al . , 1990, Curr Top Microbiol Immunol 154, 125-169; Massung et al . , 1994, Virol 201, 215-240) .
- the degree to which KSHV has incorporated cellular genes into its genome is exceptional.
- KSHV also encodes polypeptides similar to bcl-2 (ORF 16) , cyclin D (ORF 72) , complement -binding proteins si iliar to CD21/CR2 (ORF 4) , an NCAM-like adhesion protein (ORF K14) , and an IL-8 receptor (ORF 74).
- EBV also either encodes (BHRFl/bcl-2) or induces (CR-2; cyclin D; IL-6; bcl-2; adhesion molecules and an IL-8R-like EBI1 protein) these same cellular polypeptides (Cleary et al .
- both viruses may modify similar host cell signaling and regulatory pathways. EBV appears to effect these changes through induction of cellular gene expression whereas KSHV introduces the polypeptides exogenously from its own genome.
- huIL-6 inhibits ⁇ -interferon-induced, Bax-mediated apoptosis in myeloma cell lines (Lichtenstein et al . , 1995, Cellular Immunology 162, 248-255) and vIL-6 may play a similar role in infected B cells.
- KSHV-encoded vIRF, vbcl-2 and v-cyclin may also interfere with host-cell mediated apoptosis induced by virus infection and v-cyclin may prevent Gl cell cycle arrest of infected cells.
- vMIP-I and vMIP-II may have agonist or antagonist signal transduction roles. Their sequence conservation and duplicate gene dosage are indicative of a key role in KSHV replication and survival .
- KSHV vMIP-I inhibits NSI HIV-1 replication in vi tro ( Figure 9) .
- Studies from early in the AIDS epidemic indicate that survival is longer for AIDS-KS patients than for other AIDS patients, and that 93% of US AIDS patients surviving >3 years had KS compared to only 28% of remaining AIDS patients dying within 3 years of diagnosis (Hardy, 1991, J " AIDS 4, 386-391; Lemp et al . , 1990, J Am Med Assoc 263, 402-406; Rothenberg et al . , 1987, New Eng J Med 317, 1297-1302; Jacobson et al . , 1993, Am J Epidemiol 138, 953-964; Lundgren et al .
- Genomic Sequencing Genomic inserts were randomly sheared, cloned into M13mpl8, and sequenced to an average of 12 -fold redundancy with complete bidirectional sequencing.
- the descriptive nomenclature of KSHV polypeptides is based on the naming system derived for herpesvirus saimiri (Albrecht et al . , 1992, J Virol 66, 5047-5058).
- ORF Open reading frame analysis. Assembled sequence contigs were analyzed using MacVector (IBI -Kodak, Rochester NY) for potential open reading frames greater than 25 amino acid residues and analyzed using BLASTX and BEAUTY-BLASTX (Altschul et al . , 1990, J Mol Biol 215, 403-410; Worley et al . , 1995, Genome Res 5, 173 -184 ; http: //dot . imgen.bcm.tmc.edu: 9331/seq- search/nucleic_acid-search.html) .
- vMIP-II LD78 (MlP-la)
- ISGF3 human, sp Q00978, 3.9xe-9
- Northern blotting was performed using standard conditions with random- labeled probes
- vMIP-I 5' -AGC ATA TAA GGA ACT CGG CGT TAC-3' (SEQ ID NO:4), 5'-GGT AGA TAA ATC CCC CCC CTT TG-3' (SEQ ID NO: 5) ; vMIP-II: 5'-TGC ATC AGC TTC TTC ACC CAG-3' (SEQ ID NO: 6), 5'-TGC TGT CTC GGT TAC CAG AAA AG-3' (SEQ ID NO:
- vIL-6 5' -TCA CGT CGC TCT TTA CTT ATC GTG- 3'
- BCP-1, BC-1 and P3HR1 were maintained in culture conditions and induced w th TPA as previously described (Gao et al . , 1996, New Eng J Med 335, 233-241) .
- PCR amplification for these viral genes was performed using the vMIP-I, vMIP-II, vIL-6, and vIRF primer sets with 35 amplification cycles and compared to dilutions of whole BC-1 DNA as a positive control using PCR conditions previously described (Moore and Chang, 1995, New Eng J Med 332, 1181-1185).
- KS spindle cell line DNA used for these experiments was described in Dictor et al . , 1996, Am J Pathol 148, 2009-2016. Amplifiability of DNA samples was confirmed using human HLA-DQ alpha and pyruvate dehydrogenase primers .
- vIL-6 cloning was cloned from a 695 bp polymerase chain reaction (PCR) product using the following primer set: 5' -TCA CGT CGC TCT TTA CTT ATC
- CGT AAC-3' (SEQ ID NO:13), amplified for 35 cycles using the 0.1 ⁇ g of BC-1 DNA as a template.
- PCR product was intially cloned into pCR 2.1 (Invitrogen,
- the sequence was also cloned into the pMET7 vector in the reverse orientation (6-LIv) relative to the SRa promoter as a negative control, with orientation and sequence fidelity of both constructs confirmed by bidirectional sequencing using dye-primer chemistry on an ABI 377 sequenator (Applied Biosystems Inc, Foster City CA) .
- B9 mouse plasmacytoma cell line were maintained in Iscove's Modified Dulbecco's Medium (IMDM) (Gibco, Gaithersburg, MD) , 10% fetal calf serum, 1% penicillin/streptomycin, 1% glutamine, 50 ⁇ M /3-mercaptoethanol, and 10 ng per ml rhuIL-6 (R&D Systems, Minneapolis, MN) .
- IMDM Iscove's Modified Dulbecco's Medium
- IMDM Iscove's Modified Dulbecco's Medium
- penicillin/streptomycin 1% glutamine
- 50 ⁇ M /3-mercaptoethanol 50 ⁇ M /3-mercaptoethanol
- 10 ng per ml rhuIL-6 R&D Systems, Minneapolis, MN
- 3 H-thymidine uptake was used to measure B9 proliferation in response to huIL-6 or recombinant supernatants according to standard protocols (R&
- serial 1:3 dilutions of huIL-6 or Centriplus 10 concentrated recombinant supernatants were incubated with 2xl0 4 cells per well in a 96 well plate for 24 hours at 37°C with 10 ⁇ l of thymidine stock solution (50 ⁇ l of lmCi/ml 3 H-thymidine in 1 ml IMDM) added to each well during the final four hours of incubation. Cells were harvested and incorporated 3 H-thymidine determined using a liquid scintillation counter. Each data point is the average of six determinations with standard deviations shown.
- vIL-6 immunostaining Immunostaining was performed using avidin-biotin complex (ABC) method after deparaffinization of tissues and quenching for 30 minutes with 0.03% H 2 0 2 in PBS.
- the primary antibody was applied at a dilution of 1:1250 after blocking with 10% normal goat serum, 1% BSA, 0.5% Tween 20.
- the secondary biotinylated goat anti-rabbit antibody (1:200 in PBS) was applied for 30 minutes at room temperature followed by three 5 minute washes in PBS.
- Peroxidase-linked ABC (1:100 in PBS) was applied for 30 minutes followed by three 5 minute washes in PBS.
- a diamino-benzidine (DAB) chromogen detection solution (0.25% DAB, 0.01% H 2 0 2 in PBS) was applied for 5 minutes. Slides are then washed, counterstained with hematoxylin and coverslipped. Amino ethyl carbazole (AEC) or Vector Red staining was also used allowing better discrimination of double- labeled cells with Fast Blue counterstaining for some surface antigens. For CD68, in which staining might be obscured by vIL-6 cytoplasmic staining, double label immunofluorescence was used.
- DAB diamino-benzidine
- AEC Amino ethyl carbazole
- Vector Red staining was also used allowing better discrimination of double- labeled cells with Fast Blue counterstaining for some surface antigens.
- CD68 in which staining might be obscured by vIL-6 cytoplasmic staining, double label immunofluorescence was used.
- Microwaved tissue sections were blocked with 2% human serum, 1% bovine serum albumin (BSA) in PBS for 30 minutes, incubated overnight with primary antibodies and developed with fluorescein-conjugated goat anti-rabbit IgG (1:100, Sigma) for vIL-6 localization and rhodamine-conjugated horse anti-mouse IgG (1:100, Sigma) for CD68 localization for 30 minutes. After washing, secondary antibody incubation was repeated twice with washing for 15 minutes each to amplify staining.
- BSA bovine serum albumin
- vIL-6 For the remaining membrane antigens, slides were developed first for vIL-6 and then then secondly with the cellular antigen, as well as the reverse localization (cellular antigen antibody first, ant ⁇ -vIL-6 second) to achieve optimal visualization and discrimination of both antigens.
- the first antibody was developed using AEC (Sigma) with blocking solution preincubation (1% BSA, 10% normal horse serum, 0.5% Tween 20 for 30 minutes) and development per manufacturer's instructions.
- the second antibody was developed using the ABC-alkaline phosphatase technique with Fast Blue chromagen. Both microwaving and trypsinization resulted in poorer localization and specificity of vIL-6 immunolocalization.
- Vector-Red (Vector, Burlingame, CA) staining was used as an alternative stain to AEC to achieve optimal discrimination and was performed per manufacturer's protocol using the ABC-alkaline phosphatase technique.
- EMA epithelial membrane antigen
- Immunohistochemical vIL-6 localization was performed on exponential phase BCP-1 cells with or without 48 hour TPA incubation after embedding in 1% agar in saline. The percentages of positive cells were determined from cell counts of three random high power microscopic fields per slide. Lower percentages of BCP-1 cells stain positively for vIL-6 after TPA treatment possibly reflecting cell lysis and death from lytic virus replication induction by TPA. Immunostaining of cells and tissues was demonstrated to be specific by neutralization using overnight incubation of antisera with 0.1 ⁇ g/ml vIL-6 synthetic peptides at 4°C and by use of preimmune rabbit antisera run in parallel with the postim une sera for the tissues or cell preparations. No specific staining was seen after either peptide neutralization or use of preimmune sera.
- CCR5 and vMIP-I cloning were cloned into pRcCMV vector (Invitrogen) and both forward and reverse orientations of the vMIP-I gene were cloned into pMET7 after PCR amplification using the following primer pairs: 5' -AGC ATA TAA GGA ACT CGG CGT TAC-3' (SEQ ID NO: 1
- vMIP-I the reverse construct (I-PIMv) and empty pMET7 vector were transfected into CCC/CD4 cells (CCC cat cells stably expressing human CD4 , see McKnight et al . , 1994, Virol 201, 8-18) using Lipofectamine
- ORF36 Viral protein kinase
- Name e . g. Kl or ORF4 ) refers to the KSHV ORF designation; Pol signifies polarity of the ORF within the KSHV genome; Start refers to the position of the first LUR nucleotide in the start codon; Stop refers to the position of the last LUR nucleotide in the stop codon; Size indicates the number of amino acid residues encoded by the KSHV ORF; HVS%Sim indicates the percent similarity of the indicated KSHV ORF to the corresponding ORF of herpesvirus saimiri; HVS%Id indicates the percent identity of the indicated KSHV ORF to the corresponding ORF of herpesvirus saimiri; EBV Name indicates the EBV ORF designation; EBV%Sim indicates the percent similarity of the indicated KSHV ORF to the named Epstein-Barr virus ORF; EBV%Id indicates the percent identity of the indicated KSHV ORF to the named Epstein-Barr virus ORF.
- nucleotides 1-35,100 of the LUR are set forth in SEQ ID NO: 17 numbered nucleotides 1-35,100, respectively; nucleotides 35,101-70,200 of the LUR are set forth in SEQ ID NO: 18 numbered nucleotides 1- 35,100, respectively; nucleotides 70,201-105,300 of the LUR are set forth in SEQ ID NO: 19 numbered nucleotides 1-35,100, respectively; and nucleotides 105,301-137,507 of the LUR are set forth in SEQ ID NO: 20 numbered nucleotides 1-32,207, respectively.
- Lys Asn Asn Pro His Asp Arg Arg lie lie Met Cys Ala Trp Asn Pro 195 200 205
- Gly Asp Met Gly Leu Gly Val Pro Phe Asn lie Ala Ser Tyr Ser Leu 245 250 255
- Leu Arg Leu Gin Leu Thr Arg Thr Pro Arg Pro Phe Pro Arg Leu Glu 290 295 300 lie Leu Arg Ser Val Ser Ser Met Glu Glu Phe Thr Pro Asp Asp Phe 305 310 315 320
- MOLECULE TYPE DNA (genomic) nil) HYPOTHETICAL: N (iv) ANTI -SENSE: N
- MOLECULE TYPE DNA (genomic) (ill) HYPOTHETICAL: N (iv) ANTI-SENSE: N
- MOLECULE TYPE DNA (genomic)
- HYPOTHETICAL N ( ⁇ v> ANTI-SENSE: N
- MOLECULE TYPE DNA (genomic)
- HYPOTHETICAL N
- ANTI -SENSE N
- MOLECULE TYPE DNA (genomic)
- HYPOTHETICAL N
- ANTI-SENSE N
- MOLECULE TYPE DNA (genomic)
- HYPOTHETICAL N
- ANTI-SENSE N
- MOLECULE TYPE DNA (genomic)
- HYPOTHETICAL N
- ANTI-SENSE N
- MOLECULE TYPE DNA (genomic)
- HYPOTHETICAL N
- ANTI-SENSE N
- MOLECULE TYPE DNA (genomic)
- HYPOTHETICAL N
- ANTI -SENSE N
- MOLECULE TYPE DNA (genomic)
- HYPOTHETICAL N
- ANTI -SENSE N
- MOLECULE TYPE DNA (genomic)
- HYPOTHETICAL N
- ANTI -SENSE N
- MOLECULE TYPE DNA (genomic)
- HYPOTHETICAL N
- MOLECULE TYPE DNA (genomic)
- CAACTCACAC AAAAATGACA CCGGAGGCAT ATACACAACA TTAAACAAAA CAACACAGTT 2520
- CAAAAAATCC CATACTACCA GGTGTCTCGG GGGAACACCT AACGGAGTTA TGTAATTATG 5640
- AGTACCCCCA CGTACTGGGG CCAGTGGGGT TGTCATCTCC AGATGAATAC AGGGCAAAAG 5880
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP50910598A JP2002513274A (ja) | 1996-07-25 | 1997-07-22 | カポジ肉腫関連ウイルスのユニークな配列およびその使用 |
EP97938064A EP0934333A4 (fr) | 1996-07-25 | 1997-07-22 | Sequences de virus uniques associees au sarcome de kaposi et utilisations de ces dernieres |
US09/230,371 US6348586B1 (en) | 1996-07-25 | 1997-07-22 | Unique associated Kaposi's sarcoma virus sequences and uses thereof |
AU40478/97A AU4047897A (en) | 1996-07-25 | 1997-07-22 | Unique associated kaposi's sarcoma virus sequences and uses thereof |
CA002261164A CA2261164A1 (fr) | 1996-07-25 | 1997-07-22 | Sequences de virus uniques associees au sarcome de kaposi et utilisations de ces dernieres |
Applications Claiming Priority (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/686,349 US5861500A (en) | 1996-07-25 | 1996-07-25 | Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin 6 (IL-6) and uses thereof |
US08/686,350 US5831064A (en) | 1996-07-25 | 1996-07-25 | Kaposi's sarcoma-associated herpes virus (KSHV) interferon consensus sequence binding protein (ICSBP) and uses thereof |
US08/686,243 US5863787A (en) | 1996-07-25 | 1996-07-25 | Kaposi's sarcoma-associated herpesvirus (KSHV) glycoprotein B (GB) and uses thereof |
US08/687,253 US5854418A (en) | 1996-07-25 | 1996-07-25 | Kaposi's sarcoma-associated herpesvirus (KSHV) viral macrophage inflammatory protein-1α II (vMIP-1α II) and uses thereof |
US08/686,349 | 1996-07-25 | ||
US08/688,814 | 1996-07-25 | ||
US08/687,253 | 1996-07-25 | ||
US08/686,350 | 1996-07-25 | ||
US08/686,243 | 1996-07-25 | ||
US08/708,678 US5859225A (en) | 1996-09-05 | 1996-09-05 | Virion protein 26 from Kaposi's sarcoma-associated herpesvirus, DNA encoding same and uses thereof |
US08/708,678 | 1996-09-05 | ||
US08/728,323 US5948676A (en) | 1996-10-10 | 1996-10-10 | Immediate early protein from Kaposi's sarcoma-associated herpesvirus, DNA encoding same and uses thereof |
US08/728,323 | 1996-10-10 | ||
US08/747,887 US5853734A (en) | 1996-11-13 | 1996-11-13 | Glycoprotein L and clycoprotein M from kaposi's sarcoma associated herpesvirus, DNA encoding same and uses thereof |
US08/748,640 | 1996-11-13 | ||
US08/748,640 US5854398A (en) | 1996-07-25 | 1996-11-13 | Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin 6 (IL-6) and uses thereof |
US08/747,887 | 1996-11-13 | ||
US08/757,669 | 1996-11-29 | ||
US08/757,669 US6183751B1 (en) | 1994-08-18 | 1996-11-29 | Unique associated Kaposi's Sarcoma virus sequences and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998004576A1 true WO1998004576A1 (fr) | 1998-02-05 |
Family
ID=27578898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/013346 WO1998004576A1 (fr) | 1996-07-25 | 1997-07-22 | Sequences de virus uniques associees au sarcome de kaposi et utilisations de ces dernieres |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0934333A4 (fr) |
JP (1) | JP2002513274A (fr) |
AU (1) | AU4047897A (fr) |
CA (1) | CA2261164A1 (fr) |
WO (1) | WO1998004576A1 (fr) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999061909A2 (fr) * | 1998-05-26 | 1999-12-02 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methodes et compositions de detection du virus de l'herpes humain |
WO1999062938A2 (fr) * | 1998-05-29 | 1999-12-09 | Octavian Schatz | Nouveaux (poly)peptides representant des epitopes du virus 8 de l'herpes humain |
WO2001006849A1 (fr) * | 1999-07-21 | 2001-02-01 | Schering Corporation | Modele d'animal transgenique destine au sarcome de kaposi |
WO2001068833A2 (fr) * | 2000-03-16 | 2001-09-20 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Adn hhv8 recombinant |
US6348586B1 (en) | 1996-07-25 | 2002-02-19 | The Trustees Of Columbia University In The City Of New York | Unique associated Kaposi's sarcoma virus sequences and uses thereof |
CN1111069C (zh) * | 1999-07-13 | 2003-06-11 | 暨南大学 | Hhv8的mip同源物在防治艾滋病的药物中的应用 |
US6653465B2 (en) | 2000-12-08 | 2003-11-25 | The Trustees Of Columbia University In The City Of New York | Spliced gene of KSHV / HHV8, its promoter and monoclonal antibodies specific for LANA2 |
US6939547B2 (en) * | 2000-07-31 | 2005-09-06 | The United States Of America As Represented By The Department Of Health And Human Services | Specific binding agents for KSHV vIL-6 that neutralize a biological activity |
US7932066B2 (en) | 1994-08-18 | 2011-04-26 | The Trustees Of Columbia University In The City Of New York | Unique associated kaposi's sarcoma virus sequences and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU700913B2 (en) * | 1994-08-18 | 1999-01-14 | Trustees Of Columbia University In The City Of New York, The | Unique associated kaposi's sarcoma virus sequences and uses thereof |
US6183751B1 (en) * | 1994-08-18 | 2001-02-06 | The Trustees Of Columbia University In The City Of New York | Unique associated Kaposi's Sarcoma virus sequences and uses thereof |
US6022542A (en) * | 1995-09-26 | 2000-02-08 | University Of Washington | Glycoprotein B of the RFHV/KSHV subfamily of herpes viruses |
WO1997024057A2 (fr) * | 1995-12-27 | 1997-07-10 | Yale University | Essais de detection des antigenes du cycle lytique et d'anticorps du virus de l'herpes associe a la maladie de kaposi |
US7968696B1 (en) * | 1996-07-19 | 2011-06-28 | Behring Diagnostics Gmbh | Viral interleukin-6 |
AU3672597A (en) * | 1996-07-25 | 1998-02-20 | Johns Hopkins University, The | Novel genes of kaposi's sarcoma associated herpesvirus |
GB9618890D0 (en) * | 1996-09-10 | 1996-10-23 | Univ Liverpool | An immunogenic determinant |
US6093806A (en) * | 1996-10-10 | 2000-07-25 | Cornell Research Foundation, Inc. | DNA encoding proteins of Kaposi's sarcoma associated herpesvirus |
-
1997
- 1997-07-22 EP EP97938064A patent/EP0934333A4/fr not_active Withdrawn
- 1997-07-22 AU AU40478/97A patent/AU4047897A/en not_active Abandoned
- 1997-07-22 JP JP50910598A patent/JP2002513274A/ja active Pending
- 1997-07-22 WO PCT/US1997/013346 patent/WO1998004576A1/fr not_active Application Discontinuation
- 1997-07-22 CA CA002261164A patent/CA2261164A1/fr not_active Abandoned
Non-Patent Citations (7)
Title |
---|
ABSTRACTS OF THE 3RD CONF. RETRO. AND OPPORTUN. INFECT., 28 January - 01 February 1996, PARRAVICINI et al., "In Situ Detection of Human Herpesvirus-8 DNA Sequences in AIDS-Associated Kaposi's Sarcoma", page 55. * |
INT. CONF. AIDS, 07-12 July 1996, Vol. 11, No. 2, BENNETT et al., "Characterization of the DNA Polymerase and Glycoprotein B Genes of Kaposi's Sarcoma-Associated and Related Herpesviruses", page 7, Abstract No. We.A.161. * |
INT. CONF. AIDS, 07-12 July 1996, Vol. 11, No. 2, BLACKBOURN et al., "The Infectious Nature of the Novel Herpesvirus-Like DNA Sequences Detected in Kaposi's Sarcoma", page 215, Abstract No. Th.A.273. * |
INT. CONF. AIDS, 07-12 July 1996, Vol. 11, No. 2, STRAND et al., "Simian Homologues of Human Herpesvirus-8 (or KSHV) in Retroperitoneal Fibromatosis in Macaques", page 216, Abstract No. Th.A.275. * |
J. MOL. MED., December 1995, Vol. 73, No. 12, MEMAR et al., "Human Herpesvirus-8: Detection of Novel Herpesvirus-Like DNA Sequences in Kaposi's Sarcoma and Other Lesions", pages 603-609. * |
J. VIROL., January 1996, Vol. 70, No. 1, MOORE et al., "Primary Characterization of a Herpesvirus Agent Associated with Kaposi's Sarcoma", pages 549-558. * |
See also references of EP0934333A4 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7932066B2 (en) | 1994-08-18 | 2011-04-26 | The Trustees Of Columbia University In The City Of New York | Unique associated kaposi's sarcoma virus sequences and uses thereof |
US6348586B1 (en) | 1996-07-25 | 2002-02-19 | The Trustees Of Columbia University In The City Of New York | Unique associated Kaposi's sarcoma virus sequences and uses thereof |
WO1999061909A3 (fr) * | 1998-05-26 | 2000-03-23 | Us Health | Methodes et compositions de detection du virus de l'herpes humain |
WO1999061909A2 (fr) * | 1998-05-26 | 1999-12-02 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methodes et compositions de detection du virus de l'herpes humain |
WO1999062938A2 (fr) * | 1998-05-29 | 1999-12-09 | Octavian Schatz | Nouveaux (poly)peptides representant des epitopes du virus 8 de l'herpes humain |
WO1999062938A3 (fr) * | 1998-05-29 | 2000-03-23 | Octavian Schatz | Nouveaux (poly)peptides representant des epitopes du virus 8 de l'herpes humain |
US6669939B1 (en) | 1998-05-29 | 2003-12-30 | Biotrin International Properties Limited | (Poly)peptides which represent the epitopes of the human herpes virus type 8 |
CN1111069C (zh) * | 1999-07-13 | 2003-06-11 | 暨南大学 | Hhv8的mip同源物在防治艾滋病的药物中的应用 |
WO2001006849A1 (fr) * | 1999-07-21 | 2001-02-01 | Schering Corporation | Modele d'animal transgenique destine au sarcome de kaposi |
WO2001068833A3 (fr) * | 2000-03-16 | 2002-04-11 | Gsf Forschungszentrum Umwelt | Adn hhv8 recombinant |
WO2001068833A2 (fr) * | 2000-03-16 | 2001-09-20 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Adn hhv8 recombinant |
US6939547B2 (en) * | 2000-07-31 | 2005-09-06 | The United States Of America As Represented By The Department Of Health And Human Services | Specific binding agents for KSHV vIL-6 that neutralize a biological activity |
US7108981B2 (en) | 2000-07-31 | 2006-09-19 | The United States Of America As Represented By The Department Of Health And Human Services | Specific binding agents for KSHV vIL-6 that neutralize a biological activity |
US7235365B2 (en) | 2000-07-31 | 2007-06-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Specific binding agents for KSHV vIL-6 that neutralize a biological activity |
US7374756B2 (en) | 2000-07-31 | 2008-05-20 | The United States Of America As Represented By The Department Of Health And Human Services | Specific binding agents for KSHV vIL-6 that neutralize a biological activity |
US6653465B2 (en) | 2000-12-08 | 2003-11-25 | The Trustees Of Columbia University In The City Of New York | Spliced gene of KSHV / HHV8, its promoter and monoclonal antibodies specific for LANA2 |
US6866854B1 (en) | 2000-12-08 | 2005-03-15 | The Trustees Of Columbia University In The City Of New York | Spliced gene of KSHV/HHV8, its promoter and monoclonal antibodies specific for LANA2 |
Also Published As
Publication number | Publication date |
---|---|
JP2002513274A (ja) | 2002-05-08 |
AU4047897A (en) | 1998-02-20 |
EP0934333A1 (fr) | 1999-08-11 |
CA2261164A1 (fr) | 1998-02-05 |
EP0934333A4 (fr) | 1999-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6348586B1 (en) | Unique associated Kaposi's sarcoma virus sequences and uses thereof | |
US5854398A (en) | Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin 6 (IL-6) and uses thereof | |
Cesarman et al. | Kaposi's sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma | |
US5830759A (en) | Unique associated Kaposi's sarcoma virus sequences and uses thereof | |
US6183751B1 (en) | Unique associated Kaposi's Sarcoma virus sequences and uses thereof | |
. SANDVEJ et al. | Epstein‐Barr virus latent and replicative gene expression in oral hairy leukoplakia | |
EP0934333A1 (fr) | Sequences de virus uniques associees au sarcome de kaposi et utilisations de ces dernieres | |
US20110265195A1 (en) | Unique associated kaposi's sarcoma virus sequences and uses thereof | |
US5849564A (en) | Polypeptides from Kaposi's sarcoma-associated herpesvirus, DNA encoding same and uses thereof | |
US5801042A (en) | Unique associated Kaposi's sarcoma virus sequences and uses thereof | |
US6653465B2 (en) | Spliced gene of KSHV / HHV8, its promoter and monoclonal antibodies specific for LANA2 | |
US5948676A (en) | Immediate early protein from Kaposi's sarcoma-associated herpesvirus, DNA encoding same and uses thereof | |
AU700913B2 (en) | Unique associated kaposi's sarcoma virus sequences and uses thereof | |
EP2399928B1 (fr) | Séquences de virus TT spécifiques et molécules ADN à cellule hôte de virus TT chimérique à utiliser dans le diagnostic, la prévention et le traitement du cancer et auto-immunité | |
US6264958B1 (en) | Genes of kaposi's sarcoma associated herpesvirus | |
US5831064A (en) | Kaposi's sarcoma-associated herpes virus (KSHV) interferon consensus sequence binding protein (ICSBP) and uses thereof | |
WO1996015779A1 (fr) | Sequences virales specifiques associees a la maladie de kaposi et leurs utilisations | |
US5854418A (en) | Kaposi's sarcoma-associated herpesvirus (KSHV) viral macrophage inflammatory protein-1α II (vMIP-1α II) and uses thereof | |
US5859225A (en) | Virion protein 26 from Kaposi's sarcoma-associated herpesvirus, DNA encoding same and uses thereof | |
US5861500A (en) | Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin 6 (IL-6) and uses thereof | |
Sanders et al. | Characterization of human papillomavirus type 16 E2 protein and subdomains expressed in insect cells | |
US5853734A (en) | Glycoprotein L and clycoprotein M from kaposi's sarcoma associated herpesvirus, DNA encoding same and uses thereof | |
US6413522B1 (en) | Papilloma viruses, products for the detection thereof as well as for treating diseases caused by them | |
US5863787A (en) | Kaposi's sarcoma-associated herpesvirus (KSHV) glycoprotein B (GB) and uses thereof | |
US6482587B1 (en) | Methods to inhibit or enhance the binding of viral DNA to genomic host DNA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2261164 Country of ref document: CA Ref country code: CA Ref document number: 2261164 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997938064 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997938064 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09230371 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997938064 Country of ref document: EP |